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Preface 
 
My interest in genetics began when I was a Biology student at Faculdade de Ciências da 
Universidade de Lisboa in the early 90´s. During the last 2 years of my graduation I worked as a 
volunteer at the Departamento de Biologia Vegetal in the genetics of microorganisms. When I 
graduated in 1993 my genetics teacher Prof. Graça Fialho recommended that I should pursue 
my professional interests in genetics at the Departamento de Genética of the Instituto 
Nacional de Saúde Dr. Ricardo Jorge (DG-INSA). At that time, Prof. Maria Guida Boavida, who 
was in charge of DG-INSA, was looking for a graduate student to initiate the molecular 
diagnosis of leukemias in the laboratory. Luckily, I was accepted for that assignment and 
together with my colleagues Paula Ambrósio and Bárbara Marques we constituted a small 
team developing conventional cytogenetics, fluorescence in situ hybridization and molecular 
techniques to interpret and report chromosomal abnormalities in leukemia patients. With 
time, however, I gradually become interested in pursuing a more research directed activity 
towards the characterization of novel chromosomal abnormalities in leukemia. 
I started this endeavour with a comprehensive retrospective analysis of leukemia 
karyotype registries at the DG-INSA and Laboratório de Hematologia of the Instituto Português 
de Oncologia de Francisco Gentil (LH-IPOFG) in Lisbon, under the guidance of Prof. Maria 
Guida Boavida and Prof. Maria Gomes da Silva, respectively. The purpose was to select 
samples carrying reciprocal chromosome translocations undescribed in the literature and 
potentially use them to pursue molecular investigation of novel breakpoint locations and 
associated fusion genes. After a first scrutiny, I subsequently focused my interest in 
translocations in which one of the breakpoint locations was already known to constitute a 
recurrent target site. Moreover, only cytogenetic records which were obtained at the time of 
initial diagnosis were considered. Both approaches increased the likelihood of identifying novel 
leukemogenic fusion genes. The final output of the review comprised a total of 5 different 
translocations, including 2 collected from DG-INSA database and 3 obtained from the LH-
IPOFG database. 
Incidently, preliminary studies disclosed that at least one additional chromosome was 
involved in 4 out of the 5 selected translocations, thus revealing an unexpected complex 
nature. A fundamental question then rose to my mind: Is the role of extra breakpoint locations 
involved in complex translocations merely accessory or is it also relevant to the proliferation 
and survival of the leukemic clone? I then addressed Prof. Maria Gomes da Silva in 2005 with a 
tentative idea for a PhD project under her supervision involving the role of complex 
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chromosome translocations in leukemogenesis. This project soon became a reality and 6 years 
later all I can say is that I have made the right choice. 
 
xiii 
Abstract 
 
Tumourigenesis is a multistep process which results from the accumulation of successive 
genetic mutations in a normal cell. In leukemia for instance, recurrent translocations play a 
part in this process by generating fusion genes which lead to the production of hybrid proteins 
with an oncogenic role. However, a minor subset of chromosomal translocations referred to as 
complex or variant involves extra breakpoints at variable genome locations in addition to those 
implicated in the formation of fusion genes. We aimed to describe in this work the role, if any, 
of genes located at extra breakpoint locations or which are affected by breakpoint-adjacent 
deletions through the study of 5 leukemia patients. 
Two of the patients presented with ETV6(12p13)-RUNX1(21q22) and MLL(11q23)-
MLLT3(9p22) fusion genes as a result of a t(12;21;5) and a t(9;11;19), respectively. Detailed 
molecular characterization of the extra breakpoint at chromosome 19 in the latter case 
revealed that a novel ubiquitously expressed gene, CCDC94, with a potential role in cell cycle 
regulation, was disrupted by the breakpoint. We demonstrated using in vitro cellular assays 
that this gene codifies for a nuclear protein which negatively regulates cell cycle progression. 
These data shows that extra breakpoint locations of complex translocations may result in 
haplo-insufficiency of critical proliferation genes, thereby cooperating with the generation of 
hybrid proteins to provide unrestrained cell proliferation. 
In the other 3 patients there were breakpoint-associated deletions which precluded the 
formation of putative fusion genes. In a case with a t(12;6;15) we characterized a deletion at 
12p13 which eliminated ETV6 and 8 other genes including CDKN1B. These findings indicate 
that concomitant loss of ETV6 and CDKN1B, which encodes a cyclin-dependent kinase inhibitor 
responsible for blocking entry of cells into the G1 phase of the cell cycle, acted cooperatively 
to promote leukemogenic proliferation. The same notion applied to a case with a dic(9;12) in 
which 2 genes encoding hematopoietic transcription factors - ETV6 and PAX5 (9p13)- were 
deleted as a result of breakpoint-adjacent deletions. Similarly, we found that 2 transcription 
factor genes involved in the regulation of cytokine expression, NFATC2 (20q13) and MAF 
(16q23), were involved in deletions contiguous to the breakpoints in a patient with a 
t(X;20;16). In vitro suppression of NFATC2 mRNA or inhibiton of NFATC2 protein activity 
enhanced cell proliferation as a result of an increase in the production of a myeloid-lineage 
stimulating hematopoietic cytokine, GM-CSF. These results suggest that haplo-insufficiency of 
NFATC2 and MAF genes had a cooperative effect in inducing cell proliferation as a result of a 
disregulation of cytokine production. 
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Two main conclusions may be drawn from our studies: (i) In complex translocations 
associated with the production of fusion genes, additional breakpoints may cooperate in 
tumourigenesis by targeting genes that control cell proliferation; (ii) In complex translocations 
associated with small breakpoint-adjacent deletions, at least 2 genes with similar or 
complementary functions need to be deregulated to promote tumourigenesis. 
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Résumé 
 
La tumorigenèse est un processus qui se déroule en de plusieurs étapes et qui résulte de 
l‘accumulation de mutations génétiques continues dans une cellule normal. Par exemple, dans 
la leucémie, les translocations récurrentes ont un rôle dans ce processus pour former des 
gènes de fusion qui conduisent à la production de protéines hybrides avec une fonction 
oncogénique. Cependant, il existe une petite minorité de translocations chromosomiques, 
appellées de complexes ou variantes, qui impliquent des points de rupture additionnels dans 
d‘autres localisations génomiques au delà des impliqués dans la formation des gènes de 
fusion. L‘objectif de cet étude était celui de déterminer le rôle, s‘il existe, des gènes localisés 
dans les points de rupture additionnels et/ou associés avec délétions contigues aux points de 
rupture, dans l‘étude de 5 patients avec de la leucémie. 
Deux de ces patients étudiés ont révélé la présence des gènes de fusion ETV6(12p13)-
RUNX1(21q22) et MLL(11q23)-MLLT3(9p22) comme résultat de t(12;21;5) et t(9;11;19), 
respectivement. Dans ce dernier cas, la caractérisation détaillée du local de rupture 
additionnel dans le chromosome 19 a révélé qu‘un nouveau gène, CCDC94, exprès 
ubiquitairement et avec un rôle potentiel dans la régulation du cycle cellulaire, était 
interrompu par le point de rupture. Par des essais cellulaires in vitro on a démontré que 
CCDC94 codifie une protéine nucléaire qui règle négativement la progression du cycle 
cellulaire. Ces résultats montrent que les points de rupture additionnels présents dans des 
translocations complexes peuvent entraîner dans la haplo-insuffisance de gènes essentiels 
impliqués dans la prolifération, en coopérant de cette façon avec la formation de protéines de 
fusion pour provoquer une prolifération cellulaire incontrôlée. 
Les 3 autres patients étudiés ont révélé des délétions associées avec les points de 
rupture qui n´ont pas conduit à la formation de gènes de fusion. Dans le cas avec t(12;6;15) on 
a caractérisé une délétion dans la bande 12p13 qui a résulté dans l‘élimination du gène ETV6 
et encore les 8 autres gènes en comprenant CDKN1B. Ces résultats indiquent que la perte 
simultanée de ETV6 et de CDKN1B, qui codifie une protéine responsable par le blocage de 
l‘entrée de cellules en phase G1 du cycle cellulaire, a une action de coopération dans la 
promotion de la leucémogenèse. On applique la même notion dans un cas avec dic(9;12) dans 
lequel 2 gènes qui codifient pour des facteurs de transcription, étaient éliminés comme 
résultat de délétions contigues aux points de rupture. De même on a constaté que 2 gènes, 
NFATC2 (20q13) et MAF (16q23), tous 2 impliqués dans la régulation de l‘expression des 
cytokines hématopoïétiques, étaient incluses dans les régions délétionées adjacentes aux 
points de rupture dans un patient avec t(X;20;16). La suppression de l´expression du gène 
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NFATC2, ou l´inhibition de l‘activité de la respective protéine ont augmenté la prolifération 
cellulaire in vitro dû à la plus grande production de la cytokine GM-CSF. Ces résultats suggèrent 
que la haplo-insuffisance des 2 gènes a eu un effet coopératif dans l´induction de la 
prolifération cellulaire par la dérégulation de l‘expression des cytokines hématopoïétiques. 
De ces études 2 conclusions principales peuvent être tirées: (i) Les points de rupture 
additionnels, qui se produisent dans les translocations complexes associées avec la formation 
de gènes de fusion, peuvent avoir pour conséquence la dérégulation des gènes contrôleurs de 
la prolifération cellulaire; (ii) dans des translocations complexes caractérisées par délétions 
associées aux points de rupture, il aura besoin d‘éliminer au moins 2 gènes avec des fonctions 
similaires ou complémentaires, pour promouvoir coopérativement la tumorigenèse.  
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Resumo 
 
A tumorigénese é um processo de transformação celular que se desenrola tipicamente 
em várias etapas. Os diferentes níveis de evolução tumoral resultam da acumulação sucessiva 
de mutações genéticas numa célula normal que lhe conferem uma vantagem selectiva no 
respectivo meio tecidular. As mutações podem manifestar-se sob a forma de alterações 
nucleotídicas pontuais ao nível da sequência de DNA, levando a uma desregulação da função 
proteíca ou à formação de proteínas não-funcionais, ou através de alterações cromossómicas 
numéricas ou estruturais. Na leucemia, por exemplo, os genes híbridos que resultam de 
translocações cromossómicas desempenham um importante papel no processo tumorigénico. 
Estes genes são transcritos sob a forma de um RNA mensageiro de fusão, o qual é traduzido 
numa proteína híbrida com função oncogénica. 
Frequentemente, os subtipos de doença leucémica estão associados com translocações 
cromossómicas que envolvem 2 pontos de quebra recorrentes e específicos. É disto exemplo a 
leucemia mielóide crónica, em que uma translocação recíproca entre os cromossomas 9 e 22 
conduz à formação de um gene de fusão BCR-ABL1. Em diferentes subtipos de doença, existe 
também uma pequena proporção de casos que apresenta translocações cromossómicas 
complexas, que envolvem um ou mais pontos de quebra adicionais em outras localizações 
genómicas além das que estão implicadas na formação dos genes de fusão. Por vezes, os 
pontos de quebra estão também associados a delecções extensas de material genético que se 
pensa terem uma função importante na tumorigénese. No entanto, o papel destas regiões 
genómicas no desenvolvimento tumoral não tem sido um motivo recorrente de estudo. Neste 
contexto, o objectivo desta dissertação foi o de determinar o potencial papel tumorigénico de 
alterações génicas adicionais ocorridas nos pontos de quebra de translocações cromossómicas 
complexas. 
Para a prossecução do objectivo proposto, foram estudados 5 rearranjos cromossómicos 
distintos associados com diferentes tipos de doença hematológica maligna, nomeadamente a 
leucemia linfoblástica aguda de células B (2 casos), leucemia mielóide aguda, neoplasma 
mieloproliferativo e síndrome mielodisplásico/neoplasma mieloproliferativo, não classificável. 
O mapeamento dos pontos de quebra foi efectuado utilizando a hibridação fluorescente in situ 
e diferentes metodologias de biologia molecular, tendo como base a informação inicial da 
análise citogenética. Em casos seleccionados, o papel dos novos genes candidatos foi avaliado 
in vitro utilizando modelos de linhas celulares, nomeadamente no que respeita às funções de 
controlo da proliferação celular e de regulação transcricional. 
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De entre os 5 casos estudados, quatro deles evidenciaram translocações complexas 
envolvendo 3 cromossomas, nomeadamente t(12;21;5)(p13;q22;q13), 
t(12;6;15)(p13;p24~25;q22), t(9;11;19)(p22;q23;p13) e t(X;20;16)(p11;q13;q23). No caso 
remanescente, foi observada uma translocação dicêntrica dic(9;12)(p11;p11) acompanhada de 
delecções extensas em ambos os pontos de quebra. Nos casos com t(12;21;5) e t(9;11;19) as 
translocações estavam associadas com a presença de genes de fusão recorrentes, 
nomeadamente ETV6(12p13)-RUNX1(21q22) e MLL(11q23)-MLLT3(9p22), indicando que se 
tratavam de rearranjos complexos das translocações t(12;21) e t(9;11) associadas com a 
leucemia linfoblástica aguda de células B e a leucemia mielóide aguda, respectivamente. 
O papel dos pontos de quebra adicionais foi estudado em detalhe no caso com 
t(9;11;19). Através da metodologia de long distance inverse-polymerase chain reaction, foram 
identificados os pontos de quebra na sequência de DNA dos 3 cromossomas envolvidos na 
translocação. Além dos pontos de quebra nos genes MLL e MLLT3, foi observado que o local de 
quebra no cromossoma 19 interrompeu a sequência de um novo gene, designado CCDC94, 
conduzindo à sua haplo-insuficiência nas células com t(9;11;19). Através de ensaios de reverse 
transcription-polymerase chain reaction verificámos que o gene CCDC94 é expresso 
ubiquitariamente em tecidos humanos normais. A análise informática da sequência prevista da 
proteína CCDC94 indicou uma elevada identidade de aminoácidos com a proteína cwf16, 
envolvida na regulação do ciclo celular da levedura Schizosaccharomyces pombe. Através da 
clonagem do DNA complementar de CCDC94 em vectores de expressão, e após a transfecção 
destes em culturas de linhas celulares in vitro, observámos que este gene codifica uma 
proteína de localização exclusivamente nuclear. A expressão ectópica da proteína CCDC94 
diminuiu a progressão do ciclo celular e a proliferação das células em cultura. Inversamente, a 
supressão do transcrito do gene CCDC94 através de interferência de RNA conduziu a um 
aumento significativo da proliferação celular, confirmando que CCDC94 regula negativamente 
a proliferação e a progressão do ciclo celular. Estes resultados mostram que os pontos de 
quebra adicionais, presentes em translocações cromossómicas complexas em leucemia, 
podem resultar na haplo-insuficiência de genes controladores dos mecanismos proliferativos, 
cooperando desta forma com a acção das proteínas de fusão para proporcionar ao clone 
leucémico uma proliferação celular descontrolada. 
Nos restantes 3 casos estudados não foram identificados genes de fusão. Ao invés, todos 
aqueles apresentaram delecções de extensão variável associadas com os pontos de quebra 
cromossómicos. No caso com t(12;6;15), identificámos uma delecção de 1.2 megabases de 
DNA na banda 12p13 que resultou na eliminação de 9 genes incluindo ETV6 e CDKN1B. O gene 
ETV6 codifica um factor de transcrição que é essencial para a formação das diferentes 
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linhagens hematopoiéticas na medula óssea, enquanto CDKN1B é traduzido numa proteína 
responsável por bloquear a entrada das células na fase G1 do ciclo celular e, 
consequentemente, por travar a proliferação celular. Neste contexto, os resultados obtidos 
indicam que a perda simultânea de ETV6 e de CDKN1B, através de uma translocação 
cromossómica complexa, constituiu uma acção cooperativa na leucemogénese. A mesma 
noção pode aplicar-se ao caso com dic(9;12), no qual pelo menos 2 genes que codificam para 
factores de transcrição importantes na linhagem hematopoiética, PAX5 no cromossoma 9 e 
ETV6 no cromossoma 12, estavam  deleccionados como resultado do rearranjo cromossómico. 
Dado que o factor de transcrição PAX5 regula negativamente a expressão do gene FLT3, que 
desempenha uma função pró-proliferativa, é expectável que a haplo-insuficiência de PAX5 no 
caso com dic(9;12) terá tido como consequência uma elevação dos níveis de expressão de 
FLT3, contribuindo deste modo para uma proliferação celular aumentada. 
A t(X;20;16) foi identificada num doente com trombocitémia essencial (TE), uma doença 
que está intimamente relacionada com alterações de vias intracelulares reguladas por 
citocinas. Neste caso, através da utilização de um array genómico, identificámos a presença de 
pequenas delecções associadas com os pontos de quebra nos cromossomas 16 e 20. No 
cromossoma 16 apenas um gene, MAF, estava deleccionado, enquanto no cromossoma 20 a 
delecção tinha abrangido 3 genes. Dos genes deleccionados, dois deles, NFATC2 (20q13) e 
MAF (16q23), codificam proteínas que operam como reguladores transcricionais de citocinas 
hematopoiéticas. Dado que NFATC2 se localiza numa região que constitui um alvo frequente 
de delecções em neoplasmas mieloproliferativos, incluindo a trombocitémia essencial, 
efectuámos um estudo detalhado do papel deste gene na proliferação megacariocítica e na 
regulação da expressão de uma citocina hematopoiética (GM-CSF), implicada na maturação 
das diferentes linhagens mielóides. 
Utilizando um modelo de linha celular de trombocitémia essencial, verificámos que a 
supressão do transcrito do gene NFATC2 in vitro, por interferência de RNA, estava associada 
com um aumento da proliferação celular. Em concordância, o bloqueio da activação da 
proteína NFATC2 através de um inibidor específico da sua interacção com a calcineurina, 
conduziu a um aumento da proliferação celular in vitro. Utilizando a PCR quantitativa em 
tempo real, detectou-se um aumento da produção do RNA de GM-CSF em ambos os ensaios 
celulares, indicando que o factor de transcrição NFATC2 pode regular negativamente a 
expressão de GM-CSF em células de trombocitémia essencial. No geral, estes resultados 
mostram que a redução dos níveis fisiológicos do transcrito NFATC2, ou a redução da 
respectiva actividade proteica, estão relacionados com a proliferação de megacariocitos 
através do aumento da produção de GM-CSF. De acordo com estes resultados, verificámos que 
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as células dos doentes com TE apresentam níveis mais baixos do transcrito NFATC2 do que a 
população normal. Dado que o factor de transcrição MAF desempenha igualmente um papel 
como regular transcricional de citocinas, é plausível que a haplo-insuficiência dos genes 
NFATC2 e MAF, resultante do rearranjo cromossómico complexo t(X;20;16), teve um efeito 
cooperativo importante na patogénese da trombocitémia essencial através da alteração do 
padrão normal de expressão das citocinas hematopoiéticas. 
Em síntese, efectuámos nesta dissertação um estudo citogenético de 4 translocações 
cromossómicas complexas incluindo t(12;21;5), t(12;6;15), t(9;11;19) e t(X;20;16), e de uma 
translocação dicêntrica dic(9;12), associadas com diferentes neoplasmas hematológicos. Em 
casos seleccionados efectuámos também um estudo molecular detalhado das regiões dos 
pontos de quebra. Esta análise permitiu-nos identificar 2 genes, CCDC94 no cromossoma 19 e 
NFATC2 no cromossoma 20, cuja haplo-insuficiência pode promover o aumento da 
proliferação celular das células leucémicas. A partir destes estudos podem ser retiradas 2 
noções principais: (i) Os pontos de quebra adicionais, que ocorrem em translocações 
complexas associadas com a formação de genes de fusão, podem ter como consequência a 
desregulação de genes controladores da proliferação celular (e.g., CCDC94); (ii) As 
translocações complexas caracterizadas pela ausência de genes de fusão recorrentes poderão 
estar preferencialmente associadas com a presença de delecções, envolvendo um ou mais 
genes, nos pontos de quebra; nestas situações, serão necessários pelo menos 2 genes com 
funções celulares semelhantes (e.g., NFATC2 e MAF) ou complementares (e.g., ETV6 e 
CDKN1B) para, quando deleccionados, promoverem de forma cooperativa a leucemogénese. 
Nestes termos, o modelo de alterações genéticas sequenciais que caracteriza o 
desenvolvimento do cancro pode ser substituído por um modelo em que vários genes-alvo são 
simultaneamente desregulados pela formação de uma translocação cromossómica complexa, 
evitando deste modo a necessidade de ocorrência de alterações genéticas subsequentes.  
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3 1. General Introduction 
1.1. THE PHILADELPHIA CHROMOSOME AS A PARADIGM OF CANCER GENETICS 
 
Physical integrity of the eukaryotic chromosome complement is crucial for normal cell 
physiology and homeostasis. The notion that chromosome abnormalities could play a role in 
the formation of tumours began to develop with the work of 2 German pathologists at the 
nineteenth-twentieth century transition. David von Hansemann initially speculated that 
chromosome aberrations and mitotic abnormalities were associated with the formation and 
progression of tumours, whereas Theodor Boveri later proposed that the alteration in the 
number of chromosomes in a normal somatic cell might have a role in the initiation of cancer 
(von Hansemann, 1890; Boveri, 1914). However, scientific evidence to corroborate these 
hypotheses waited almost 50 years for the development of new cytogenetic techniques which 
improved the overall quality of metaphase chromosome preparations. 
Taking advantage of technical improvements in tissue culture procedures, Peter Nowell 
and David Hungerford firstly identified a characteristic small chromosome in the neoplastic 
bone marrow metaphase cells of patients with chronic myeloid leukemia (CML) (Nowell & 
Hungerford, 1960; Nowell & Hungerford, 1961). This somatic chromosome abnormality was 
designated as the Philadelphia chromosome, in accordance to the location of its discovery 
(Tough et al., 1961). Using fluorescence analysis with quinacrine mustard, Caspersson et al. 
(1970) initially established that the Philadelphia chromosome was a chromosome 22 with a 
deletion at the long arm, i.e., a 22q- chromosome. Later, it was revealed by the combined use 
of quinacrine mustard fluorescence and Giemsa staining that the end of the long arm of one 
chromosome 9 contained an extra material from another chromosome, most probably 
chromosome 22 (Rowley, 1973a). These results established that the Philadelphia chromosome 
was a derivative chromosome 22 [der(22)] resulting from a reciprocal translocation between 
one homologue of each pair of chromosomes 9 and 22. 
The development of DNA hybridization probes to detect genomic rearrangements 
allowed the identification of the sequences disrupted at the breakpoints. It was shown that the 
DNA sequence of the breakpoint cluster region (BCR) gene at chromosome band 22q11, and of 
the human homologue of the transforming sequence of Abelson murine leukemia virus gene, 
the c-abl oncogene 1, non-receptor tyrosine kinase (ABL1) gene at chromosome band 9q34, 
were interrupted by the translocation breakpoints (de Klein et al., 1982; Heisterkamp et al., 
1983; Groffen et al., 1984; Heisterkamp et al., 1985). Since both genes are oriented from 5´ to 
3´ in the centromere to telomere direction, the translocation produces a 5´BCR-3´ABL1 fusion 
gene on the 22q- chromosome and a reciprocal 5´ABL1-3´BCR hybrid gene on the 9q+ 
chromosome (Fig. 1). 
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Figure 1. Diagrammatic representation of the t(9;22) and its molecular consequences in CML. 
The reciprocal exchange of material between one homologue of each pair of chromosomes 9 and 22 leads to the 
formation of a BCR-ABL1 hybrid gene on the derivative chromosome 22 and of an ABL1-BCR hybrid gene on the 
derivative chromosome 9. For simplicity only the BCR-ABL1 fusion transcript is shown in detail. Transcription of the 
BCR-ABL1 hybrid gene originates an in-frame fusion mRNA which is translated into a fusion protein. The fusion 
protein interferes with normal intracellular signaling pathways resulting in increased proliferation and blockage of 
apoptosis of CML cells. Arrows pointing downwards indicate the breakpoint positions within the BCR and ABL1 
genes. The example shown here represents the formation of a common e14a2 BCR-ABL1 fusion transcript, however, 
other transcript configurations (e.g., e13a2 or, rarely, e13a3 or e14a3) are also possible depending on the intron in 
which the breakpoints occur. Each green or orange box represents an ABL1 or BCR exon, respectively. Exons are not 
shown to scale. Designations of exons are shown above each box. The stretch of adenosine (A) nucleotides 
represents the poly-A tail of mature BCR-ABL1 mRNA. 
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Molecular studies have shown that the BCR-ABL1 fusion gene is transcribed in all 
Philadelphia chromosome-positive patients whereas the reciprocal fusion mRNA is present in 
only 60% of BCR-ABL1-positive cases (Shtivelman et al., 1985; Melo et al., 1993). The product 
of the BCR-ABL1 fusion gene is a novel 210 KiloDalton (KDa) hybrid protein which displays 
increased tyrosine kinase activity (Konopka et al., 1984; Lugo et al., 1990). The oncogenic 
activity of BCR-ABL1 involves the activation of various cellular signaling pathways that promote 
proliferation and block apoptosis of CML cells (reviewed in Sawyers, 1997). Moreover, a 
myeloproliferative disorder resembling the chronic phase of human CML is produced in mice 
which have been transplanted with bone marrow hematopoietic stem cells infected with BCR-
ABL1 encoding-retroviruses (Daley et al., 1990; Kelliher et al., 1990). These data showed that 
the BCR-ABL1 fusion gene is a critical leukemogenic lesion in CML. 
An inhibitor of ABL1 tyrosine kinase activity, imatinib mesylate (IM), was successfully 
developed to block BCR-ABL1 kinase activity in CML cells (Druker et al., 1996). IM induces 
major cytogenetic remissions (i.e., between 0-35% of metaphases with the Ph chromosome) in 
almost 90% of cases and is thus the preferred first-line treatment approach for CML patients in 
chronic phase (O´Brien et al., 2003). Improvement of the genetic characterization of cancers by 
application of the binomial Philadelphia chromosome-IM is fundamental to achive therapeutic 
success in other tumour types in the future (Sherbenou & Druker, 2007). 
 
 
1.2. RECURRENT CHROMOSOME TRANSLOCATIONS IN ACUTE MYELOID LEUKEMIA 
 
In contrast to CML, leukemic cells from patients diagnosed with acute myeloid leukemia 
(AML) display extensive karyotypic heterogeneity. Among the various types of chromosomal 
rearrangements which can be observed in AML patients, four of these comprise approximately 
50% of cases overall (reviewed in Rowley, 2001). These include t(8;21)(q22;q22), 
inv(16)(p13q22) or t(16;16)(p13;q22), t(15;17)(q22;q21) and t(9;11)(p22;q23). Each of these 
rearrangements generates a fusion gene which leads to the production of an oncogenic hybrid 
protein responsible for inducing a differentiation and/or maturation arrest at an early 
developmental stage of myeloid cells. In this section we will briefly review the main molecular 
and functional features of t(8;21), inv(16)/t(16;16) and t(15;17). The t(9;11) will be dealt in 
further detail in chapter 3 (section 3.2). 
 
 
  
6 
1.2.1. TRANSLOCATION (8;21)(q22;q22) 
 
The t(8;21)(q22;q22) was the only recurrent chromosome translocation in human 
leukemia to be discovered before the t(9;22) (Rowley, 1973b). Its presence is associated with a 
high frequency of Auer rods in the leukemic cells, significant neutrophil maturation and 
prominent eosinophilia in the bone marrow (Bitter et al., 1987). The molecular consequence of 
the rearrangement is a fusion of the 5´ part of the runt-related transcription factor 1 (RUNX1, 
formerly known as AML1 or CBFA2) gene from 21q22 to 3´ sequences of the runt-related 
transcription factor 1, translocated to 1 (RUNX1T1, previously known as ETO) gene at 
chromosome 8q22 (Miyoshi et al., 1991; Erickson et al., 1992; Nisson et al., 1992; Miyoshi et 
al., 1993). Since RUNX1T1 is not expressed in hematopoietic cells, the putative reciprocal 
5´RUNX1T1-3´RUNX1 fusion transcripts have not been identified (Nucifora & Rowley, 1995). 
The RUNX1 gene encodes the alpha subunit of the heterodimeric core binding factor 
(CBF) complex which drives transcription of several hematopoietic lineage specific genes 
(Ogawa et al., 1993; reviewed in Downing, 1999). Differentiation arrest in t(8;21)-positive cells 
likely results from an impaired transcriptional activity of the RUNX1-RUNX1T1 hybrid protein at 
CBF sites within gene promoters (reviewed in Downing, 1999). Recently, corticosteroids and 
dihydrofolate reductase inhibitors have been shown to modulate the activity of the RUNX1-
RUNX1T1 fusion protein in vitro and to induce differentiation of RUNX1-RUNX1T1 positive cells 
whilst inhibiting cell proliferation, suggesting that those compounds may be useful as 
therapeutic agents for treating AML patients with t(8;21) in the future (Corsello et al., 2009). 
 
 
1.2.2. INVERSION (16)(p13q22)/TRANSLOCATION (16;16)(p13;q22) 
 
A pericentric inversion of chromosome 16, inv(16)(p13q22) or, less frequently, an 
alternative configuration in the form of a translocation between both homologues, 
t(16;16)(p13;q22), are characteristically associated to AML with bone marrow and peripheral 
blood eosinophilia (de la Chapelle & Lahtinen, 1983; Le Beau et al., 1983; Liu et al., 1995). As a 
result of either rearrangement, the core binding factor, beta subunit (CBFB) gene located at 
16q22 fuses to the myosin, heavy chain 11, smooth muscle (MYH11) gene at 16p13, giving rise 
to a CBFB-MYH11 fusion gene at 16q22 (Liu et al., 1993b; van der Reijden et al., 1993). The 
putative reciprocal MYH11-CBFB fusion transcript was not identified, either because of the 
existence of deletions adjacent to the 16p13 breakpoint in some inv(16)-positive patients or 
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because of a lack of activity of the MYH11 promoter in hematopoietic cells (reviewed in Liu et 
al., 1995). 
The CBFB gene codes for the non-DNA binding subunit of the CBF complex whereas 
MYH11 codes for a smooth muscle form of myosin heavy chain. As in the case of RUNX1-
RUNX1T1, the CBFB-MYH11 fusion protein acts by repressing gene transcription. A new 
heterodimerization domain generated at the junctional region of the protein moieties is 
capable of sequestering RUNX1 with much higher affinity compared with normal interaction 
between CBFB and RUNX1, thereby impairing its DNA-binding function (Huang et al., 2004). 
Furthermore, a repression domain encoded by the C-terminal region of MYH11 is capable of 
association with the mSin3A co-repressor, further contributing to transcriptional inactivation 
mediated by the CBFB-MYH11 chimeric protein (Durst et al., 2003). In view of the similarities 
between the mode of action of the CBFB-MYH11 and RUNX1-RUNX1T1 hybrid proteins, it is 
possible that corticosteroids or dihydrofolate reductase enzyme inhibitors may also be 
effective in inducing maturation of leukemic myeloid cells with CBFB-MYH11 rearrangement. 
 
 
1.2.3. TRANSLOCATION (15;17)(q22;q21) 
 
Rowley et al. (1977) initially proposed that a chromosomal insertion was responsible for 
the presence of chromosome 17 material at the long arm of chromosome 15 in a patient with 
acute promyelocytic leukemia (APL). However, subsequent reports of other APL patients 
clearly showed that the rearrangement involved a reciprocal translocation between 
chromosomes 15 and 17 instead of an insertion (Scheres et al., 1978; Testa et al., 1978). As a 
consequence of the t(15;17), a fusion occurs between the retinoic acid receptor, alpha (RARA) 
gene at chromosome 17q21 and the promyelocytic leukemia (PML) gene at chromosome 
15q22 (de Thé et al., 1990). The resultant fusion on the der(15) chromosome generates an in-
frame PML-RARA fusion transcript which can be detected in all patients with the translocation 
(de Thé et al., 1990; Kakizuka et al., 1991). In contrast, the reciprocal RARA-PML fusion gene on 
the der(17) chromosome is expressed in only 67-78% of the PML-RARA-positive APL patients 
(Alcalay et al., 1992; Borrow et al., 1992), thus reflecting its minor role as a critical 
leukemogenic lesion. 
The PML protein associates with subnuclear bodies which are involved in the regulation 
of transcription (reviewed in Zhong et al., 2000) whereas RARA belongs to the superfamily of 
vitamin D3, steroid and thyroid hormone nuclear receptors (Giguere et al., 1987; Petkovich et 
al., 1987; Evans, 1988). Both the wild-type RARA protein and the PML-RARA fusion protein can 
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bind to promoter response elements in the DNA sequences of target genes (reviewed in Lin et 
al., 2001). However, the transactivation potential of the PML-RARA hybrid protein is weaker 
than that of the native RARA protein (de Thé et al., 1991), indicating that repression of 
transcriptional activity is also responsible for a maturation arrest in APL. However, in contrast 
to AML patients with t(8;21) or inv(16), patients with t(15;17) can be successfully treated with 
arsenic trioxide or all-trans retinoic acid (ATRA) (Huang et al., 1988; Chen et al., 1996). For 
instance, the interaction between PML-RARA, co-repressors and histone deacetylases is lost 
under pharmacological concentrations of ATRA, thus allowing relaxation of the chromatin and 
restart of RARA target gene transcription, and ultimately leading to normal myeloid terminal 
maturation (Lin et al., 2001). 
 
 
1.3. GENERATION OF FUSION GENES BY ALTERNATIVE CHROMOSOMAL 
REARRANGEMENTS 
 
In a minority of newly-diagnosed leukemia patients, one or more extra chromosomes 
may also intervene in the rearrangement between the 2 chromosomes involved in the 
standard translocation, leading to the formation of complex chromosomal rearrangements. In 
other rare patients, gene fusion may also occur by mechanisms other than standard or 
complex translocations. In this section we will review alternative chromosomal 
rearrangements associated with CML and its pathognomonic BCR-ABL1 fusion as an example 
of the cytogenetic portfolio associated with the formation of fusion genes in leukemia. 
 
 
1.3.1. COMPLEX TRANSLOCATIONS 
 
It was early observed in some CML patients that rearrangement of chromosomes 9 and 
22 could also implicate rearrangements of additional chromosome bands without 
compromising the formation of the Philadelphia chromosome (Hayata et al., 1973; Gahrton et 
al., 1974; Hayata et al., 1975; Sonta & Sandberg, 1977; Pasquali et al., 1979; Sandberg, 1980). 
These alternative rearrangements were originally subdivided into separate cytogenetic classes 
designated as “complex” and “unusual” translocations (Sonta & Sandberg, 1977). An example 
of a complex translocation is illustrated in Fig. 2. This hypothetical rearrangement involves a 
breakpoint at 11q21 in addition to the recurrent breakpoints at bands 9q34 and 22q11. As in 
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the case of a standard t(9;22), the terminal region of the long arm of chromosome 9 containing 
the 3´ part of ABL1 is translocated to chromosome band 22q11 where it fuses to 5´ BCR. In 
turn, the 3´ BCR sequence along with the remaining region of the long arm of chromosome 22 
is translocated to chromosome band 11q21 whereas the translocated segment of 
chromosome 11q is joined to the 5´ ABL1 sequence at the 9q34 breakpoint. As expected, the 
reciprocal 5´ABL1-3´BCR fusion gene is not generated because the 3´ side of BCR is relocated to 
chromosome 11 instead of chromosome 9. 
 
A
B
ABL -
- BCR
chr. 9 chr. 22
- ABL-BCR
- BCR-ABL
der(9) der(22)
chr. 9 chr. 22 chr. 11 der(9)
- BCR-ABL
der(22) der(11)
- 5´ ABL
- 3´ BCR
Translocation
Translocation
 
 
Figure 2. Schematic representation of a standard t(9;22) and a complex t(9;22;11) in CML. 
(A) A standard t(9;22)(q34;q11) is formed as a result of breakpoints at chromosomes 9 (band 9q34) and 22 (band 
22q11) followed by rejoining of the partial segments of the long arm of each chromosome to the opposite partner. 
As a consequence, a BCR-ABL1 fusion gene is formed at the der(22), the Philadelphia chromosome, whereas a 
reciprocal ABL1-BCR hybrid gene is generated at the der(9). (B) In contrast to the standard translocation, a complex 
t(9;22;11)(q34;q11;q21) involves an extra breakpoint at band 11q21. In this single-step rearrangement, the terminal 
part of chromosome 9 joins the chromosome 22 to produce a BCR-ABL1 fusion gene. Simultaneously, the terminal 
part of chromosome 22 moves to the long arm of chromosome 11 whereas the translocated segment of this 
chromosome fuses to the 9q34 region. Consequently, no reciprocal ABL1-BCR fusion is produced. Dashed lines with 
arrows are used to indicate the movement of material between each of the chromosomes involved in the 
rearrangement. Vertical blue, red and orange lines correspond to chromosome 9, 22 and 11 sequences, 
respectively. Vertical arrows adjacent to the BCR and ABL1 genes indicate the direction of gene transcription. 
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In contrast to complex rearrangements, unusual or “variant” translocations referred to 
those cases in which only the Philadelphia chromosome and a rearranged chromosome other 
than the der(9), were detectable by conventional cytogenetic techniques (reviewed in Huret, 
1990). These observations initially suggested that the Philadelphia chromosome could be 
originated by a translocation involving band 22q11 and other genomic regions besides 
chromosome band 9q34. However, a comparative study of complex and variant translocations 
suggested that the differences observed between them derived mostly from the inability of 
chromosome banding techniques to distinguish between the translocated region of 
chromosome 9 and that of the extra chromosome involved in the translocation, because of 
their similar size and microscopic appearance (Pasquali et al., 1979). Indeed, it was 
subsequently demonstrated using higher resolution cytogenetic techniques such as reverse 
banding, or in situ hybridization (ISH), that in variant translocations a fusion had also occurred 
between the terminal part of chromosome 9q and the 22q11 region, or between the ABL1 and 
BCR genes (Hagemeijer et al., 1984; Bartram et al., 1985; Morris & Fitzgerald, 1987; Morris et 
al., 1988), indicating that these rearrangements are actually complex translocations in most if 
not in all patients (Fitzgerald & Morris, 1991). 
 
 
1.3.2. SUBMICROSCOPIC INSERTIONS 
 
A BCR rearrangement or juxtaposition between the BCR and ABL1 genes was initially 
demonstrated in some CML patients with a normal karyotype (Kurzrock et al., 1986; Fitzgerald 
et al., 1987; Ohyashiki et al., 1988). The formation of the BCR-ABL1 fusion gene in these 
“Philadelphia-negative” CML patients was shown to result mostly from submicroscopic 
insertions of the 3´ part of the ABL1 gene into BCR at 22q11, or of 5´ BCR into ABL1 at 9q34, 
without apparent reciprocal transfer of genetic material to the other chromosome (Morris et 
al., 1986; Dreazen et al., 1987; Rassool et al., 1990; Nishigaki et al., 1992; Hagemeijer et al., 
1993; Lazaridou et al., 1994; Nacheva et al., 1994; Abeliovich et al., 1995; Vieira et al., 1999). 
Similarly, submicroscopic insertions also explained the existence of RUNX1-RUNX1T1-positive 
or PML-RARA-positive AML cases without t(8;21) or t(15;17), respectively (Hiorns et al., 1994; 
Grimwade et al., 1997; Grimwade et al., 2000; Gamerdinger et al., 2003). 
In CML the BCR-ABL1 fusion gene can be detected in over 50% of Philadelphia-negative 
patients using fluorescence in situ hybridization (FISH) and/or molecular techniques (Melo, 
1997). Hematological parameters, clinical course and response to treatment of Philadelphia-
negative BCR-ABL1-positive patients are similar to those observed in patients presenting with 
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the Philadelphia chromosome (van der Plas et al., 1991). In this context, the designation 
“Philadelphia-negative CML” should be eliminated to avoid misinterpretation with rare 
patients whose disease is otherwise clinically and hematologically classified as CML but who do 
not present the BCR-ABL1 fusion gene (Melo, 1997). The same notion should be applied to 
AML patients lacking the presence of t(8;21), inv(16)/t(16;16) or t(15;17) who show the 
presence of the correspondent fusion gene counterpart. 
 
 
1.4. BIOLOGICAL CHARACTERISTICS OF COMPLEX TRANSLOCATIONS 
 
The existence of complex translocations raises some questions concerning their 
biological characteristics: (i) What is the frequency of complex translocations among leukemia 
patients? (ii) Do complex translocations grant any modification of disease characteristics 
compared to the counterpart standard translocation? (iii) Are extra breakpoints evenly 
distributed throughout the genome or is there any clustering? (iv) Do complex translocations 
succeed to a single breakage and joining event as in the case of standard translocations or do 
they occur by consecutive events? And (iv) the molecular features mediating inter-
chromosomal recombination in complex translocations are also shared by their 2-way 
equivalents? Again, we will use CML and AML as model disorders for answering these 
questions. These examples have been chosen due to the high number of available literature 
reports and not because of an intention to indicate the existence of a particular pattern of 
karyotypic variability that distinguishes CML or AML from other types of hematopoietic 
neoplasms. 
 
 
1.4.1. INCIDENCE IN CHRONIC MYELOID LEUKEMIA AND ACUTE MYELOID LEUKEMIA  
 
De Braekeleer (1987) calculated, on the basis of a retrospective analysis of 4061 patients 
for whom cytogenetic data was available, that the overall proportion of CML cases with a 
complex translocation was 4.3%. The author also noticed that the percentage of patients with 
a complex translocation varied according to the geographic origin of the patient. As an 
example, complex translocations comprised 9.01% of United Kingdom patients whereas the 
corresponding percentage in Italy was only 3.62% (De Braekeleer, 1987). To overcome the risks 
of literature bias, Fisher et al. (2005) conducted a retrospective analysis of an independent 
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series of patients belonging to the Wessex Regional Genetics Laboratory in England. The 
authors observed that 9.3% of the 428 registered CML cases showed a complex translocation, 
which is in close agreement with data from De Braekeleer (1987). Representative examples of 
the proportion of complex translocations observed in various countries are shown in Table I 
for comparison. 
 
 
Table I. Proportion of complex translocations among Philadelphia-positive CML patients originating from 
different countries. 
Total number of 
Ph-positive cases 
Number of cases with 
complex translocations 
Percentage Geographic origin Reference 
119 (a) 20 (b)
 
16.8% United Kingdom Potter et al. (1981) 
103 3 2.9% Japan Oshimura et al. (1982) 
180 14 7.8% South Africa Bernstein et al. (1984) 
126 (c) 18 14.0% United States Przepiorka &Thomas (1988) 
105 6 5.7% Italy Zaccaria et al. (1989) 
166 7 4.2% Germany Hild & Fonatsch (1990) 
111 8 7.2% France Morel et al. (2003) 
Only series exceeding 100 patients are presented. Results are listed in chronological order. (a) Includes 16 patients studied after 
disease transformation; (b) includes 2 cases presenting with del(22)(q11); (c) karyotype analysis was performed in the accelerated 
or blastic crisis phase of disease. 
 
 
Similarly to the t(9;22), the incidence of complex rearrangements of t(8;21) in AML 
patients also appears to differ according to the country of origin. As an example, a study on 
French, Belgian and German patients with t(8;21) reported that complex rearrangements 
involving one or more extra chromosome bands in addition to 8q22 and 21q22 were found in 
3.4% of cases whereas the corresponding percentage among Japanese and North-american 
patients was of 15.2% and 8.6%, respectively (Groupe Français de Cytogénétique 
Hématologique, 1990; Maseki et al., 1993; Gallego et al., 1994). Moreover, Fisher et al. (2005) 
determined that 6.3% of t(8;21)-positive cases registered at the United Kingdom Cancer 
Cytogenetics Group (UKCCG) karyotype database in acute leukemia presented the 
translocation in a complex configuration. 
Complex rearrangements of t(15;17) are apparently less frequent than those of t(9;22) 
or t(8;21). A retrospective review study of PML-RARA-positive European APL cases lacking the 
archetypal t(15;17) estimated that the proportion of patients with complex translocations is of 
approximately 2% (Grimwade et al., 2000). In agreement with these data, Fisher et al. (2005) 
identified 2.6% of patients with complex translocations among APL cases with rearrangements 
of chromosomes 15q22 and 17q21 registered at the UKCCG database. In the case of 
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inv(16)/t(16;16) the presence of complex rearrangements is also well documented. However, 
assessment of the corresponding proportion has not been estimated because of the very low 
number of reported cases (reviewed in Martinez-Climent et al., 1999; Li et al., 2001; Ohsaka et 
al., 2008). This may in part be related to the fact that inv(16) is present in a lower proportion 
(6%) of AML patients compared to those presenting with either t(15;17) (14%) or t(8;21) (18%) 
(reviewed in Rowley, 2001). 
 
  
1.4.2. RELEVANCE FOR PATHOGENESIS 
 
Following a review of over 400 CML patients with complex translocations described in 
the literature, Mitelman (1993) ascertained that all chromosomes except the Y chromosome 
had already been reported as translocation partners of chromosomes 9 and 22. Although some 
degree of breakpoint clustering was noticeable, the majority of breakpoint locations differed 
widely among patients (Mitelman, 1993), underscoring the notion that those additional 
genomic lesions do not induce important biological changes in BCR-ABL1-positive CML cells. 
This view is also supported by various clinical-cytogenetic studies which have demonstrated 
that clinical features, hematologic parameters, prognosis and/or survival did not differ 
between patients presenting with a standard t(9;22) or with a complex rearrangement (Hayata 
et al., 1975; Sonta & Sandberg, 1977; Sandberg, 1980; De Braekeleer, 1987). 
However, not all studies reached the same conclusions. In one of the first reports 
covering a large series of patients, Potter et al. (1981) determined that the duration of the 
chronic phase of the disease was significantly shorter for patients younger than 60 years-old 
who presented with non-standard rearrangements than for those who did not. In agreement 
with these data, individual CML and AML cases with complex translocations have been 
associated with an aggressive disease phenotype and/or a diminished survival (Martin et al., 
1997; De Weer et al., 2008). 
One possible explanation for the contradictory data may be related to the specific 
chromosomal regions which are targeted by additional breakpoints. According to the 
hypothesis put forward by O´Brien et al. (1997), it is possible that the similar overall survival 
between patients with complex translocations and those with a standard t(9;22) results from 
the inclusion of patients with different complex abnormalities in the same group, where some 
aberrations confer a worse prognosis and others do not, and therefore compensate each other 
on the whole. 
 
  
14 
1.4.3. GENOME DISTRIBUTION OF ADDITIONAL BREAKPOINT LOCATIONS 
 
At least 50 AML patients with 3-way (Lindgren & Rowley, 1977; Kondo et al., 1978; 
Fitzgerald et al., 1983; Oguma et al., 1983; Slater et al., 1983; Ayraud et al., 1985; Testa et al., 
1985; Tagushi et al., 1986; Berger et al., 1987; Minamihisamatsu & Ishihara, 1988; Uchida et 
al., 1988; Groupe Français de Cytogénetique Hématologique, 1990; Hurwitz et al., 1992; 
Sundareshan et al., 1992; Downing et al., 1993; Maseki et al., 1993; Gallego et al., 1994; Starza 
et al., 1997; Wong et al., 1998; Harrison et al., 1999; Shinagawa et al., 1999; Xue et al., 2001; 
Ishida et al., 2002; Miyagi et al., 2002; Gamerdinger et al., 2003; Mathew et al., 2003; Farra et 
al., 2004; Ahmad et al., 2008; Kawakami et al., 2008; Udayakumar et al., 2008; Vundinti et al., 
2008; Tirado et al., 2009) or 4-way complex (de Greef et al., 1995; Vieira et al., 2001) 
rearrangements of t(8;21) have been reported between 1977 and 2009. Complex 
translocations in these patients have been shown to involve additional breakpoints at all 
chromosomes except chromosomes 21, 22 and Y (Table II). The most frequently involved 
included chromosomes 1 and 17 (8 breakpoints each), chromosome 15 (5 breakpoints), 
chromosome 12 (4 breakpoints) and chromosome 11 (3 breakpoints). Among a total of 40 
different breakpoint locations, nine were involved at least twice. These included bands 17q23 
(4 cases), 1p36 (3 cases) and 1q23, 5q31, 8p23, 11p15, 12q13, 15q21 and 20q13 (2 cases each). 
Notably, bands 1p36 and 17q23 comprise altogether 18% of all alternative breakpoint 
locations in our review of AML patients with complex rearrangements of t(8;21).  
To our knowledge, 3-way or 4-way complex rearrangements of t(15;17) have been 
reported in at least 26 AML patients between 1980 and 2000 (Bernstein et al., 1980; Misawa et 
al., 1986; Berger et al., 1987; Bjerrum et al., 1987; Huret et al., 1987; Osella et al., 1991; Chen 
et al., 1994; McKinney et al., 1994; Calabrese et al., 1996; Galieni et al., 1996; Grimwade et al., 
1996; Saitoh et al., 1998; Yamamoto et al., 1998; Wan et al., 1999; Grimwade et al., 2000). 
Among 14 different extra chromosomes involved in complex translocations, eight were 
implicated at least twice including chromosome 2 (4 cases), chromosomes 1, 3 and 5 (3 cases 
each), and chromosomes 4, 11 and 19 (2 cases each). Among a total of 23 different breakpoint 
locations, bands 3p21, 4q21, 11q13 and 19p13 were reported in 2 cases each. 
Between 1983 and 2008 3-way complex rearrangements of inv(16)/t(16;16) have been 
reported in 12 AML patients at least (de la Chapelle & Lahtinen, 1983; Bhambhani et al., 1986; 
Bernard et al., 1989; Thompson et al., 1991; Yip et al., 1991; Berger et al., 1993; Dierlamm et 
al., 1998; Martinez-Climent et al., 1999; Li et al., 2001; Ohsaka et al., 2008), comprising a total 
of 11 different additional breakpoint locations. Interestingly, involvement of chromosomes 1 
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or 3 was found in 3 patients each, embracing half of all reported cases. Only one chromosomal 
band, 1p32, was a target of rearrangement in 2 patients. 
In contrast to the examples described above, and as previously mentioned, hundreds of 
complex rearrangements of t(9;22) have been reported in the literature (De Braekeleer, 1987; 
Mitelman, 1993; Fisher et al., 2005). In a review of complex translocations in CML patients, De 
Braekeleer (1987) initially showed that a total of 28 chromosome bands were statistically over-
represented (P<0.001) among 117 different breakpoint locations reported in the literature. 
The top 9 breakpoint hotspots included bands 2q11, 3p21, 6p21, 11q13, 12p13, 14q32, 17p13, 
17q12 and 17q25 (De Braekeleer, 1987). A non-random occurence of breaks at these and other 
regions was also observed at the chromosome abnormality database (CAD) of the United 
Kingdom (Fisher et al., 2005), indicating that the classification of breakpoint hotspots was not 
influenced by literature bias. The number of observed breaks for bands 11q13, 14q32 and 
17q1, for example, was calculated as 4-5 times higher than expected if breakpoints occurred 
randomly in the genome (Fisher et al., 2005). Moreover, the location of breakpoint hotspots 
determined at the CAD was also found to coincide largely with the genome distribution of 
cytosine-guanine (CG)-rich regions (Fisher et al., 2005). These CG-rich regions of genomic DNA 
are particularly found at CpG islands located within promoter regions of genes, within genes 
themselfes as well as at repetitive sequences such as the Alu (see section 1.4.6.). 
Taken together, available cytogenetic data in CML and AML patients with complex 
translocations suggests that additional breakpoints are not randomly distributed in the 
genome. This evidence highlights the possibility that alterations at other genomic regions in 
addition to the recurrent breakpoint locations could also be of importance in tumour 
development. 
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Table II. Summary of chromosome bands involved in 3- or 4-way complex rearrangements of t(8;21), t(15;17) and 
inv(16) reported in the literature. 
Chromosome arm t(8;21) t(15;17) inv(16) 
1p 1p36 (3); 1p13; 1p35 1p32; 1p36 1p32 (2) 
1q 1q23 (2); 1q32 1q23 1q32 
2p 2p25 2p24; 2p21 - 
2q 2q* 2q21; 2q2?1 - 
3p - 3p21 (2); 3p12 - 
3q 3q27 - 3q21; 3q22;3q26 
4q 4q35 4q21 (2) - 
5q 5q31 (2) 5q13; 5q14; 5q35 5q33 
6p 6p21 6p21 - 
6q 6q21 - - 
7p - 7p22 - 
7q 7q32 7q22 - 
8p 8p23 (2) - - 
8q - 8q22 8q24 
9p - - 9p23 
9q 9q34 - - 
10p 10p15 - - 
11p 11p15 (2); 11p13 - - 
11q - 11q13 (2) 11q14 
12p 12p12-13; 12p13 - - 
12q 12q13 (2) - 12q24 
13p - 13p13 - 
13q 13q12; 13q14 - - 
14q 14q11; 14q24 - - 
15q 15q21 (2); 15q15; 15q?21q?26; 15q26 - - 
16q 16q* - - 
17p 17p23; 17p13; 17p11 - - 
17q 17q23 (4); 17q21 - - 
18q 18q23 - 18q12 
19p 19p13 19p13 (2) - 
19q 19q13 - - 
20p - 20p13 - 
20q 20q13 (2) - - 
21q - 21q22 - 
Xp Xp22 - - 
Xq - Xq13 - 
This review excludes cases with more complex chromosome rearrangements involving translocations in association with deletions 
or insertions. The total number of breakpoints does not tally with the number of patients with complex rearrangements of t(8;21) 
and t(15;17) because some of these rearrangements involve more than one additional breakpoint location. Breakpoints are 
grouped according to chromosome arm. Numbers in parenthesis indicate number of cases with involvement of a particular 
chromosome band; *, unspecified breakpoint location. 
 
 
1.4.4. STEPWISE FORMATION OF TRANSLOCATIONS 
 
The simultaneous identification of at least 2 abnormal cellular clones in the same CML 
patient, one presenting with a t(9;22) and the other(s) showing a complex rearrangement of 
the standard translocation, was initially considered as clear-cut evidence that complex 
translocations arised through sequential events (Lessard & Le Prisé, 1982; Hogge et al., 1984; 
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Pederson, 1984). However, in the vast majority of cases with a complex rearrangement only a 
single abnormal clone is detected by cytogenetic analysis. In these cases, it is not certain that a 
complex translocation may have resulted from a secondary rearrangement which followed the 
formation of the t(9;22). The easiest technical way to demonstrate that a stepwise 
rearrangement had occurred is by means of the identification of reminiscent material from 
chromosome 22 on the der(9) chromosome, thus reflecting the ocurrence of a secondary 9q 
breakpoint telomeric to the one involved in t(9;22) (Fig. 3). In this situation, the integrity of the 
reciprocal ABL1-BCR fusion gene is not likely to be affected by the secondary translocation. 
 
 
chr. 11
- ABL1-BCR
- BCR-ABL1
der(9)der(22) der(9)
- BCR-ABL1
der(22) der(11)
- ABL1-BCR
- 3´ BCR
chr. 9 chr. 22
Initial
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Secondary
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Figure 3. Formation of a complex translocation by stepwise rearrangements involving chromosomes 9, 22 and 11. 
In this hypothetical example a complex translocation is generated following the formation of a secondary 
translocation between the der(9) chromosome which resulted from a t(9;22) and an additional chromosome (e.g., 
chromosome 11). Because the 9q breakpoint occurs at a position telomeric to the original breakpoint in the ABL1 
gene, material derived from chromosome 22 is detectable on the der(9) chromosome in addition to chromosome 
11. In contrast to the single-step rearrangement which lacks an ABL1-BCR hybrid gene, the integrity of the fusion 
gene during a stepwise rearrangement is likely to be maintained. Dashed lines with arrows indicate the exchange of 
material between chromosomes at each of the corresponding breakpoints. The blue, red and orange vertical lines 
represent chromosome 9, 22 and 11 sequences, respectively. 
 
 
The introduction of isotopic ISH and, later, of FISH as technical adjuncts to conventional 
cytogenetics, has tremendously improved the analysis and interpretation of the mechanisms 
of translocation at a single cell level. Initial studies used radioactive-labeled probes for BCR and 
the platelet-derived growth factor beta polypeptide (PDGFB) gene, which lies distally to BCR at 
chromosome band 22q13.1, to identify the presence of chromosome 22 sequences on the 
der(9) chromosome (Ohyashiki et al., 1987; Abe et al., 1989; Zaccaria et al., 1989; Calabrese et 
al., 1992). Using whole chromosome painting (WCP) fluorescent probes for chromosomes 9 
and 22 as an alternative approach, Calabrese et al. (1994) later demonstrated that complex 
translocations in 9 out of 10 CML patients investigated resulted from a secondary translocation 
which occurred after the appearance of the t(9;22). Moreover, using BCR- and ABL1-gene 
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specific fluorescent probes (Arnoldus et al., 1990; Tkachuk et al., 1990; Dewald et al., 1993), it 
was shown that stepwise rearrangements were also potentially involved in the generation of 
BCR-ABL1-positive CML cases with an apparently normal karyotype (Morris et al., 1990; Morris 
et al., 1991). However, is the observation of chromosome 22 material on the der(9) 
chromosome sufficient evidence to prove the existence of sequential translocations? 
Fitzgerald & Morris (1991) proposed that a single breakage and reunion event could 
explain that in some complex translocations material from chromosome 22 is observed on 
both the der(9) chromosome and the additional chromosome involved in the translocation. 
This “concerted genomic rearrangement” illustrates how 4 or more breakpoints occurring 
simultaneously, including 2 breakpoints at the 22q11 region, may generate a 3-way complex 
translocation by incorrect rejoining of the broken ends (Fitzgerald & Morris, 1991). The same 
model can explain the occurrence of submicroscopic insertions of 3´ ABL1 sequences into 
chromosome 22 in CML patients with a normal karyotype as an alternative to 2 consecutive 
translocations (Morris et al., 1990; Fitzgerald & Morris, 1991). A significant advantage of the 
“concerted genomic rearrangement” model is that it avoids the need for a chromosomal 
damaging agent to target the same chromosome 22 region twice on different occasions, as 
required by the alternative stepwise model of formation of complex translocations. 
 
 
1.4.5. BREAKPOINT-ADJACENT DELETIONS 
 
The consequences of a standard reciprocal translocation in a leukemic cell may extend 
far more than the formation of fusion genes. In CML for instance, approximately 10-15% of 
patients with a standard t(9;22) display large genomic deletions on the der(9) chromosome 
which encompass the ABL1/BCR junction and that may extend centromeric or telomeric to the 
ABL1 breakpoint (Sinclair et al., 2000; Lee et al., 2006; Kreil et al., 2007). In these patients, 
deletions are present in all metaphase cells with a t(9;22) and are equally frequent at diagnosis 
and following disease progression (Huntly et al., 2001). These observations strongly suggest 
that deletions occur at the time of generation of the t(9;22) (Huntly et al., 2001) and are, 
therefore, a relevant feature of the CML clone during the chronic phase of the disease. 
An immediate consequence of deletions at the der(9) chromosome is the loss of ABL1-
BCR fusion gene expression (Huntly et al., 2002). However, lack of ABL1-BCR expression was 
also demonstrated in CML patients without genomic deletions, indicating that transcription of 
the fusion gene may be regulated by other mechanisms (Huntly et al., 2002). Consistent with 
these observations, the loss of ABL1-BCR expression was not found to be associated with a 
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poorer patient prognosis (Huntly et al., 2002). In contrast, the presence of the deletion itself 
severely affected the survival of patients comparatively to those without deletions (Sinclair et 
al., 2000; Huntly et al., 2001; Huntly et al., 2002; Lee et al., 2003; Lee et al., 2006). 
Furthermore, the prognostic significance of the deletion was also shown to be independent of 
the age, sex, percentage of peripheral blood blasts and platelet count (Sinclair et al., 2000), 
indicating that it constitutes a strong prognostic factor in t(9;22)-positive CML. Taken together, 
these data is consistent with a model of disease in which rapid progression may be due to loss 
of one or more critical genes mapping along the deleted regions at the der(9) chromosome. 
Ultimately, this model may be adapted to every malignancy associated with a recurrent 
reciprocal chromosomal rearrangement and/or fusion gene formation, thus providing a 
biological basis for disease heterogeneity (Huntly et al., 2003). 
Deletions at the der(9) chromosome have been found to occur more frequently in CML 
patients with complex rearrangements than in those with a classic translocation (Sinclair et al., 
2000). In a study of 253 CML patients, deletions were present in 39% of cases with complex 
translocations as compared to only 12% of those with the standard t(9;22) (Huntly et al., 
2001). Moreover, genomic deletions have also been observed at the extra breakpoint locations 
involved in complex rearrangements (Albano et al., 2003), therefore increasing the complexity 
of molecular defects associated with complex translocations. FISH mapping has been used as 
an attempt to identify potential disease-related genes lying within the deleted regions (Albano 
et al., 2003; Anelli et al., 2004). As an example, the tumour necrosis factor receptor 
superfamily member 21 (TNFRSF21) gene was included in the deleted region at 6p12 in one 
CML patient presenting with a complex t(6;9;22)(p12;q34;q11) (Albano et al., 2003). TNFRSF21 
is a member of a subgroup of the tumor necrosis factor receptor superfamily known as the 
death receptors. These receptors are characterized by the presence of a cytoplasmic domain 
(death domain) which triggers apoptosis when stimulated by a cognate ligand. In mammalian 
cells ectopic expression of TNFRSF21 stimulates apoptosis (Pan et al., 1998). In this context, it 
is possible that haplo-insufficiency of TNFRSF21 may reduce its apoptotic effect, thus 
contributing to increased survival of BCR-ABL1-positive cells.  
The breakpoint positions of the interstitial deletions detected at the der(9) breakpoint in 
t(9;22)-positive cells are highly heterogeneous in different patients (Sinclair et al., 2000). The 
consequence of this phenomenon is that deletions may vary extensively in length and 
eliminate different sets of genes located at the long arm of chromosome 9. Whether a single 
gene or 2 or more genes contribute to the overall worse prognosis conferred by deletions in 
CML patients remains to be solved. A similar scenario may also apply to the Philadelphia-
negative chronic myeloproliferative neoplasms (MPN) characterized cytogenetically by the 
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presence of interstitial deletions of the long arm of chromosome 20 [del(20q)]. Among MPN 
patients a del(20q) has been found to occur in 8.4% of polycythemia vera (PV), 7.1% of primary 
myelofibrosis (PMF) and 0.2% of essential thrombocythemia (ET) patients at diagnosis or 
during the course of the disease (Bench et al., 1998a). Deletions typically extend from band 
20q11.2 to band 20q13.1 (small deletions) or from band 20q11.2 to band 20q13.3 (large 
deletions), respectively (Nacheva et al., 1995). As in the case of CML patients with der(9) 
deletions, the locations of the centromeric and telomeric breakpoints of the del(20q) are 
highly heterogeneous in different MPN patients (reviewed in Bench et al., 2001). 
Several studies attempted to define the smallest common deleted segment (CDS) in 
different patients with myeloid disorders and del(20q), using southern blot complemented 
with restriction fragment length polymorphism analysis (Hollings, 1994), FISH and/or 
polymerase chain reaction (PCR) analysis of microsatellite markers (Roulston et al., 1993; 
Asimakopoulos et al., 1994; Bench et al., 1998b; Wang et al., 1998a; Bench et al., 2000; Wang 
et al., 2000; MacGrogan et al., 2001; Douet-Gilbert et al., 2008), real-time quantitative PCR (Q-
PCR) (Schaub et al., 2009) and genome-wide high-resolution single nucleotide polymorphism 
(SNP) array analysis (Huh et al., 2010). Until recently a 2.7 megabase (Mb) CDS at 20q11.2-q13 
prevailed as the smallest single common region of deletion in MPN patients with del(20q) 
(Bench et al., 2000). A candidate imprinted gene located within the CDS and expressed in 
CD34+ cells, L3MBTL, was identified and found not to be mutated in MPN patients with or 
without a del(20q) (Li et al., 2004). A more recent study has shown that a second CDS spanning 
1.8 Mb at 20q13.12 can also be defined in patients with different myeloid disorders and a 
del(20q) (Huh et al., 2010). However, no candidate gene in this region has yet been identified. 
Altogether, available data suggest that the notion of a common deleted region as a site which 
contains a putative tumour suppressor gene may not apply to the recurrent del(20q) in MPN 
patients. 
In MPN patients the occurrence of a del(20q) was found to be significantly associated 
with the presence of a somatic activating mutation in the Janus kinase 2 (JAK2) gene located at 
chromosome 9p24, JAK2V617F (Baxter et al., 2005; James et al., 2005; Jones et al., 2005; 
Kralovics et al., 2005), indicating that these genetic alterations are likely to cooperate in MPN 
pathogenesis (Campbell et al., 2006). JAK2 is a cytoplasmic tyrosine kinase protein which 
associates with the intracytoplasmic portion of several membrane cytokine receptors including 
those for erythropoietin, thrombopoietin, interleukin-3 or granulocyte macrophage-colony 
stimulating factor (GM-CSF) (Parganas et al., 1998). These receptors as well as those for 
interleukin-5, prolactin, leptin and growth hormone signal exclusively through JAK2 to promote 
hematopoietic cell development and proliferation (reviewed in Murray, 2007). Ligand-receptor 
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coupling leads to JAK2 phosphorylation, which in turn phosphorylates back the receptor and 
activates various downstream signaling pathways involved in cell proliferation and survival 
(reviewed in Delhommeau et al., 2006). 
The JAK2V617F mutation confers constitutive activity of the tyrosine kinase domain of 
JAK2 in a cytokine-independent or hypersensitive way (James et al., 2005). Hypersensitivity to 
cytokines suggests that physiological mechanisms of cytokine production and regulation in 
clonal MPN cells may also be affected. For instance, up-regulation of serum levels of colony 
stimulating factor-1 has been found in patients with classic MPN (Gilbert et al., 1989) whereas 
overproduction of interleukin-8 and interleukin-11 was found in PV patients (Hermouet et al., 
2002). Moreover, plasma levels of tissue inhibitor of metalloproteinase, macrophage 
inflammatory protein-1β and insulin-like growth factor binding factor-2 are elevated in PMF 
patients (Ho et al., 2007). However, the mechanisms involved and the protein factors 
responsible for their up-regulation remain to be determined. 
 
 
1.4.6. MOLECULAR MECHANISMS OF CHROMOSOMAL REARRANGEMENT 
 
The breakage and reunion of chromosome segments through translocation or other 
mechanisms have had a major role in the shaping of the eukaryote genome during evolution 
(Kazazian, 2004). In humans such processes have been largely mediated by a class of mobile 
DNA sequences called non-long terminal repeat (LTR) retrotransposons. These DNA sequences 
have the capability to integrate into new locations within the genome following transcription 
to RNA and subsequent reverse transcription to DNA (Kazazian, 2004). One common type of 
non-LTR retrotransposon is the Alu element which constitutes roughly 11% of the human 
genome sequence (Kazazian, 2004). Interestingly, it was earlier determined that either the BCR 
or the ABL1 gene have an approximately 39% homology to Alu sequences (Chissoe et al., 
1995), suggesting that these DNA elements might be implicated in the recombination 
mechanism between chromosomes 9 and 22. This hypothesis had obtained previous support 
from a study of a CML patient in which Alu sequences were found to overlap the breakpoints 
at both genes (de Klein et al., 1986). However, in later studies comprising a total of 23 patients, 
no significant clustering of breakpoints at Alu sequences was observed in ABL1 and/or in BCR 
(Sowerby et al., 1993; Chissoe et al., 1995; Zhang et al., 1995). In acute leukemias Alu 
sequences were found to be present at the breakpoints of chromosomal rearrangements 
involving the myeloid/lymphoid or mixed-lineage leukemia (MLL) gene at chromosome band 
11q23 (Megonigal et al., 1997). 
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If complex translocations arise preferentially through a single concerted breakage and 
reunion mechanism as proposed by Fitzgerald & Morris (1991), and if Alu sequences may be 
found at the breakpoints of the ABL1 and BCR genes, then these specific DNA sequences are 
also likely to be present at the breakpoint location on the additional chromosome(s) involved 
in the translocation. In this context, a chromosome 11 breakpoint was analyzed in 2 different 
CML patients presenting with a complex t(9;22;11)(q34;q11;q13). Although breakpoints in 
both patients were located 100-250 kilobases (kb) apart within band 11q13, Alu sequences 
were found in very close proximity to the breakpoints in each case (Koduru et al., 1993; Morris 
et al., 1996). Involvement of Alu sequences in complex rearrangements was further stressed in 
2 other CML patients in whom an Alu element mapped near or at the breakpoint site directly 
in the partner chromosome sequence fused to 3´ BCR (Jeffs et al., 1998). In an additional 
patient with an extra rearrangement of band 22q11.2, the breakpoint was found to occur at 
the immunoglobulin lambda locus (IGL@) gene (Benjes et al., 1999). However, it was not 
possible to identify potential recombination sequences recurrently involved in the somatic 
rearrangement of immunoglobulin genes in lymphoid cells, at the breakpoint regions of IGL@ 
or of 3´ BCR (Benjes et al., 1999). 
More recent bioinformatics data showed that Alu sequences are significantly under-
represented within the 5 kb major breakpoint region of BCR and within a common 25 kb 
breakpoint region of ABL1 (Jeffs et al., 2001). In turn, several different types of interspersed 
repeat elements are present at a higher frequency than expected at the junction sequences of 
both genes (Mattarucchi et al., 2008). However, no specific type of DNA repeat sequence was 
yet found to be recurrently present at breakpoint positions within BCR or ABL1. Taken 
together, the presence of similar sequence features such as Alu(s) at the 9q34 and 22q11 
breakpoints, as well as at the extra breakpoints implicated in complex translocations, raises 
the possibility that a common pathogenetic mechanism underlies the formation of both 
standard and complex rearrangements. In this setting it can be anticipated that additional 
breakpoints may also target genes whose disruption contributes to transformation of 
hematopoietic cells. 
 
 
1.5. THE NEUTRAL VERSUS THE ALTERNATIVE HYPOTHESIS 
 
A putative pathogenetic role of the additional breakpoints involved in complex 
translocations can be addressed at least by 2 opposing views, herein tentatively classified as 
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the “neutral hypothesis” and the “alternative hypothesis”. The neutral hypothesis supports the 
notion that extra breakpoints play no part in disease development, in addition to the role 
provided by the recurrent breakpoints of the standard translocation. This hypothesis stems 
from the observation that the nature of the extra chromosomes involved in complex 
rearrangements, as well as the localization of their respective breakpoints, is highly 
heterogeneous (Mitelman, 1993). In other words, no recognizable pattern of complex 
chromosome rearrangement exists that can be considered pathognomonic. Consequently, it is 
unlikely that physical disruption of genes located at such a variety of chromosome locations, or 
changes in their expression levels, may be equally relevant in the natural history of disease. 
In contrast, the alternative hypothesis proposes that extra breakpoints may provide a 
further biological advantage to leukemic cells by affecting genes important for normal cell 
growth and differentiation. This hypothesis is supported by 2 lines of evidence obtained from 
the analysis of complex chromosome translocations in CML. First, the location of extra 
breakpoints is not randomly distributed throughout the genome (De Braekeleer, 1987). 
Secondly, as previously mentioned, the location of extra breakpoints largely coincides with the 
genome distribution of CG-rich regions (Fisher et al., 2005), suggesting that additional 
breakpoints may target specific genes. Data supporting the alternative hypothesis was 
provided by the recent molecular characterization of breakpoints of a 4-way translocation 
involving extra breaks at chromosomes 3 and 17 in a CML patient at blast crisis. In this case, 
sequences from chromosome 17 juxtaposed to the 5´ side of the EVI1 oncogene at 
chromosome band 3q26 resulting in an increase in the expression levels of this gene (De Weer 
et al., 2008). This case shows compelling evidence that complex translocations in CML may 
simultaneously target tumour-related genes in addition to the BCR and ABL1 genes.  
The alternative hypothesis constituted the basis for the present dissertation. Although 
abundant studies have been made available in the literature which describes the presence of 
complex chromosomal translocations in leukemia, only a few cases have been studied in the 
light of the involvement of the extra chromosomal regions (Koduru et al., 1993; Morris et al., 
1996; Jeffs et al., 1998; De Weer et al., 2008). This is mostly due to the fact that the mapping 
and cloning of additional breakpoint locations is time-consuming and requires the use of 
several different techniques. As a consequence, a significant lack of experimental data exists to 
support the notion that additional breakpoints in complex translocations target important 
genes for maintenance of normal cell homeostasis. In summary, evidence obtained from 
detailed molecular analysis of breakpoints in complex translocations may aid in the 
identification of potential novel tumour-associated genes. 
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The primary aim of this work was to address the contributing role of genes located at 
extra breakpoints of complex chromosome translocations for the pathogenesis of 
hematopoietic neoplasms. According to this main goal, five secondary objectives were 
proposed: 
(i) To localize and describe the genes located at the breakpoint regions involved in the 
chromosomal rearrangements of 5 patients with hematopoietic neoplasms, 
including: 
-  A t(5;12)(q13;p13) in B-cell acute lymphoblastic leukemia (ALL); 
- A t(12;15)(p13;q22) in myelodysplastic syndrome/myeloproliferative neoplasm, 
unclassifiable (MDS/MPN, U); 
- A dic(9;12)(p11;p11) in B-cell ALL; 
- A t(9;11;19)(p22;q23;p13) in AML; 
- A  t(X;20)(p11;q13) in ET; 
(ii) To detect putative fusion genes and characterize hybrid transcripts involved in 
complex translocations; 
(iii) To perform mutational analysis of candidate genes located at the breakpoint 
regions; 
(iv) To determine the expression profile of novel potentially pathogenic genes in normal 
and leukemic cells; 
(v) To assess a role of the protein product of these genes in in vitro cell proliferation 
and/or survival assays. 
 
A similar methodological approach was conducted in the 5 cases. Initially, adequate DNA 
probes for mapping of chromosome breakpoints were selected from available databases and 
labeled with fluorophores for FISH analysis. The localization of novel breakpoint regions was 
performed by “chromosome-walking”. In 2 cases, detailed localization of breakpoint regions 
was performed by long distance inverse-polymerase chain reaction (LDI-PCR) or by PCR 
analysis of polymorphic markers complemented with a whole-genome array study, 
respectively. 
Putative fusion transcripts generated by chromosomal translocations were identified 
using different technical approaches based on reverse transcription-polymerase chain reaction 
(RT-PCR) and characterized by sequencing analysis. In addition, candidate genes at breakpoint 
regions were analyzed using PCR and direct sequencing for the presence of nucleotide 
mutations. 
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The expression profile of 2 genes located at newly-identified breakpoint positions was 
studied by RT-PCR in normal cells and/or in leukemic cell lines originating from different 
hematopoietic lineages. Finally, the role of these disease-candidate genes in proliferation, 
apoptosis or transcription regulation was evaluated using cell line models in vitro. To these 
purposes, we suppressed the transcripts of interest using RNA interference and/or inactivated 
the protein function with a specific inhibitory drug. In one case we also ectopically expressed 
the protein of interest in cell line cultures. At the end, a comprehensive approach was utilized 
to relate molecular changes at each of the breakpoint locations with a differential role of 
complex translocations in leukemogenesis. 
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3.1. MOLECULAR CYTOGENETIC CHARACTERIZATION OF 
REARRANGEMENTS INVOLVING 12p IN LEUKEMIA 
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3.1.1. ABSTRACT 
 
Translocations involving the short arm of chromosome 12 are frequent events among 
patients with various hematological malignancies. In approximately half of the patients, FISH 
analysis has shown that the breakpoints are clustered within the Ets variant 6 (ETV6, also 
known as TEL) gene at 12p13, leading to its fusion with a variety of partner genes on different 
chromosomes. The remaining patients have breakpoints centromeric or telomeric to ETV6 or, 
less frequently, interstitial 12p13 deletions, which invariably involve this gene. In most cases 
reported, 12p translocations were found associated with other structural and/or numerical 
abnormalities as part of a complex karyotype. Initially, using conventional cytogenetic analysis 
we characterized the chromosomal breakpoints of 3 leukemia patients presenting with a 
t(5;12)(q13;p13), dic(9;12)(p11;p11) and a t(12;15)(p13;q22), respectively, as the sole 
structural abnormalities in the karyotype. These rearrangements were further investigated 
using FISH and molecular studies. The cases with t(5;12) and t(12;15) revealed cryptic 3-way 
translocations, undetected on conventional cytogenetic analysis. One of the cases presented 
an ETV6 rearrangement with an unsuspected fusion with the RUNX1 gene at 21q22. In the 
other patient, an interstitial 12p deletion was found which included ETV6 and 8 other genes. In 
the patient with dic(9;12) both the ETV6 and the paired box 5 (PAX5) gene at 9p13 were 
deleted, indicating that dic(9;12) in B-cell ALL does not always conduct to a PAX5-ETV6 fusion 
gene. This study illustrates the chromosomal and molecular heterogeneity of rearrangements 
underlying 12p chromosome translocations in leukemia. 
 
 
3.1.2. INTRODUCTION 
 
Aberrations of the short arm of chromosome 12 consisting mainly of balanced or 
unbalanced translocations, insertions and deletions are frequently implicated in both lymphoid 
and myeloid hematological malignancies (Mitelman, 2004). The ETV6 gene, a member of the 
Ets family of transcriptional regulators, was initially found as a target gene at the 12p13 region 
by way of its fusion to the platelet-derived growth factor receptor, beta polypeptide (PDGFRB) 
gene in 3 patients with chronic myelomonocytic leukemia and t(5;12)(q33;p13) (Golub et al., 
1994). Since this first report, several different chromosomal rearrangements involving ETV6 in 
a wide spectrum of hematological malignancies have been described (Berger et al., 1997; Sato 
et al., 1997; Tosi et al., 1998; Wlodarska et al., 1998; Odero et al., 2001). To date, at least 20 
different partner genes involved in ETV6 translocations have been identified including MDS2 
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(1p36), ARNT (1q21), ARG (1q25), MDS/EVI1 (3q26), FGFR3 (4p16), BTL (4q11-q12), ACS2 
(5q31), PDGFRB (5q33), STL (6q23), MNX1 (7q36), PAX5 (9p13), JAK2 (9p24), SYK (9q22), ABL1 
(9q34), CDX2 (13q12), TTL (13q14), TRKC (15q25), PER1 (17p12-13), RUNX1 (21q22) and MN1 
(22q11) (reviewed in Odero et al., 2001; Yagasaki et al., 2001; Odero et al., 2002; Penas et al., 
2003; Qiao et al., 2003). In particular, the ETV6-RUNX1 fusion gene generated by a 
t(12;21)(p13;q22), was found to be the most common fusion gene in childhood precursor B-
cell ALL, accounting for approximately 25% of the cases (Golub et al., 1995; Romana et al., 
1995). 
FISH analysis has shown that ETV6 rearrangements occur in approximately half of the 
patients with 12p13 balanced translocations (Sato et al., 1997; Odero et al., 2001) while, in the 
remaining cases, breakpoints can be found telomeric or centromeric to ETV6 (Sato et al., 
1997). In a few other cases, apparently balanced 12p translocations were found to harbour 
interstitial deletions at 12p13, which included ETV6 and the cyclin-dependent kinase inhibitor 
1B (CDKN1B) gene (Wlodarska et al., 1996). However, 12p13 rearrangements are frequently 
found as part of a complex karyotype in which several additional structural and/or numerical 
abnormalities were present (Wlodarska et al., 1996; Berger et al., 1997; Sato et al., 1997; Tosi 
et al., 1998; Wlodarska et al., 1998; Odero et al., 2001). In this report, we used FISH to 
characterize the 12p breakpoints in 3 leukemia patients with cytogenetic evidence of a 
t(5;12)(q13;p13), t(12;15)(p13;q22) and dic(9;12)(p11;p11), and to access the involvement of 
ETV6 in each rearrangement. We also used molecular approaches in the cases with t(5;12) and 
t(12;15) to characterize alterations of ETV6. 
 
 
3.1.3. CASES SUMMARY 
 
Two patients with B-cell ALL and one with MDS/MPN, U presenting with 12p structural 
rearrangements were included in this study (Table III). 
 
Table III. Summary of clinical features, G-banded karyotype, FISH analysis and ETV6 status in the 3 patients. 
Patient Sex/age (years) Diagnosis G-banded karyotype/Revised karyotype (FISH) ETV6 status 
1 M/6 B-cell ALL 
47,XY,+21,t(5;12)(q13;p13)[11]/46,XY[1] 
rearranged 
47,XY,+21,t(12;21;5)(p13;q22;q13)[11]/46,XY[1] 
2 M/82 MDS/MPN, U 
47,XY,+8,t(12;15)(p13;q22)[30] 
deleted 
47,XY,+8,t(12;6;15)(p13;p24~25;q22) [30] 
3 M/9 B-cell ALL 45,XY,dic(9;12)(p11;p11)[17]/46,XY[3] deleted 
Abbreviations: B-ALL, B-cell acute lymphoblastic leukemia; M, male; MDS/MPN, U, myelodysplastic syndrome/myeloproliferative 
neoplasm, unclassifiable. 
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3.1.4. MATERIALS AND METHODS 
 
3.1.4.1. CYTOGENETIC AND FLUORESCENCE IN SITU HYBRIDIZATION ANALYSES OF CHROMOSOME 
REARRANGEMENTS 
 
Cytogenetic analysis was performed on bone marrow samples collected at diagnosis and 
cultured following standard protocols. A G-banded karyotype was produced according to the 
International System for Human Cytogenetic Nomenclature (ISCN, 1995). Cell suspensions 
prepared for cytogenetic analysis were used for characterization of translocation breakpoints 
by FISH. A total of 15 RPCI11 library-bacterial artificial chromosome (BAC) probes were chosen 
to cover an almost contiguous 3 Mb region at 12p13 including ETV6. These are ordered as 
follows (http://www.ncbi.nlm.nih.gov/mapview/): centromere – 688K16 – 377D9 – 392P7 – 
59H1 – 180M15 – 253I19 – 267J23 – 525I3 – 418C2 – 96B19 – 434C1 – 407P10 – 711K1 – 
289M22 – 291B21 - telomere. Additionally, 12p and 6p subtelomeric BAC probes 467M14 and 
328C17, respectively, were used (kindly supplied by Dr. Mariano Rocchi, University of Bari, 
Italy). The ETV6 gene was analysed using a yeast artificial chromosome (YAC) probe (YAC 
964C10) and 6 LL12NCO1-cosmid library clones including 179A6 (exon 1A), 50F4 (exon 2), 
175F2 (intron 2), 2G8 (intron 1B-exon 4), 184C4 (introns 3-5) and 148B6 (exon 8 and 3´ region), 
kindly provided by Dr. Peter Marynen (University of Leuven & Flanders, Interuniversity 
Institute for Biotechnology, Belgium) (Baens et al., 1996). Chromosome 12 was also identified 
by means of a centromeric probe (pBR12) whereas a heterochromatic region probe (pHUR198) 
was used for chromosome 9. Additionally, two YAC probes (764A6 and 742H2) were used for 
the 9p13-p21 region, the latter covering the PAX5 gene. 
DNA was extracted from YAC, BAC and cosmid clones using conventional procedures and 
labelled by nick-translation with digoxigenin-11-dUTP according to standard protocols or 
biotin-14-dATP (BioNick Labeling System, Invitrogen). Furthermore, labeled WCP probes for 
chromosomes 5, 6, 12, 15 and 21 (Cambio), as well as the LSI TEL/AML1 ES dual color 
translocation probe (Vysis), were utilized. Hybridization of the probes, post-hybridization 
washes and detection of signals were performed as described (Matos et al., 2000). 
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3.1.4.2. MOLECULAR ANALYSIS OF ETV6-RUNX1 FUSION TRANSCRIPTS 
 
Analysis of ETV6-RUNX1 fusion transcripts in patient 1 was carried out by RT-PCR as 
described (van Dongen et al., 1999) using a bone marrow sample obtained at diagnosis. The 
amplified fragments were purified using the Concert Rapid Gel Extraction System (Genomed) 
and sequenced using the ABI Prism 3100 Genetic Analyzer (Applied Biosystems). Sequences 
were compared to ETV6 and RUNX1 mRNA sequences (GenBank accession number U11732.1 
and D43969.1, respectively). 
 
 
3.1.4.3. MUTATIONAL ANALYSIS OF ETV6 
 
Screening of ETV6 mutations was carried out in patient 2. Genomic DNA was extracted 
from a bone marrow sample using a salting-out procedure followed by standard phenol-
chloroform purification and ethanol precipitation. Amplification of ETV6 exons was performed 
according to Stegmaier et al. (1996) with minor adjustments. Products were sequenced as 
described above. 
 
 
3.1.5. RESULTS 
 
3.1.5.1. HIDDEN ETV6-RUNX1 FUSION AS A RESULT OF A COMPLEX t(12;21;5)(p13;q22;q13) 
IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA 
 
Cytogenetic analysis of bone marrow cells from patient 1 revealed an apparently 
reciprocal translocation t(5;12)(q13;p13) on the majority of metaphases analysed. In order to 
localize the 12p13 breakpoint, FISH was performed with a BAC clone which covers a region 
from intron 2 to the 3´ end of ETV6 (RPCI11-418C2) and 2 others localized distal (RPCI11-434C1 
and -96B19) and proximal (RPCI11-525I3 and -267J23) to it. Results showed that BAC 418C2 
overlapped the 12p13 breakpoint, indicating that the ETV6 sequence was rearranged (results 
not shown). It was also noticed that the hybridization signal on the der(12) was weaker than 
on the partner chromosome, suggesting that the breakpoint occurred closer to the 3´ end of 
the gene. Subsequent analysis with ETV6 cosmids 148B6 and 184C4 showed that 148B6 
hybridized on the der(12) while 184C4 hybridized on the partner chromosome, revealing that 
the breakpoint was localized between exons 5 and 8 of ETV6 (results not shown). 
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Figure 4. Analysis of chromosome rearrangements by FISH on a bone marrow metaphase cell with t(12;21;5). 
(A) Left: Hybridization of a metaphase cell with WCP probe for chromosome 5 (red signal) and WCP probe for 
chromosome 12 (green signal). Right: Corresponding diagrammatic representation of derivative chromosomes 
showing a 3-way t(12;21;5). Dashed lines are used to indicate the movement of material between each of the 
chromosomes involved in the rearrangement. Vertical red and green lines on the right side of chromosomes show 
the location of chromosome 5 and chromosome 12 materials respectively, after formation of the translocation. (B) 
Left: Hybridization of the same metaphase cell shown in (A) with WCP probe for chromosome 21 (red signal). Right: 
Corresponding diagrammatic representation of der(5) and der(21) chromosomes showing the location of FISH 
signals. 
 
 
Unexpectedly, all probes used that mapped distally to the breakpoint on der(12) were 
localized on a small G-group chromosome instead of on chromosome 5. Using WCP probes, a 
3-way rearrangement was observed, with chromosome 5q material on the short arm of 
chromosome 12, the terminal part of chromosome 12p on the long arm of chromosome 21, 
and the remaining part of chromosome 21q on chromosome 5q (Fig. 4). The involvement of 
chromosomes 12 and 21 in the translocation was highly suggestive that an ETV6-RUNX1 fusion 
gene was present. To confirm this hypothesis, FISH and RT-PCR studies were conducted to 
detect gene fusion in the patient´s cells. Hybridization with the TEL/AML1 translocation probe 
in metaphase cells showed a co-localization of ETV6 and RUNX1 signals on chromosome band 
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21q22 (Fig. 5A). Accordingly, RT-PCR followed by sequencing analysis showed 2 types of fusion 
transcripts consisting of an in-frame joining between exon 5 of ETV6 and exon 2 (or exon 3) of 
RUNX1 (Fig. 5B and C). 
 
ETV6 (ex. 5) RUNX1 (ex. 3)1033 542
ETV6 (ex. 5) RUNX1 (ex. 2)1033 503
A
298 bp
259 bp
B C
der(21)
chr. 21
chr. 21
ETV6-RUNX1 -
der(21)
A
 
 
Figure 5.  Detection of ETV6-RUNX1 fusion by FISH, RT-PCR and direct sequencing analyses. 
(A) Left: Hybridization of a metaphase cell with the TEL/AML1 probes. An ETV6 signal (green) co-localizes with a 
RUNX1 signal (red) on the der(21) chromosome. The native ETV6 signal on normal chromosome 12p13 is not visible 
on this metaphase. Right: Schematic representation of FISH results on the der(21) chromosome. Horizontal arrow 
indicates the approximate location of translocation breakpoint. (B) Ethidium bromide-stained agarose gel (2%) 
electrophoresis of RT-PCR products. Two different ETV6-RUNX1 fusion products of 298 basepairs (bp) and 259 bp 
(less intense) were detected in the patient cDNA sample. HL-60 is an ETV6-RUNX1-negative cell line whereas REH is 
an ETV6-RUNX1-positive cell line (van Dongen et al., 1999). The blank control contains water instead of template 
cDNA. (C) Partial electropherograms obtained by direct sequencing of amplification products detected in the patient 
sample. The upper sequence corresponds to the 298 bp band and shows a fusion of ETV6 exon 5 to RUNX1 exon 2. 
The lower sequence corresponds to the 259 bp band and shows an alternatively-spliced variant ETV6-RUNX1 fusion 
transcript which lacks RUNX1 exon 2. The numbers above the nucleotide sequences indicate the most 3´ nucleotide 
of ETV6 and the most 5´ nucleotide of RUNX1 according to the corresponding mRNA sequences (GenBank accession 
number U11732.1 and D43969.1, respectively). 
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3.1.5.2. INTERSTITIAL DELETION AT 12p13 AS A CONSEQUENCE OF A 3-WAY 
t(12;6;15)(p13;p24~25;q22) IN A PATIENT WITH MYELODYSPLASTIC 
SYNDROME/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE 
 
A seemingly balanced translocation t(12;15)(p13;q22) was found in all metaphases 
analysed in patient 2. However, FISH with WCP and subtelomeric probes disclosed that the 
terminal region of the short arm of chromosome 12 was present on the short arm of 
chromosome 6, band 6p24~25, instead of on chromosome 15. In turn, the 6p terminal region 
was joined to the long arm of chromosome 15 while the 15q22-qter region moved to 
chromosome 12 (Fig. 6A and B). These results revealed that the translocation was definitely a 
3-way rearrangement involving chromosomes 6, 12 and 15.  
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Figure 6. Analysis of chromosome rearrangements by FISH on bone marrow cells with t(12;6;15). 
(A) Left: Hybridization with WCP probe for chromosome 12 (green signal) and WCP probe for chromosome 15 (red 
signal). Right: Corresponding diagrammatic representation of derivative chromosomes demonstrating the presence 
of a 3-way translocation involving chromosomes 6, 12 and 15. Dashed lines are used to indicate the movement of 
material between each of the chromosomes involved in the rearrangement. Vertical red and green lines at the right 
side of the chromosomes show the location of chromosome 15 and chromosome 12 materials, respectively, after 
formation of the translocation. (B) Left: Hybridization with subtelomeric BAC clones 467M14 (green signal) and 
328C17 (red signal) for 12p and 6p, respectively, confirming a t(12;6;15). Right: Corresponding diagrammatic 
representation of derivative chromosomes showing the location of FISH signals. 
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Additionally, FISH studies showed that the translocated 12p13-12pter chromosomal 
region was present at both chromosomes 6. This finding indicated that mitotic recombination 
had occurred between the normal and rearranged chromosomes 6 or, alternatively, that the 
rearranged chromosome 6 was duplicated whereas the normal homologue was lost. 
Subsequent FISH studies were meant to verify if ETV6 had been disrupted by the translocation 
breakpoints as in the case of patient 1. Hybridization with YAC 964C10, which covers a large 
genomic region (~1.5 Mb) at band 12p13, including the ETV6 gene, revealed a strong signal on 
normal chromosome 12 but no signal on the der(12) (results not shown). However, a weak 
signal was observed on both der(6), suggesting that a breakpoint had occurred telomeric to 
ETV6 at band 12p13. To confirm this hypothesis, metaphase cells were subsequently 
hybridized with each of the 6 ETV6 cosmids. Results unequivocally showed that signals were 
only present on the normal chromosome 12 confirming that one copy of ETV6 was deleted as a 
result of the translocation. To test if the remaining copy of the ETV6 gene had been rendered 
non-functional as a result of nucleotide mutations, the entire ETV6 coding sequence was 
screened by PCR and direct sequencing analysis. However, nucleotide alterations were not 
detected in the non-rearranged ETV6 allele (data not shown), suggesting that the contribution 
of ETV6 to leukemogenesis was accomplished through a haplo-insufficiency mechanism. 
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Figure 7. Diagrammatic representation of human chromosome 12 and of an enlarged 12p13 region targeted by 
the translocation breakpoints in the t(12;6;15)(p13;p24~25;q22). 
The breakpoints were associated with an interstitial deletion of 1.2 Mb which comprised ETV6 and 8 other genes 
located centromeric to it. The distal and proximal breakpoints were positioned between probe 434C1 and 407P10, 
and probe 180M15 and 59H1, respectively. Probes used in breakpoint mapping are shown as black (non-deleted) or 
grey (deleted) vertical lines at the right side of the chromosome. The approximate location of deleted genes is 
shown on the right side of the figure. 
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To further localize the 12p13 breakpoints, FISH was conducted using a panel of 15 
closely-spaced BAC probes. Results showed that 7 consecutive probes (from 434C1 to 180M15, 
including both of these) hybridized on normal chromosome 12 only. In contrast, distal and 
proximal positioned probes hybridized on der(6) and on der(12), respectively, in addition to 
normal chromosome 12, thus confirming translocation t(12;6;15)(p13;p24~25;q22). In 
conclusion, FISH results in metaphase cells with t(12;6;15) established the presence of a cryptic 
interstitial deletion at band 12p13 with an approximate length of 1.2 Mb comprising at least 9 
known genes, ordered from telomere to centromere as follows: ETV6, BCL2L14, LRP6, 
FLJ10298, LOH12CR1, DUSP16, CREBL2, GPR19 and CDKN1B (Fig. 7). 
 
 
3.1.5.3. DELETION OF ETV6 AT 12p13 AND OF PAX5 AT 9p13 AS A RESULT OF 
dic(9;12)(p11;p11) IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA 
 
Cytogenetic studies complemented with FISH analysis using a centromeric probe for 
chromosome 12 and a heterochromatic region probe for chromosome 9, showed a dicentric 
fusion dic(9;12)(p11;p11) in the majority of cells analysed in patient 3 (Fig. 8A). Because this 
patient was a 9 year-old boy with B-cell ALL, FISH analysis was performed with the TEL/AML1 
translocation probe to exclude a cryptic ETV6-RUNX1 fusion as seen in patient 1 (results not 
shown). 
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Figure 8. Analysis of chromosome rearrangements by FISH on bone marrow metaphases with dic(9;12)(p11;p11). 
(A) Hybridization with a heterochromatic region probe for chromosome 9 (green) and a centromeric probe for 
chromosome 12 (red), showing the presence of a dic(9;12) (B) Hybridization with YAC probe 964C10 (red) and 
742H2 (green) covering ETV6 (12p13) and PAX5 (9p13), respectively. Signals are only observed on the normal 
chromosomes 9 and 12, indicating that ETV6 and PAX5 are deleted in the rearranged chromosomes. 
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Subsequent FISH studies with ETV6 cosmids showed signals on the normal chromosome 
12 only, indicating that ETV6 was deleted on the rearranged chromosome homologue. 
Identical results were obtained using BAC probes 267J23 and 688K16, both of which map 
centromeric to ETV6 at band 12p13. Hybridization with YAC probes 764A6 and 742H2 was 
performed to confirm absence of the 9p13 region including the PAX5 gene. In both 
experiments, hybridization signals were present on the normal chromosome 9 only (Fig. 8B). In 
summary, at least the 12p13-12pter and the 9p13-pter regions including the ETV6 and the 
PAX5 genes, respectively, were lost as a result of dic(9;12). 
 
 
3.1.6. DISCUSSION 
 
Heterogeneity of breakpoint locations has been reported in patients with hematological 
malignant disorders and 12p13 translocations (Sato et al., 1997; La Starza et al., 1999; Odero 
et al., 2001; Odero et al., 2003). In approximately half of the patients, the breakpoints occur in 
the ETV6 gene (Sato et al., 1997; Odero et al., 2001) and lead to gene fusion with different 
partner genes on various chromosomes (reviewed in Odero et al., 2001; Yagasaki et al., 2001; 
Odero et al., 2002; Penas et al., 2003; Qiao et al., 2003). In the remaining cases, the 
breakpoints at 12p13 occur either telomeric or centromeric to ETV6, suggesting that other 
genes lying in the vicinity of ETV6 could also play a role in malignant transformation. In 
agreement with these data, molecular cytogenetic analysis of apparently balanced 12p 
translocations has uncovered the presence of interstitial deletions at 12p13, which included 
several other genes in addition to ETV6 (Wlodarska et al., 1996; La Starza et al., 1999). This was 
also the case of our patient 2 in whom an apparently balanced chromosomal translocation 
between chromosomes 12 and 15 masked the presence of a 1.2-Mb interstitial deletion at 
12p13, which included ETV6 and 8 other genes lying centromeric to it. The length and 
chromosomal position of the interstitial deletion detected in our patient matched the location 
of a commonly deleted segment at 12p13 which has been defined in patients with different 
hematological malignancies presenting with cytogenetically visible deletions (Wlodarska et al., 
1996). Whether ETV6 is likely to be the main target gene in these patients and in ours remains 
to be determined. However, the complexity of chromosome rearrangements detected in our 
patient, including additional breakpoints at chromosomes 6 and 15, as well as a duplication of 
the der(6), suggests that leukemogenesis resulted from several gene changes at the involved 
chromosomes rather than from deletion of one allele of the ETV6 gene only. In agreement 
with this hypothesis, we have not detected the presence of nucleotide mutations in the non-
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rearranged ETV6 allele, suggesting that ETV6 was haplo-insufficient but otherwise functional in 
cells with t(12;6;15). 
On the other hand, patients presenting with cytogenetically balanced translocations 
involving breakpoints in ETV6 and in a partner chromosome other than chromosome 21, may 
hide an ETV6-RUNX1 fusion as we found in our patient 1. In this case, gene fusion resulted 
from a 3-way translocation involving chromosomes 5, 12 and 21. These 3-way rearrangements 
of t(12;21) are apparently rare among the universe of ETV6-RUNX1-positive patients (Berger et 
al., 1997; Wiemels et al., 2000; Mathew et al., 2001). However, the t(12;21) is not easily 
detected by conventional cytogenetic analysis because of the similar length and cytogenetic 
appearance of the terminal regions of chromosomes 12 and 21 involved in the translocation. 
Thus, it is possible that complex translocations involving an extra chromosome in addition to 
chromosomes 12 and 21 may be easily mistaken for a 2-way translocation involving 
chromosome 12 and a different partner chromosome. Thus, in view of the present results and 
of the knowledge that the ETV6-RUNX1 fusion gene is usually associated with a better 
outcome in children with B-cell ALL, detection of the molecular rearrangement by FISH or RT-
PCR should be recurrently performed in B-cell ALL patients presenting with cytogenetic 
evidence of 12p13 rearrangement other than the classical t(12;21)(p13;q22). 
The PAX5 gene, a transcription factor which encodes the B-cell-specific activator protein, 
is a partner gene of ETV6 in ALL with t(9;12)(q11;p13) (Cazzaniga et al., 2001). Recently, PAX5-
ETV6 fusion was described as the molecular counterpart of the dicentric translocation 
dic(9;12)(p11-13;p11-12), a recurrent abnormality which accounts for close to 1% of ALL in 
children (Strehl et al., 2003). In the later study, it was proposed that the translocations 
dic(9;12)(p11-13;p11-12) with ETV6 and PAX5 rearrangement should be referred to as 
dic(9;12)(p13;p13) since these genes are localized at 12p13 and 9p13, respectively. However, 
in our patient 3, both genes were deleted, excluding the presence of a PAX5-ETV6 
rearrangement. Since the dic(9;12)(p11;p11) was the sole chromosomal abnormality in the 
karyotype of the patient, we hypothesize that the hemizygous presence of one or both of 
these genes may also be relevant in leukemogenesis. In particular, since PAX5 is essential to 
initiate and maintain the B lymphoid transcription program during early B-cell development 
(Mikkola et al., 2002), when it is expressed from one allele only (Nutt et al., 1999), deletion of 
PAX5 as a result of the dicentric fusion in our case may result in loss of function and, 
consequently, in a blockage of B-cell lineage commitment. Taken together, the present study 
illustrates the heterogeneity of chromosomal and molecular rearrangements underlying 12p 
translocations in leukemia patients. 
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3.2. THREE-WAY TRANSLOCATION INVOLVES MLL, MLLT3 AND A 
NOVEL CELL CYCLE CONTROL GENE, CCDC94, IN THE 
PATHOGENESIS OF ACUTE MYELOID LEUKEMIA WITH 
t(9;11;19)(p22;q23;p13) 
 
 
 
Published in: Vieira L, Sousa AC, Matos P, Marques B, Alaiz H, Ribeiro MJ, Braga P, da Silva MG, 
Jordan P (2006) Three-way translocation involves MLL, MLLT3 and a novel cell cycle control 
gene, FLJ10374, in the pathogenesis of acute myeloid leukemia with t(9;11;19)(p22;q23;p13.3). 
Genes Chromosomes Cancer 45: 455-469. 
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3.2.1. ABSTRACT 
 
The MLL gene at 11q23 undergoes chromosomal translocation with a large number of 
partner genes in both ALL and AML. We report a novel t(9;11;19)(p22;q23;p13.3) disrupting 
MLL in an infant AML patient. The 5´ end of MLL fused to chromosome 9 sequences on the 
der(11), whereas the 3´ end was translocated to chromosome 19. We developed LDI-PCR 
assays to investigate the localization of the breakpoints on der(11) and der(19). We found that 
intron 5 of MLL was fused to intron 5 of the myeloid/lymphoid or mixed-lineage, translocated 
to 3 (MLLT3, previously known as AF9) gene at the der(11) genomic breakpoint, resulting in a 
novel in-frame MLL exon 5-MLLT3 exon 6 fusion transcript. On the der(19), a novel gene 
annotated as coiled-coil domain containing 94 (CCDC94, formerly known as FLJ10374) was 
disrupted by the breakpoint. Using RT-PCR analysis, we showed that CCDC94 is ubiquitously 
expressed in human cells. Expression of the CCDC94 protein in different cell lines revealed that 
it localized exclusively to the nucleus. In serum-starved NIH-3T3 cells the expression of CCDC94 
decreased the rate of G1- to S-phase transition of the cell cycle, whereas the suppression of 
CCDC94 through short interfering RNA (siRNA) oligos increased cell proliferation. These results 
indicate that CCDC94 negatively regulates cell cycle progression and proliferation. Thus, a 
single chromosomal rearrangement resulting in formation of the MLL-MLLT3 fusion gene and 
haplo-insufficiency of CCDC94 may have cooperated to promote leukemogenesis in the AML 
patient with t(9;11;19). 
 
 
3.2.2. INTRODUCTION 
 
Translocations of chromosome 11q23 are observed in 5-10% of patients with de novo 
AML and ALL. Notably, 11q23 translocations are present in over 50% of children under one 
year of age with ALL and AML (Sorensen et al., 1994; Martinez-Climent et al., 1995). In 
addition, approximately 30% of cancer patients who develop therapy-related acute leukemia 
(t-AML or t-ALL) or therapy-related myelodysplastic syndrome also show 11q23 balanced 
chromosome aberrations, particularly after treatment with DNA topoisomerase II (DNAt2)-
inhibitors (Bloomfield et al., 2002). The MLL gene was originally found to be the target gene 
disrupted at 11q23 in leukemia patients with t(4;11) and t(11;19) (Ziemin-Van Der Poel et al., 
1991; Djabali et al., 1992; Gu et al., 1992; Tkachuk et al., 1992). The MLL gene shows 3 regions 
of sequence similarity to the trithorax gene, a known transcriptional regulator in Drosophila 
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melanogaster. Like trithorax, MLL positively maintains the expression of various homeobox 
genes during development (Ayton & Cleary, 2001). 
The t(9;11)(p22;q23) is the most common translocation involving 11q23 in de novo AML 
and t-AML and results in fusion of the MLL to the MLLT3 gene (Iida et al., 1993; Nakamura et 
al., 1993). In the t(9;11) and other 11q23 translocations, the MLL breakpoints are clustered 
within an 8.3-kb BamHI breakpoint cluster region (bcr), which includes the genomic sequence 
beginning at the 3´ side of exon 5 and extending to the 5´ side of exon 11 (Gu et al., 1992). In 
contrast, two major breakpoint cluster regions, known as BCR1 (or site A) and BCR2 (or site B), 
have been recognized in MLLT3. BCR1 includes the 3´ region of intron 4 and BCR2 
encompasses introns 7-8 of MLLT3 (Iida et al., 1993; Nakamura et al., 1993; Negrini et al., 
1993; Yamamoto et al., 1994; Super et al., 1997; Atlas et al., 1998; Odero et al., 2000; Strissel 
et al., 2000; Langer et al., 2003). Despite the heterogeneity of the genomic breakpoints, the 
RNA junctions in t(9;11)-positive patients show in-frame MLL-MLLT3 fusion transcripts 
consisting of a variable MLL bcr exon fused to the exons 5, 8, or 9 of MLLT3 (Iida et al., 1993; 
Nakamura et al., 1993; Yamamoto et al., 1994; Super et al., 1997; Atlas et al., 1998; Odero et 
al., 2000). Structural elements like DNAt2 cleavage sites and scaffold-associated regions (SARs) 
have been found at the breakpoints in MLL and MLLT3, indicating that illegitimate 
recombination events mediated by specific DNA elements are likely to contribute to the fusion 
of these genes (Felix et al., 1995; Strissel et al., 2000). 
Like MLL-associated acute leukemias, most other hematopoietic malignancies are 
characterized by reciprocal chromosome translocations. Routine cytogenetic analysis has 
shown that, in addition to both recurrent breakpoints, these translocations can involve further 
breaks in one or more chromosomes. In particular, 3-way or more translocations were found 
to account for 9.3%, 6.3%, and 2.6% of complex t(9;22), t(8;21), and t(15;17), respectively 
(Fisher et al., 2005). Nevertheless, little is known about the contribution of additional 
breakpoints to the process of leukemogenesis. In this article, we describe an infant AML 
patient whose leukemic cells harbored a complex t(9;11) presenting as a novel 3-way 
t(9;11;19)(p22;q23;p13.3). We found that this rearrangement led to the formation of a variant 
MLL-MLLT3 fusion transcript. Furthermore, the extra breakpoint at 19p13.3 disrupted CCDC94, 
a previously uncharacterized gene that negatively regulates cell cycle progression and 
proliferation. We propose that the concomitant formation of the MLL-MLLT3 fusion gene and 
disruption of CCDC94 mutually promoted leukemogenesis in this patient with t(9;11;19). 
 
 
 
  
46 
3.2.3. CASE SUMMARY 
 
An 11-month-old girl was admitted to the hospital with a 4-day history of fever, cough, 
and paleness. Peripheral blood counts revealed anemia (hemoglobin 6.9 g/dL) and normal 
numbers of white blood cells and platelets. Hepatomegaly was present. The morphologic 
examination of the bone marrow aspirate suggested AML. Immunophenotypic studies showed 
the presence of 54% blasts positive for CD33, CD15, CD4, HLA-DR and CD45, of which 50% and 
25% were positive for CD117 and CD11b, respectively. The blasts were CD13 negative. A 
diagnosis of AML-M4 was made. 
 
 
3.2.4. MATERIALS AND METHODS 
 
3.2.4.1. CYTOGENETIC AND FLUORESCENCE IN SITU HYBRIDIZATION ANALYSES OF CHROMOSOME 
REARRANGEMENTS 
 
A bone marrow sample collected at diagnosis was used for routine cytogenetic analysis. 
G-banded metaphase chromosomes of bone marrow cells were prepared following standard 
techniques, and the karyotype was established according to ISCN (1995) guidelines. Fixed cells 
prepared for cytogenetics were used for FISH analysis of chromosome rearrangements, as 
described previously (Vieira et al., 2005). Hybridization experiments were performed with WCP 
probes for chromosomes 9, 11, and 19 (Cambio), the MLL gene probe (Q-Biogene) and BAC 
clones RP11-336O12 (GenBank accession number AL513498; kindly provided by Dr. Mariano 
Rocchi, University of Bari, Italy) and CTB-144D21 (GenBank accession number AC008616, 
obtained from Research Genetics). 
 
3.2.4.2. MOLECULAR ANALYSIS AND CLONING OF MLL-MLLT3 FUSION TRANSCRIPTS 
 
A bone marrow sample obtained at disease relapse following a sex-mismatched bone 
marrow transplantation was used for the molecular analysis and characterization of 
chromosome rearrangements. The technique of cDNA panhandle PCR was used, with minor 
modifications, to identify MLL-containing transcripts originating on der(11) (Megonigal et al., 
2000). Amplification products were cloned using the TOPO TA Cloning Kit (Invitrogen) 
according to the manufacturer´s instructions. Transformants were screened by whole-cell PCR 
for the presence of MLL-containing sequences. Positive clones were sequenced using Big-Dye 
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technology and the ABI Prism 3100 Genetic Analyzer (Applied Biosystems). For direct analysis 
of MLL-MLLT3 fusion transcripts, three micrograms of total RNA were reverse transcribed to 
cDNA using Ready-to-go You-prime First Strand Beads (Amersham Biosciences) and random 
hexamers (Invitrogen) as primers. One-tenth of the cDNA (4 μl) was subsequently amplified by 
PCR with MLL-ex5s and MLLT3-ex8as primers (Table IV). PCR products were analyzed on 2% 
agarose gels stained with ethidium bromide. 
 
 
Table IV. Designation of primers and corresponding sequences used in this study. 
Primer name Sequence 5´ → 3´ Technique 
MLL-ex5s TCCTCCACGAAAGCCCGTCGAG RT-PCR 
MLLT3-ex8as CTTGTCACATTCACCATTCTT RT-PCR 
MLLT3-ex6 CTGCGACTTCGGCTGCCTCCTCTA LDI-PCR 
MLLT3-int6  TTGGAAGGAAAGGGGTTGCCTGTG LDI-PCR 
MLL-ex6 GATACTTGGGCGGGGAGCCACTTTT LDI-PCR 
MLL-int6 TGTTTCTCTGCCATTTCTCAGGGATGT LDI-PCR 
MLL-int5 GTTTCTGTTTCTTTATTATTAAAC LDI-PCR 
MLL-int6.1 CCAGGTACTCAGGAGGCT LDI-PCR 
CCDC94-ex5s ACGTGGACTTCGAGGCTATG RACE, RT-PCR 
CCDC94-ex6s AAGCCAGAAAGCGAAGACTG RACE 
CCDC94-ex8as GTCCAGGTATGCACCCAGTT RT-PCR 
CCDC94-NTER ATGTCGGAGCGAAAAGTATTAAAC Cloning 
CCDC94-CTER CCTGGGAGGGCTCAGTTGCT Cloning 
msCCDC94_s AGCTTCTGGAGGAGGAGGAG RT-PCR mouse cells 
msCCDC94_as TGCCAACTGTGCTTTACTGC RT-PCR mouse cells 
 
 
3.2.4.3. CLONING OF GENOMIC FUSIONS ON THE der(11) AND der(19) CHROMOSOMES 
 
The technique of LDI-PCR, described by Willis et al. (1997), was adapted with minor 
modifications to clone the MLL breakpoints on der(11) and der(19). For identification of the 
fusion point between MLL and MLLT3 genomic sequences on the der(11), suitable DraI 
restriction sites in introns 5 and 6 of MLLT3 were identified using the genomic sequence of the 
chromosome 9 BAC RP11-336O12 (GenBank accession number AL513498) as template. 
Amplification of circular DNA was performed with MLLT3-ex6 and MLLT3-int6 primers, which 
yield a 2103 bp fragment from a non-rearranged MLLT3 locus. To localize the fusion point of 3´ 
MLL on the der(19), PstI restriction sites within the MLL gene were identified using the 
genomic sequence of the chromosome 11 BAC RP11-770J1 (GenBank accession number 
AP001267) as template. Amplification was performed with MLL-ex6 and MLL-int6 primers, 
which produce a 1305 bp fragment from a non-rearranged MLL gene. Because of the presence 
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of adenosine and thymine tracts more than 14 nucleotides long within the LDI-PCR products, 
sequencing of the latter was performed with MLL-int5 and MLL-int6.1 primers. PCR products 
were run on 0.8% agarose gels stained with ethidium bromide, cloned, and sequenced as 
indicated above. 
 
 
3.2.4.4. DETECTION OF TRUNCATED CCDC94 TRANSCRIPTS 
 
The rapid amplification of cDNA ends (RACE) methodology was used for detection of the 
truncated CCDC94 mRNA in the patient´s bone marrow cells. One microgram of total RNA was 
converted into cDNA using the 3´ RACE System (Invitrogen) according to the manufacturer´s 
instructions. The CCDC94 cDNA was amplified by nested PCR using the primers provided by the 
manufacturer in conjunction with CCDC94-ex5s primer on the first round and CCDC94-ex6s 
primer on the second round. PCR products were analyzed on an ethidium bromide-stained 
2.5% agarose gel, cloned and sequenced as described beyond. 
 
 
3.2.4.5. DETECTION OF CCDC94 MRNA EXPRESSION IN CELL LINES AND NORMAL TISSUES  
 
Expression of the CCDC94 gene was evaluated by RT-PCR using cDNA samples obtained 
from 16 different normal human tissues and cells (Human Multiple Tissue cDNA Panels I and II, 
Clontech) as well as from 6 hematopoietic (697, NB4, LAMA-84, TOM-1, Kasumi-1, and REH) 
and 6 non-hematopoietic (SW480, HCT116, HeLa, HEK-293, HT29, and RH-30) cell lines. 
Samples were amplified using primers CCDC94-ex5s and CCDC94-ex8as. To check for the 
integrity of RNA and efficient cDNA synthesis in each cell line, a partial sequence of the 
ubiquitously expressed ABL1 transcript was amplified using primers described in Cross et al. 
(1993). Amplification of the G3PDH transcript was performed with primers included in the 
Human Multiple Tissue cDNA Panels and used as a normalizer of CCDC94 expression in normal 
tissues. Amplifications were carried out using standard reaction conditions and cycling 
parameters. Reaction products were electrophoresed on ethidium bromide-stained 2% 
agarose gels. 
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3.2.4.6. SUBCELLULAR LOCALIZATION OF CCDC94 PROTEIN 
 
A full-length CCDC94 cDNA was amplified from total RNA obtained from the HT29 colon 
cell line by RT-PCR using primers CCDC94-NTER and CCDC94-CTER. A 983 bp fragment of 
CCDC94 beginning at the ATG codon in exon 1 and ending 11 bp distally to the stop codon in 
exon 8 was amplified and subcloned into the pcDNA3.1/NT-GFP-TOPO expression vector 
(Invitrogen) according to the manufacturer´s instructions. Additionally, a FLAG-tagged CCDC94 
cDNA was made by digestion of the GFP-CCDC94 construct with KpnI and XbaI and subsequent 
ligation into the pFLAG-CMV-2 expression vector (Sigma) using the Rapid DNA Ligation Kit 
(Roche Applied Science). Both constructs were sequenced to confirm authenticity of the 
sequence and conservation of the reading frame at the cloning sites. 
Transfection experiments were independently conducted in 3 different cell lines from 
distinct cellular origins (NIH-3T3 mouse fibroblasts, DLD1 human colon carcinoma cells, and 
HeLa human cervix carcinoma cells) to access localization of the tagged CCDC94 protein. Cells 
were maintained in culture using Dulbecoo´s Modified Essential Medium supplemented with 
10% (v/v) of either new born calf serum (CS) for NIH-3T3 or fetal CS for DLD1 and HeLa cell 
lines (Invitrogen). Initially, approximately 4 x 105 cultured cells were seeded on 6 glass 
coverslips placed within 35 mm-diameter culture dishes. Two micrograms of plasmid 
constructs were transfected 24 hr later using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer´s instructions. Cells were incubated for an additional 18 hr period before 
harvesting. Immunofluorescence analysis including fixation and permeabilization of cells, 
incubation of antibodies for detection of green fluorescent protein (GFP) expression, and 
imaging were performed as described (Matos & Jordan, 2005). The CCDC94 protein expression 
in cells transfected with FLAG-tagged CCDC94 cDNA was detected using a primary mouse anti-
FLAG M2 antibody (Sigma) followed by a secondary goat anti-mouse fluorescein isothiocyanate 
(FITC) antibody (Jackson ImmunoResearch). The actin cytoskeleton and nuclear morphology 
were visualized using phalloidin-tetramethylrhodamine isothiocyanate (TRITC) (Sigma) and 
4´,6-diamidino-2-phenylindole (DAPI) (Sigma), respectively, in cells transfected with either tag. 
Expression of the transfected plasmid constructs was also evaluated by sodium dodecyl 
sulphate-polyacrilamide gel electrophoresis (SDS-PAGE) and Western blotting as previously 
described (Matos et al., 2003) using monoclonal anti-FLAG M2 antibody (Sigma) or polyclonal 
rabbit anti-GFP ab290 antibody (Abcam). 
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3.2.4.7. EFFECT OF CCDC94 EXPRESSION ON CELL CYCLE PROGRESSION AND CELL SURVIVAL 
 
CS-starved NIH-3T3 mouse fibroblasts were used as a model system for evaluating the 
effect of CCDC94 protein expression on cell survival and on the transition from the gap1 phase 
(G1-phase) to the synthesis phase (S-phase) of the cell cycle, as described (Matos & Jordan, 
2005). The statistical significance of the results was accessed using the two-tailed Student t 
test. 
 
 
3.2.4.8. EFFECT OF CCDC94 MRNA SUPPRESSION ON CELL PROLIFERATION  
 
Two different 21-mer chemically synthesized siRNA oligos (msCCDC94_1 and 
msCCDC94_2) obtained from MWG (Ebersberg, Germany) were designed using the mouse 
CCDC94 cDNA sequence (GenBank accession number NM_028381) as template (Table V). 
Additionally, a siRNA specific for the mRNA of the non-endogenous GFP was used as a control. 
Transfection of each of the siRNA oligos (100 pmoles) was independently performed in CS-
starved NIH-3T3 cells placed on coverslips within 35 mm-diameter culture dishes. Cells were 
incubated in the presence of bromodeoxyuridine (BrdU) for 24 hr, and then the coverslips 
removed and analyzed as described previously (Matos & Jordan, 2005). Total RNA was 
extracted from the remaining cells and converted to cDNA, as described above, following a 
previous incubation with Dnase I Rnase-free enzyme (Ambion). Amplification of cDNA was 
carried out using msCCDC94_s and msCCDC94_as primers for CCDC94 and ABL1 primers as a 
control, as described above. Amplification products were run on ethidium bromide-stained 2% 
agarose gels. The level of CCDC94 transcript knock-down was documented by densitometric 
analysis of amplified products. 
 
 
Table V. Designation of siRNA oligos and corresponding sequences used in this study. 
siRNA name Sequence 5´ → 3´ 
msCCDC94_1 UCUUCCGAUUCUACAUCAATT 
msCCDC94_2 AGCACAGUUGGCAGGCUUATT 
GFP GGCUACGUCCAGGAGCGCACCTT 
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3.2.4.9. COMPUTATIONAL SEQUENCE ANALYSIS 
 
Resources available at the National Center for Biotechnology Information (NCBI) Web 
site (http://www.ncbi.nlm.nih.gov) including Evidence Viewer, Map Viewer, or basic local 
alignment search tool (BLAST), were used for obtaining the RNA sequence from CCDC94, for 
selection of BAC probes for chromosomes 9 and 19, and for analysis of cDNA panhandle PCR 
and LDI-PCR sequencing data, respectively. The Webcutter 2.0 software 
(http://rna.lundberg.gu.se/cutter2) was used to select appropriate restriction enzymes for the 
LDI-PCR assays. Primers for LDI-PCR and CCDC94 transcript analyses were designed using 
Primer3 software available at http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi 
(Rozen & Skaletsky, 2000). Alignment of protein sequences was conducted using the BLASTP 
2.2.24+ program (Altschul et al., 1997) with a compositional score matrix adjustment (Altschul 
et al., 2005). Prediction of localization sites of CCDC94 protein in the cells and potential motifs 
was performed with the PSORT WWW server (http://psort.ims.u-tokyo.ac.jp). The siRNA oligos 
were designed with software available at MWG Web site (http://www.mwg-
biotech.com/html/s_synthetic_acids/s_rna.shtml). Densitometric analysis of agarose gels was 
performed with ImageJ software from the National Institutes of Health 
(http://rsb.info.nih.gov/ij). 
 
 
3.2.5. RESULTS 
 
3.2.5.1. TRANSLOCATION t(9;11;19) IS A 3-WAY COMPLEX OF t(9;11) THAT REARRANGES MLL 
WITH MLLT3 AND RESULTS IN AN MLL EXON 5-MLLT3 EXON 6 FUSION TRANSCRIPT 
 
In karyotype analysis combined with WCP of the patient´s bone marrow cells at 
diagnosis, all metaphases analysed showed a single rearrangement involving chromosomes 9, 
11, and 19: 46,XX,t(9;11;19)(p22;q23;p13.3)[15] (Fig. 9). The breakpoint at 11q23 prompted 
the use of FISH to search for an MLL gene rearrangement. Metaphase cells hybridized with the 
MLL probe showed signals on the normal chromosome 11 and on der(11) and der(19), 
revealing that the breakpoint disrupted the MLL gene (results not shown). Thus, the 3´ end of 
MLL was translocated to chromosome 19 while the 5´ end of the gene remained on 
chromosome 11 and was fused to sequences from chromosome 9. These results suggested 
that the t(9;11;19) was a complex rearrangement of t(9;11)(p22;q23) that had fused the MLL 
with the MLLT3 gene from 9p22 (Iida et al., 1993; Nakamura et al., 1993). The MLL-MLLT3 
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fusion gene was indeed confirmed by 2-color FISH in metaphases with a t(9;11;19) using the 
MLL probe and the BAC probe RP11-336O12 covering the MLLT3 gene (Fig. 10A). 
 
 
der(11)
11q23
- 19p13
der(19)
9p22 -
der(9)
chr. 11
der(19)
der(9)
der(11)
chr. 9
 
 
Figure 9. Analysis of chromosome rearrangements by FISH in a bone marrow cell with t(9;11;19). 
Left: Hybridization with WCP probes for chromosomes 9 (green) and 11 (red) showing a der(9), a der(11), and a 
der(19), resulting from a 3-way complex t(9;11;19)(p22;q23;p13.3). Right: Corresponding diagrammatic 
representation of derivative chromosomes. Dashed lines are used to indicate the movement of material between 
each of the chromosomes involved in the rearrangement. Vertical green and red lines at the right side of 
chromosomes show the location of chromosome 9 and chromosome 11 materials, respectively, after formation of 
the translocation. 
 
 
Because of the heterogeneous fusion sites in the MLL-MLLT3 hybrid genes and of the 
possibility of alternative splicing events (Iida et al., 1993; Nakamura et al., 1993; Yamamoto et 
al., 1994), a cDNA panhandle PCR technique was used to identify fusion transcripts involving 
the 5´ side of MLL (Megonigal et al., 2000). After nested PCR, this assay yielded several discrete 
amplification products that were subsequently cloned and sequenced (results not shown). 
A BLAST analysis of the cloned sequences revealed MLL-derived transcripts, one 
corresponding to a fusion of MLL exon 5 to the MLLT3 gene. RT-PCR with gene-specific primers 
was then performed which resulted in the amplification of a 532-bp product, the sequencing of 
which confirmed the presence of an MLL-MLLT3 fusion transcript that consisted of an in-frame 
fusion between exon 5 of MLL and exon 6 of MLLT3 (Fig. 10B and C). 
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Figure 10. Detection of the MLL-MLLT3 fusion by FISH, RT-PCR and direct sequencing analyses. 
(A) Left: Hybridization with the MLL gene probe (green) and the BAC probe RP11-336O12 (red) covering the MLLT3 
gene at 9p22. Signals from the MLL probe were present on the normal chromosome 11, der(11), and der(19) 
whereas signals from probe RP11-336O12 were observed on the der(9) and der(11) in addition to the normal 
chromosome 9. The der(11) showed a co-localization of green and red signals corresponding to the MLL-MLLT3 
fusion gene. Right: Schematic representation of corresponding derivative chromosomes and location of 
hybridization signals. (B) Agarose gel electrophoresis analysis of RT-PCR products for detection of MLL-MLLT3 fusion 
transcripts. A 532 bp amplification product was present in the patient cDNA sample. No amplification products were 
detected in a cDNA sample from a normal individual and in the blank (no cDNA) control. (C) Partial mRNA sequences 
of normal MLL exon 5-exon 6 and MLLT3 exon 5-exon 6 junctions, and corresponding MLL-MLLT3 fusion in the 
patient. Capital letters below the mRNA sequences indicate the corresponding aminoacid residues. 
 
 
3.2.5.2. A NOVEL GENE AT 19p13.3, CCDC94, IS DISRUPTED BY FUSION TO THE 3´ END OF MLL 
 
LDI-PCR has been previously used to amplify immunoglobulin heavy joining group 
(IGHJ@) translocations in B-cell malignancies in order to identify the fusion partner gene 
sequence (Willis et al., 1997). Briefly, genomic DNA was digested with an appropriate 
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restriction enzyme, re-ligated to form monomeric circles, and amplified using primers 
annealing to a known IGHJ@ sequence in the circularized molecules. In the present work, an 
LDI-PCR assay was designed to identify the MLL-MLLT3 genomic fusion sequence at the MLL 
bcr in the der(11).  
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Figure 11. LDI-PCR analyses of the genomic breakpoint junctions on der(11) and der(19). 
(A) Left: Detection of normal and rearranged MLLT3 alleles by agarose gel electrophoresis analysis of LDI-PCR 
products. Bands of 2103 and 1601 bp, corresponding to the non-rearranged and rearranged MLLT3 alleles on the 
normal chromosome 9 and der(11), respectively, were observed. The molecular weight marker is 1 kb ladder 
(Invitrogen). Right: Corresponding diagrammatic representation of genomic fragments amplified by LDI-PCR. The 
horizontal arrows indicate the position and orientation of the primers used in the LDI-PCR assay. The vertical arrow 
shows the localization of the genomic junction of MLL and MLLT3 on the der(11). The MLLT3 genomic sequence is 
represented by a solid line whereas the MLL sequence is shown by a dotted line. D, DraI restriction site ; cen, 
centromere ; tel, telomere. (B) Left: Detection of normal and rearranged MLL alleles by agarose gel electrophoresis 
analysis of LDI-PCR products. Bands of 1459 and 1305 bp, corresponding to the rearranged and non-rearranged MLL 
alleles on der(19) and normal chromosome 11, respectively, were observed. The molecular weight marker is 1 kb 
ladder (Invitrogen). Right: Corresponding diagrammatic representation of genomic fragments amplified by LDI-PCR. 
The horizontal arrows indicate the position and orientation of the primers used in the LDI-PCR assay and sequencing 
analysis. The vertical arrow shows the localization of the genomic junction of CCDC94 and MLL on the der(19). The 
MLL genomic sequence is represented by a solid line whereas the CCDC94 sequence is shown by a dotted line. P, 
PstI restriction site; cen, centromere ; tel, telomere. 
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After DraI digestion and subsequent ligation, DNA was amplified with primers located in 
exon 6 and in the proximal 5´ side of intron 6 of MLLT3. Agarose gel electrophoresis analysis of 
PCR products showed a 2103 bp band corresponding to the normal MLLT3 allele derived from 
the non-rearranged chromosome 9 and an extra band of 1601 bp (Fig. 11A). Sequencing 
analysis of the latter band showed a fusion of intron 5 of MLL with intron 5 of MLLT3 which 
was expected because of the results of RT-PCR analysis. 
The definition of the MLL intronic sequence flanking the der(11) breakpoint 
subsequently allowed the design of another LDI-PCR assay to identify the 19p13.3 sequence 
fused to the 3´ portion of MLL. A band of 1305 bp which corresponded to the germline MLL 
allele and an additional band of 1459 bp were observed on the gel after amplification of PstI 
digested-DNA with primers located in exon 6 and in the proximal 5´ side of intron 6 of MLL 
(Fig. 11B). Sequencing analysis of the latter PCR product showed that a 641 bp unknown 
sequence was fused to MLL. Database searches identified this sequence as part of intron 6 of 
the CCDC94 gene which maps to the 19p13.3 chromosomal region. 
The MLL breakpoint on the der(11) was at nucleotide position 367, 368, or 369 in intron 
5 (GenBank accession number U04737), whereas the MLLT3 breakpoint on the der(11) was 
after either nucleotide 31868, 31869, or 31870 in intron 5 (GenBank accession number 
AL513498). The repetition of 2 and 5 thymine nucleotides at the breakpoints of MLL and 
MLLT3, respectively, precluded exact assignment of the breakpoint locations (Fig. 12). The MLL 
breakpoint on the der(19) was at nucleotide position 206 or 207 in exon 5 (GenBank accession 
number U04737), and the CCDC94 breakpoint was either after nucleotide 58267 or 58268 in 
intron 6 (GenBank accession number AC008616). Again, these breakpoints could not be 
precisely defined because of the 2 thymine nucleotides at the breakpoints of both genes. 
Depending on the exact breakpoint positions, there were 161-164 nucleotides from the 
same MLL sequence on der(11) and der(19). This observation is compatible with the 
occurrence of 2 breaks occurring in each strand of MLL separated by 161-164 bases that 
originated single-stranded configuration overhangs. Subsequently, the double-stranded 
configuration would have been restored by polymerization of the sequence between both 
breaks in a template-dependent manner, therefore originating a duplicated sequence from 
MLL on both derivative chromosomes. We detected short homologous sequences at the 
breakpoint junctions of MLL and MLLT3, and of CCDC94 and MLL, suggesting that the non-
homologous end joining (NHEJ) pathway of double strand break repair was involved in fusion 
of 5´ MLL to MLLT3 and of CCDC94 to 3´ MLL (Felix et al., 1995). 
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5´-AGGACCGCCAAGAAAAGAAGTTCCCAAAACCACTCCT...GTATGATTTGAAGTCTTCAGTTCAAGAAAATCAGCT-3´
5´-GACCCTTTAATCTATATTATTAAAAAAATTTTTTTGGGGGGAAGGTCTCACTCTATTGCCCAGGCTGGAGTGCAGT-3´
5´-CCTAACAAAACATTCAATTTACTGATAGATTTTTCTTTTTCTTTTTATGTATAATTTTTCTTAGGGAAGAAAAATA-3´
206 207
5´-GACCCTTTAATCTATATTATTTCCCAAAACCACTCCT...GTATGATTTGAAGTCTTCAGTTCAAGAAAATCAGCT-3´
der(11) 5´-AGGACCGCCAAGAAAAGAAGTTCCCAAAACCACTCCT...GTATGATTTGAAGTCTTTTCTTAGGGAAGAAAAATA-3´
der(19)
MLL
CCDC94
MLLT3
↓↓
367 369
↑↑
↑ ↑
58267 58268
↑
(31870) (31868)
↑↑↑
 
 
Figure 12. Genomic sequence fusions originated at the der(19) and der(11) breakpoints.  
Partial genomic sequences of the antisense strand of CCDC94 (reverse of GenBank accession number AC008616), 
MLL (GenBank accession number U04737), and MLLT3 (reverse complement of GenBank accession number 
AL513498), and of the corresponding junction sequences on the der(19) and der(11). Numbers between brackets 
indicate nucleotide positions in the original GenBank sequence. Vertical solid lines indicates homology between 
CCDC94, MLL, or MLLT3, and the corresponding derivative chromosomes. A box represents a duplicated MLL 
sequence between nucleotide positions 206 or 207 in exon 5 and nucleotide positions 367, 368 or 369 in intron 5. 
An arrow pointing downwards indicates localization of possible breakpoints in CCDC94 and MLL, whereas an arrow 
pointing upwards indicates localization of possible breakpoints in MLL and MLLT3. The MLL exon 5 sequence is 
shown in italics. Microhomologies of 3-5 bp between MLL and MLLT3 and between CCDC94 and MLL are underlined. 
 
 
In theory a truncated CCDC94 protein could be expressed on the der(9) as a result of the 
fusion of the translocated CCDC94 allele to chromosome 9 sequences. To test this hypothesis, 
a 3´ RACE analysis was performed to identify the rearranged CCDC94 transcript. After nested 
PCR, two major bands of 827 bp and 297 bp were amplified (Fig. 13). Sequencing analysis 
showed that the upper band corresponded to the non-rearranged CCDC94 transcript 
originating from the normal chromosome 19 whereas the lower one consisted in the fusion of 
exon 6 of CCDC94 to the antisense strand of the MLLT3 gene. This fusion transcript comprised 
112 nucleotides from the antisense strand of MLLT3 corresponding to positions 43009-43120 
in BAC RP11-336O12 (GenBank accession number AL513498) and contained a poly-A signal 
(AAUAAA) resulting in the addition of a poly-A tail 18 nucleotides downstream. Because there 
was no stop codon within this sequence to end protein synthesis, the hybrid protein cannot 
detach from the ribosome, thus rendering the truncated CCDC94 transcript non-functional. 
The transcribed sequence from the MLLT3 antisense strand on the der(9) started at position 
43009 while the genomic breakpoint of MLLT3 on the der(11) was at the more telomeric 
positions 31870, 31869, or 31868 (GenBank accession number AL513498). A detailed 
inspection of the genomic sequence surrounding position 43009 from MLLT3 revealed the 
presence of an AG dinucleotide at positions 43007-43008, suggesting that a cryptic splice site 
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was used to add the additional 112 nucleotides from chromosome 9 to the CCDC94 truncated 
transcript. 
 
 
GAAGCCAGAAAGCGAAGACTGCTGGAGGACTCCGACTCAGAGGATGAGGCTGCT
E  A  R  K  R  R  L  L  E  D  S  D  S  E  D  E  A  A
CCCTCGCCCCTGCAGCCAGCCCTTCGGCCCAACCCCACCGCCATCCTGGATGAG
P  S  P  L  Q  P  A  L  R  P  N  P  T  A  I  L  D  E 
GACACAGCAAGAACGCAGCCATCTGCAAGCCAGGAAGAGAGACCTTACCAGATT
D  T  A  R  T  Q  P  S  A  S  Q  E  E  R  P  Y  Q  I 
CCTTGTTGGACTTCCCAGCCTTTAAAACTGCGAGAAATAAATTGCTGTTGCTTA
P  C  W  T  S  Q  P  L  K  L  R
AGACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
↑
43120
43009
827 bp
297 bp
 
 
Figure 13. Analysis of CCDC94 transcripts by 3´ RACE and direct sequencing. 
Left: Agarose gel electrophoresis analysis of PCR products obtained by RACE. Bands of 827 bp and 297 bp were 
amplified corresponding to the non-rearranged and rearranged CCDC94 transcripts, respectively. Right: Partial 
sequence of the CCDC94 rearranged transcript. The CCDC94 exon 6 sequence is shown in italics whereas the 
remaining sequence corresponds to the antisense strand of MLLT3 between nucleotide positions 43009 and 43120 
(GenBank accession number AL513498), followed by a poly-A tail. The arrow indicates the fusion point (position 
43009) of MLLT3 to CCDC94. The poly-A signal (AATAAA) is shown in boldface. The four base sequence TGAG 
(underlined) at the end of CCDC94 exon 6 sequence is also present on the antisense strand of MLLT3 between 
positions 43005 and 43008 immediately before the fusion point (not shown on this sequence). Capital letters below 
the mRNA sequence indicate the corresponding aminoacid residues. 
 
 
Confirmation that the 19p13.3 breakpoint interrupted the CCDC94 gene was obtained 
by FISH following hybridization of the patient´s metaphase cells with the BAC probe CTB-
144D21, which contains the genomic sequence from exon 2 to the 3´ end of CCDC94 (Fig. 14). 
Interestingly, the breakpoint was only approximately 90 kb telomeric of the SH3GL1 gene, 
another known partner gene of MLL in the t(11;19)(q23;p13.3) (So et al., 1997), suggesting 
preferential breakage at this chromosomal region in MLL-associated leukemias. 
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Figure 14. Analysis of CCDC94 rearrangement by FISH in a metaphase with t(9;11;19). 
(A) Representation of human chromosome 19 and of a partial 19p13.3 segment indicating the localization and 
orientation (vertical arrows) of CCDC94 and 8 other known genes in this region. SH3GL1 and MLLT1 are 2 MLL 
partner genes involved in t(11;19)(q23;p13.3). The location of BAC CTB-144D21 covering the CCDC94 gene at 
chromosome band 19p13.3 is shown as a red vertical line. The horizontal arrow indicates the approximate location 
of the chromosomal breakpoint in the t(9;11;19). A scale is shown in kb starting from the telomere of the short arm. 
(B) Left: Hybridization of a metaphase cell with t(9;11;19) using BAC CTB-144D21. Right: Corresponding schematic 
representation of the location of hybridization signals on the derivative chromosomes. In addition to the normal 
chromosome 19, signals were also present on the der(9) and der(19), confirming the presence of a breakpoint 
within the CCDC94 gene. 
 
 
3.2.5.3. THE CCDC94 GENE IS UBIQUITOUSLY EXPRESSED IN HUMAN CELLS 
 
To date, there are no experimental data on the CCDC94 gene except for its mRNA 
sequence and corresponding annotation (GenBank accession number NM_018074). According 
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to the human genome reference sequence database, the coding sequence of CCDC94 is 
distributed over 8 exons in a region of approximately 27 kb. RT-PCR and sequence analysis of 
the complete CCDC94 coding sequence in 2 cell lines (SW480 and HT29) using primers at the 
initial ATG codon and at the 3´ side of the stop codon yielded an expected PCR product of 983 
bp, thus confirming the predicted exon/intron structure of the gene (results not shown). 
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Figure 15. Expression profile of the CCDC94 gene in human cells. 
(A) Agarose gel electrophoresis analysis of CCDC94 expression and G3PDH control expression in 16 different normal 
human tissues and cells. (B) Agarose gel electrophoresis analysis of CCDC94 expression and ABL1 control expression 
in 12 different tumour cell lines. The CCDC94 gene was expressed in all cDNA samples tested, although at 
apparently low levels in REH and 697 lymphoid cell lines. Sizes of PCR products are shown at the right of the gel 
images. 
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RT-PCR was also used to assess the expression of CCDC94 in 16 different normal human 
tissues and cells as well as in 12 tumour cell lines of a variety of origins. The results showed 
that the CCDC94 transcript was amplified in every normal sample, indicating that the gene is 
ubiquitously expressed in human cells (Fig. 15A). In cell lines, the expression levels of CCDC94 
were more similar among those of non-hematopoietic origin than between those of 
hematopoietic origin (Fig. 15B). In particular, expression of CCDC94 was significantly lower in 2 
(REH and 697) out of 3 B-cell lymphoblastic leukemia cell lines comparing to those of myeloid 
lineage (NB4, LAMA-84 and Kasumi-1), indicating that this gene may have a more pronounced 
role in myeloid lineage cells. 
 
 
3.2.5.4. CCDC94 IS A NUCLEAR PROTEIN WITH A ROLE IN CELL CYCLE PROGRESSION 
 
According to the GenBank database, CCDC94 has an open reading frame of 972 
nucleotides which encode a 323-aminoacid protein. Protein homology searches revealed that 
CCDC94 belongs to the conserved DUF572 family of eukaryotic proteins of unknown function. 
However, similarity searches followed by BLAST alignment showed that CCDC94 is highly 
similar to the 270-aminoacid cell cycle control protein cwf16 of the yeast Schizosaccharomyces 
pombe. The similarity region includes aminoacids 1-192 of CCDC94 and aminoacids 1-204 of 
cwf16, of which approximately half (99 residues) are identical (Fig. 16). Using the Psort II 
computer program, the complete CCDC94 hypothetical protein sequence (GenBank accession 
numbers AAH19096, AAH00561 and NP_060544) was searched for functional motifs. We 
found that CCDC94 contains 2 coiled-coil (CC) domains in the middle region of the protein and 
2 regions at aminoacid positions 203-206 and 238-246 whose corresponding residues, RKRR 
and PKPKRKVEV respectively, matched the consensus nuclear localization signal (NLS) (Fig. 
17A). Furthermore, CCDC94 contains proline at a frequency of 8%, which is above the average 
rate of 4.1% in human proteins, suggesting a possible role as a transcriptional activator 
(Nakamura et al., 1993). 
With these data in mind, the entire coding sequence of CCDC94 was cloned in 2 
expression vectors which were used to transfect 3 cell lines (HeLa, NIH-3T3 and DLD1) in order 
to determine its intracellular localization and its potential role in the cell cycle. The 
transcription of the CCDC94 mRNA originates a protein with a calculated molecular mass of 37 
kDa. To confirm the expression of the CCDC94 protein, Western blot analysis was performed 
with HeLa cell lysates using anti-GFP (Fig. 17B) and anti-FLAG (results not shown) antibodies. 
  
61 3. Results 
For every cell line/construct combination tested, the epitope-tagged CCDC94 protein localized 
to the nucleus and was absent from the cytoplasm (Fig. 17C). 
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Figure 16. Sequence alignment between the human CCDC94 protein and the cwf16 protein of S. pombe. 
(A) Aminoacid sequence alignment between CCDC94 (GenBank accession number NP_060544) and cwf16 (GenBank 
accession number Q9P7C5) using BLAST analysis with compositional score matrix adjustment (Altschul et al., 2005). 
The intervening sequence represents aminoacid identity (letter) and aminoacid similarity (plus sign) between 
CCDC94 and cwf16. Black dots indicate dissimilar aminoacids. Numbers indicate aminoacid positions. Horizontal 
bars in CCDC94 and cwf16 represent sequence gaps. (B) Dot matrix view of CCDC94 and cwf16 alignment. Lines in 
the graph indicate regions of aminoacid similarity between proteins. The region between positions 1 and 192 of 
CCDC94 is highly similar to the region comprised between aminoacids 1 and 204 of cwf16. A smaller region of 
CCDC94 between aminoacids 13 and 32 is also similar to aminoacids 251 to 270 of cwf16. X- and Y-axis represent 
CCDC94 and cwf16 aminoacid sequences, respectively. 
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Figure 17. Domain composition, expression and intracellular localization of the human CCDC94 protein. 
(A) Diagrammatic representation of the putative 323-aminoacid CCDC94 protein containing 2 CC domains and 2 
NLS. The arrow underneath the protein outline indicates the approximate location of the CCDC94 breakpoint in 
t(9;11;19) in respect to its corresponding coding sequence. The breakpoint was immediately upstream of the 
sequence coding for the most C-terminal NLS. (B) Western-blot results of GFP- and GFP-CCDC94-transfected HeLa 
cell lysates probed with rabbit anti-GFP ab290 antibody. Approximate sizes of protein bands are shown alongside 
the gel image. (C) Left panels: Red-green-blue (RGB) images corresponding to immunofluorescence analyses of NIH-
3T3 cells transfected with GFP- and GFP-CCDC94, and of HeLa cells transfected with FLAG-CCDC94. Right panels: 
Corresponding grey images of the green channel. For either cell type the CCDC94 protein was exclusively found in 
the nucleus. In NIH-3T3 cells, GFP alone and GFP-CCDC94 were detected using the same antibodies as for Western 
blot. Detection of the CCDC94 protein in cells transfected with FLAG-tagged cDNA was performed using a primary 
mouse anti-FLAG M2 antibody followed by secondary goat anti-mouse FITC antibody. The actin cytoskeleton and 
nuclear shape were visualized using phalloidin-TRITC and DAPI, respectively, in cells transfected with either tag. 
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CS-starved mouse fibroblasts are a well-characterized cell model system to study cell 
cycle progression, as previously described (Matos & Jordan, 2005). These cells significantly 
decrease the rate of the G1- to S-phase transition of the cell cycle when the CS concentration 
in culture medium is reduced from 10% to 1%. Thus, to evaluate a potential role of the CCDC94 
protein in the G1- to S-phase progression, NIH-3T3 cells were starved in 1% CS, after which the 
percentage of BrdU incorporation into replicated DNA was compared between cells 
transfected with the CCDC94 cDNA or the expression vector alone. 
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Figure 18. Effect of CCDC94 expression on G1- to S-phase cell cycle progression and on survival of NIH-3T3 cells. 
(A) Results of the G1- to S-phase cell cycle progression assays. CCDC94 induced a decreased rate of G1- to S-phase 
transition in serum-starved fibroblasts compared to the empty vector. The percentage of BrdU incorporation in 
serum-starved NIH-3T3 cells transfected with the highly oncogenic H-RAS gene (V12Ras) is also shown for 
comparison. Bars represent the average values of 2 independent experiments. Vertical lines on top of the bars 
indicate standard deviation. (B) Results of the cell survival assay. CCDC94 had no relevant positive effect on NIH-3T3 
cell survival after 24 hr of starvation in a serum-free medium compared to the empty vector. The percentage of 
viable NIH-3T3 transfected cells with oncogenic V12Ras is shown for comparison. 
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Incorporation of BrdU was observed in 54.9% of the cells [total cells counted (n)=305] 
transfected with the GFP vector alone, whereas it was restored in 83.5% of the cells (n=332) 
transfected with oncogenic H-RAS cDNA used as a control (Fig. 18A). In contrast, only 41.8% of 
cells (n=281) expressing the CCDC94 protein were BrdU-positive. Thus, the expression of the 
CCDC94 protein further inhibited the rate of G1- to S-phase transition in a statistically 
significant manner (P=0.013). However, the expression of CCDC94 had apparently no effect on 
cell viability, because after 24 hr of starvation in CS-free medium, 36% of cells (n=121) 
transfected with the empty vector were alive as compared to 38% of cells (n=116) containing 
the CCDC94 protein (Fig. 18B). 
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Figure 19. Suppression of CCDC94 transcripts in NIH-3T3 cells. 
Upper panel: Agarose gel electrophoresis analysis of CCDC94 and ABL1 RT-PCR products amplified from serum-
starved NIH-3T3 cells transfected with siRNA oligos. Corresponding sizes of amplification products are shown on 
each side of the gel image. Lower panel: Graphical representation of densitometric analysis of the RT-PCR products. 
The ABL1 amplicon was used as a loading normalizer, and the values of CCDC94 expression were plotted as a 
percentage of the cells transfected with GFP siRNA. Bars represent the average values of 2 independent 
experiments. Vertical lines on top of the bars indicate standard deviation. 
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To confirm the role of CCDC94 in cell cycle regulation, RNA interference was performed 
to knock down endogenous CCDC94 expression in NIH-3T3 cells. Following 24 hr of siRNA 
transfection, CCDC94 transcript levels assessed by densitometric analysis of semi-quantitative 
RT-PCR results showed successful suppression down to 25% and 36.4% with siRNA oligos 
msCCDC94_1 and msCCDC94_2, respectively, compared to the control GFP siRNA (Fig. 19). 
Under these conditions, incorporation of BrdU, which dropped to 46.7% (n=467) in cells 
transfected with GFP siRNA, was rescued to 77% (n=607) and 75.6% (n=599) with msCCDC94_1 
and msCCDC94_2, respectively (Fig. 20). These data show that a reduction in CCDC94 
expression stimulates cell cycle progression and proliferation. 
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Figure 20. Effect of CCDC94 suppression on G1- to S-phase cell cycle progression of NIH-3T3 cells. 
Transfection with either CCDC94 siRNA resulted in increased numbers of BrdU-positive cells after 24 hr incubation 
when compared to the control (GFP). Left: Representative immunofluorescence images of serum-starved NIH-3T3 
cells transfected with GFP, msCCDC94_1, and msCCDC94_2 siRNAs. Right: Graphical representation of quantitative 
analysis of cell numbers. The average of 2 independent experiments is shown. Vertical lines indicate standard 
deviation. 
 
 
3.2.6. DISCUSSION 
 
We have described an infant patient with AML-M4 whose leukemic cells harbored a 
t(9;11;19)(p22;q23;p13.3) with involvement of the MLL gene at 11q23. The rearrangement 
resulted in the fusion of MLL to the MLLT3 gene on the der(11), as seen in leukemia patients 
with a classical t(9;11)(p22;q23) (Iida et al., 1993; Nakamura et al., 1993). However, the 
presence of an extra chromosome breakpoint at band 19p13.3, where 2 other MLL partner 
genes, MLLT1 (Tkachuk et al., 1992) and SH3GL1 (So et al., 1997), are localized, suggested that 
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MLL could also have rearranged with another gene in the same region. To test this hypothesis, 
we developed LDI-PCR assays to clone the breakpoints on the der(11) and der(19). Sequence 
analysis of the amplified MLL-MLLT3 genomic fusion on the der(11) showed that intron 5 of 
MLL was fused to MLLT3 intron 5, resulting in an in-frame MLL exon 5-MLLT3 exon 6 fusion 
transcript. On the der(19), the 3´ part of MLL was joined to the sequence of a novel gene 
known as CCDC94. This gene runs 5´ to 3´ from the telomere to centromere on the short arm 
of chromosome 19 whereas MLL lies 5´ to 3´ from the centromere to telomere on 11q. Thus, 
no functional fusion gene can be generated between CCDC94 and MLL as a consequence of the 
translocation because these 2 genes are oriented in opposite directions on the der(19). The 
same evidence applies to the MLLT3-CCDC94 fusion on the der(9) that we amplified, because 
MLLT3 runs 5´ to 3´ from the centromere to the telomere of the chromosome 9 short arm. 
Thus, the chromosome 19 breakpoint in the t(9;11;19) likely resulted in loss of function of one 
CCDC94 allele. 
MLLT3 contains 2 major breakpoint cluster regions, BCR1, in intron 4, and BCR2, in the 
region spanning introns 7 and 8 (Strissel et al., 2000). Recently, breakpoints in intron 3 and the 
centromeric region of intron 4 were reported in rare ALL and t-AML cases (Langer et al., 2003). 
We could not find another case with a breakpoint in intron 5 and/or with a direct fusion of 
MLLT3 exon 6 to MLL, as shown in the present patient, in other reports of t(9;11)-positive 
patients in which the MLL-MLLT3 fusion had been analyzed at the genomic and/or RNA levels 
(Iida et al., 1993; Nakamura et al., 1993; Negrini et al., 1993; Yamamoto et al., 1994; Felix et 
al., 1995; Super et al., 1997; Atlas et al., 1998; Odero et al., 2000; Strissel et al., 2000; Langer et 
al., 2003; Whitmarsh et al., 2003). Despite its atypical localization, the intron 5 breakpoint 
region was nevertheless contained within the SAR2 region of MLLT3 (Strissel et al., 2000). SARs 
are A/T-rich DNA regions of variable size found mainly in the non-transcribed flanking regions 
or in transcribed intronic regions of genes. Because of their DNA unwinding properties, SARs 
facilitate the access of protein factors responsible for regulating transcription, replication, or 
chromosome condensation to target sequences (Strissel et al., 2000). In CCDC94, the 
breakpoint site is in a 23 bp A/T tract, which may indicate that it is also in a putative SAR. 
Although there is no published study on SARs in CCDC94, the present data indicate that these 
DNA structural elements may be implicated in the fusion of both MLLT3 and CCDC94 to MLL in 
the patient with t(9;11;19). 
Sequence analysis of the MLL breakpoints on the der(11) and der(19) showed that a 
duplicated sequence from MLL of 161-164 bp was present in both derivative chromosomes. De 
novo leukemias associated with MLL rearrangements often contain duplications or deletions of 
several hundred base pairs at the involved breakpoints (Super et al., 1997; Raffini et al., 2002). 
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By contrast, in treatment-related cases in which DNAt2 inhibitors have been implicated, 
interchromosomal DNA recombination was achieved with the loss of no or only a few bases 
(Lovett et al., 2001; Whitmarsh et al., 2003). Although there was no evidence to support the 
involvement of DNAt2 in DNA damage in our case, it is possible that the duplication may have 
originated from 2 staggered nicks introduced by 2 DNAt2 in the double-stranded MLL DNA 
followed by subsequent template-directed polymerization of the single-stranded overhangs 
between the staggered nicks. In this context, a large epidemiological study has shown that 
maternal consumption of specific naturally-occurring DNAt2 inhibitors during pregnancy 
increases the risk of AML cases with MLL rearrangements (Spector et al., 2005). The presence 
of microhomologies at the breakpoint junctions of MLL and MLLT3 and of MLL and CCDC94 
suggests that the NHEJ mechanism of double-strand break repair was involved in the genesis 
of the translocation (Felix et al., 1995). 
In our study expression of the CCDC94 gene was observed in all cell lines and normal 
tissue tested, indicating that this gene is ubiquitously expressed in human cells. The CCDC94 
protein contains 2 CC domains, two NLS at the C-terminus, and is rich in proline. These 
structural motifs are shared by other partner genes participating in MLL-associated 11q23 
aberrations, including AF4, MLLT3, and MLLT1 (Nakamura et al., 1993), which suggests that 
CCDC94 may also have similar properties. The fission yeast protein cwf16 is highly homologous 
to CCDC94 and is part of a large multiprotein complex containing Myb-related protein cdc5, 
implicated in pre-mRNA splicing and cell cycle progression (Ohi et al., 2002). Within the 
complex, the cwf16 gene is essential, although its exact function has not been determined (Ohi 
et al., 2002). In agreement with this, the homologous human protein CCDC94 localized 
exclusively to the nucleus in every cell line/expression vector combination analyzed in this 
study. Furthermore, expression of the protein in NIH-3T3 cells specifically resulted in a 
decrease in the G1- to S-phase transition but did not affect cell survival. When the CCDC94 
transcript was knocked down using siRNA, an increase in cell proliferation was observed. These 
results suggest that the CCDC94 protein is a negative regulator of cell cycle progression. In the 
AML patient with t(9;11;19), one copy of the CCDC94 gene was rendered non-functional. Thus, 
haplo-insufficiency of CCDC94 may have deregulated cell cycle progression of leukemic cells 
carrying t(9;11;19), therefore facilitating proliferation of the malignant clone. Assessment of 
the CCDC94 expression in the patient´s bone marrow cells was not performed due to the fact 
that the sample available for the RNA studies had been obtained at disease relapse and 
contained a significant proportion (>25%) of donor cells. 
As a means to understand the mechanism of MLL fusion proteins in vivo, knock-in 
murine models (Corral et al., 1996; Dobson et al., 1999) and retroviral-mediated transduction 
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assays (Lavau et al., 1997) have been developed for the MLL-MLLT3 and MLL-MLLT1 fusions, 
respectively. Studies using these models confirmed that expression of either fusion protein 
could promote leukemogenesis in mice. However, they also showed that the latent period for 
leukemia onset is relatively long (Lavau et al., 1997; Dobson et al., 1999). In another retrovirus-
mediated gene transfer experiment, it was demonstrated that only a very small number of 
myeloid cells expressed significant levels of the MLL fusion proteins 10 weeks after bone 
marrow transplantation of hematopoietic progenitors transduced with the MLL-ELL fusion 
gene (Lavau et al., 2000). However, high expression was observed when the animals 
succumbed to AML, between 100 and 200 days after transplantation (Lavau et al., 2000). 
These results indicate that additional mutations are likely necessary for the leukemic clone 
carrying an MLL translocation to achieve full tumorigenic potential. In particular, short latency 
leukemias like those associated with the MLL-MLLT3 fusion suggest that a simultaneous 
double hit may occur, thus reducing the need for the acquisition of subsequent mutations 
(Ayton & Cleary, 2001). In the present case, deregulated cell cycle arrest induced by haplo-
insufficiency of CCDC94 along with an MLL gain of function may have cooperatively promoted 
leukemogenesis in the AML carrying the t(9;11;19). Interestingly, molecular analysis of another 
complex translocation involving chromosomes 4, 7, and 11 in a patient with ALL disclosed that 
in addition to an MLL-AF4 fusion gene, the 3´ portion of the MLL gene was fused in-frame with 
the cyclin-dependent kinase 6 (CDK6) gene on chromosome 7 (Raffini et al., 2002). In this case, 
it is possible that the CDK6-MLL fusion protein may have contributed to leukemogenesis as 
well. The main role of CDK6 in cell cycle progression and its frequent alteration in B- and T-cell 
malignancies by chromosomal translocation (Corcoran et al., 1999; Su et al., 2004) strengthen 
the idea that disruption of cell cycle control mechanisms is critical for the progression of a 
malignancy. Whether genetic alterations of the CCDC94 gene, other than translocations, also 
occur in other MLL-MLLT3-positive patients exhibiting a reciprocal t(9;11) remains to be 
determined. 
In summary, this work provides evidence for a 3-way complex translocation involving 
MLL and MLLT3 and shows that extra breakpoints may indicate the locations of additional 
genes relevant to the proliferation of myeloid cells that otherwise might remain unnoticed. 
One such candidate gene is CCDC94. 
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3.3. THREE-WAY TRANSLOCATION (X;20;16)(p11;q13;q23) IN 
ESSENTIAL THROMBOCYTHEMIA IMPLICATES NFATC2 IN 
DISREGULATION OF GM-CSF EXPRESSION AND MEGAKARYOCYTE 
PROLIFERATION 
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3.3.1. ABSTRACT 
 
ET is a chronic MPN essentially characterized by a sustained excessive amount of 
circulating platelets. Molecular pathogenesis of ET is linked in approximately half of the 
patients to a defect in intracellular cytokine signaling pathways as a result of JAK2 and/or MPL 
gene gain-of-function mutations. However, no genetic defects associated with cytokine 
production and/or regulation has been identified in ET or in other MPN subtypes. Using 
molecular cytogenetics, PCR and whole-genome array analyses, we uncovered a 
submicroscopic deletion at 20q13 in a JAK2V617F-positive ET patient with an acquired 3-way 
t(X;20;16) which deleted the nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 2 (NFATC2, also known as NFAT1 or NFATP) gene. This gene encodes a transcription 
factor involved in the regulation of hematopoietic cytokines and is located at a genomic region 
frequently targeted by chromosome 20q deletions in MPN patients. RNA interference-
mediated suppression of NFATC2 mRNA increased the levels of GM-CSF mRNA and promoted 
proliferation of a JAK2V617F-positive ET cell line in vitro. These effects were also observed 
upon treatment of cells with a cell-permeable inhibitor of NFATC2, indicating that loss of 
NFATC2 may promote proliferation of megakaryocytes through an up-regulation of myeloid 
lineage-specific cytokines. Preliminary studies also showed lower levels of NFATC2 mRNA by Q-
PCR in granulocytes of ET patients. Moreover, because the t(X;20;16) also resulted in the 
deletion of the transcription factor MAF at 16q23, we hypothesize that haplo-insufficiency of 
NFATC2 and MAF genes concurred to promote abnormal production of cytokines in the ET 
patient. Taken together, these results indicate that pathogenesis of ET may also be linked to 
genetic defects of transcription factor genes involved in the regulation of cytokine expression 
and further suggest that megakaryocyte proliferation may be under the control of the 
calcineurin-NFAT pathway. 
 
 
3.3.2. INTRODUCTION 
 
MPNs are a group of clinically and biologically-overlapping disorders characterized by 
proliferation of terminally-differentiated erythroid, megakaryocytic and/or myeloid cells. ET is 
a MPN characterized clinically and pathologically by proliferation of enlarged megakaryocytes 
in the bone marrow and persistent increase of platelet count in the peripheral blood (Michiels 
& Thiele, 2002). ET also shares with PV and PMF several features including, for instance, non-
random chromosome abnormalities, marrow hypercellularity and fibrosis, thrombosis and 
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hemorrhage, extramedullary hematopoiesis, and a predisposition for transformation to acute 
leukemia (Spivak, 2004). In particular, the risk of transformation to other myeloid disorder 
increases from 9.1% in the first decade to 58.5% in the third decade of the disease (Wolanskyj 
et al., 2006). 
The pathogenesis of ET, PV and PMF is closely linked to abnormalities of the cytokine 
signaling apparatus (Kaushansky, 2006). Earlier works in PV patients have shown that erythroid 
progenitor cells form endogenous colonies in vitro in the absence of erythropoietin (Prchal & 
Axelrad, 1974) and that the erythroid, granulocyte-macrophage and megakaryocyte 
progenitors are hypersensitive to interleukin-3 (IL-3) and granulocyte-macrophage colony 
stimulating factor (GM-CSF) in vitro (Dai et al., 1992). In essential thrombocythemia, 
megakaryocytic progenitor cells display hypersensitivity to recombinant thrombopoietin (TPO) 
(Axelrad et al., 2000). More recently, investigations of the defects of erythropoietin signaling in 
MPN patients led to the discovery of a somatic gain-of-function mutation of the JAK2 gene 
(James et al., 2005). The JAK2V617F mutation was reported to occur in the majority of patients 
with PV and in approximately half of those with PMF or ET (Baxter et al., 2005; James et al., 
2005; Jones et al., 2005; Kralovics et al., 2005). Moreover, gain-of-function mutations in the 
MPL gene encoding the TPO receptor are additionally seen in roughly 5% of patients with PMF 
and in rare ET patients but not in those with PV (Pardanani et al., 2006; Pikman et al., 2006). 
Taken together, these data link a cytokine signaling defect in MPN patients to constitutive 
activation of the JAK-STAT pathway as a result of JAK2V617F or other mutations. However, 
genetic events in MPN patients potentially responsible for abnormalities in the expression and 
regulation of cytokine genes remain to be determined. 
Here we describe the cytogenetic and molecular study of an acquired 3-way complex 
translocation detected in the bone marrow cells of an ET patient. The rearrangement was 
associated with 2 submicroscopic deletions at chromosome bands 20q13.13 and 16q23.1-
16q23.2. The 20q deletion overlapped 3 genes only, including NFATC2, ATPase class II type 9A 
(ATP9A), and SAL-like 4 (SALL4). We focused our attention on NFATC2 because it is expressed 
at high levels in CD34+ and megakaryocytic cells (Kiani et al., 2004). NFATC2 belongs to the 
NFAT-family of transcription factor proteins which reside in the cytosol in an inactive 
phosphorylated conformation. In response to an elevation in cytosolic Ca2+ levels, NFAT 
proteins are dephosphorylated by calcineurin, a Ca2+/calmodulin-dependent phosphatase 
(Hogan et al., 2003). Dephosphorylation of serine residues in the NH2-terminal activation 
domain of NFAT exposes a NLS and masks a nuclear export signal (NES), therefore enabling 
NFAT proteins to translocate to the nucleus (Okamura et al., 2000). In the nuclear 
compartment, activated NFAT proteins associate as dimers or cooperate with other 
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transcription factors such as AP-1 (FOS/JUN) to drive the expression of several cytokines in 
hematopoietic cells including interleukin-2, IL-3, interleukin-4 and GM-CSF (Cockerill et al., 
1993; Luo et al., 1996). 
On this basis we simulated a deficient NFATC2 activity in a JAK2V617F-positive ET cell 
line through suppression of the NFATC2 transcript or inhibition of NFAT-calcineurin protein 
interaction in vitro. Results of both assays showed an up-regulation of GM-CSF mRNA levels 
and an increase in megakaryocyte proliferation. Accordingly, we found that the levels of 
NFATC2 mRNA in granulocytes of ET patients were reduced compared to normal individuals. 
Taken together, these results indicate that haplo-insufficiency of NFATC2 as a result of del(20q) 
or other mechanisms may contribute to proliferation of JAK2V617F-positive megakaryocytes. 
 
 
3.3.3. CASE SUMMARY 
 
A 54-year old female patient presented with a 2-year history of epigastric discomfort. 
Endoscopy scanning revealed hiatus hernia and gastritis. Abdominal ecographic examination 
showed splenomegaly. Peripheral blood white cell count and leukocyte differential were 
normal whereas the platelet numbers were elevated (900x109/L). Bone marrow aspirate smear 
was normocellular whilst showing markedly increased numbers of megakaryocytes with a 
hyperlobulated nucleus. Bone marrow biopsy was hypercelullar and showed proliferation of 
enlarged megakaryocytic cells. A diagnosis of ET was established based on the clinical, 
hematological and molecular findings, including absence of BCR-ABL1 fusion transcripts and 
presence of the JAK2V617F mutation in the peripheral blood. 
 
 
3.3.4. MATERIALS AND METHODS 
 
3.3.4.1. COLLECTION AND PREPARATION OF SAMPLES 
 
A prior informed consent was obtained from each patient. Leukocyte genomic DNA was 
extracted from ethylenediamine tetraacetic acid (EDTA)-collected blood samples using the 
robotic workstation MagNA Pure LC Instrument (Roche Applied Science). Peripheral blood 
mononuclear cells were separated using Lymphoprep (Axis-Shield PoC AS) whereas 
granulocytes were isolated from the lower interface of the Lymphoprep density gradient 
following standard erythrocyte lysis. 
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3.3.4.2. CYTOGENETIC AND FLUORESCENCE IN SITU HYBRIDIZATION ANALYSES OF CHROMOSOME 
REARRANGEMENTS 
 
A bone marrow cell karyotype of the patient was established at diagnosis using standard 
cytogenetic procedures. Analysis of chromosome rearrangements including breakpoint 
localization was performed using FISH as previously described (Vieira et al., 2005). FISH probes 
included WCP probes for chromosomes 16, 20 and X (Cambio) and several YAC, BAC and P1 
artificial chromosome (PAC) probes mapping to the long arm of chromosome 20 (Table VI). 
  
Table VI. Localization of clones used as FISH probes and corresponding STS markers and primer sequences. 
Clone name Clone type Localization STS marker Primer sequence (5´-3´) 
RP11-17F3 BAC 20q12 D20S108 
F:AAGACACTGTCCANACATACA 
R:CAACAAGTCAGAAGTGGCAA 
RP11-69I10 BAC 20q13.11 ns na 
RP11-169A6 BAC 20q13.12 RH66078 
F:ACCTTCAGAAGAGGCTCTTGG 
R:GGCCTTGCTCAGAAGTTTTG 
RP11-314A4 BAC 20q13.12 ns na 
RP11-124D1 BAC 20q13.12 ns na  
RP11-72F10 BAC 20q13.13 D20S109 
F:AAACACACATACAAACACACGCAG 
R:TCATACCCAGTCCTCTCAAAACTC 
773G6 YAC 
20q13.13 D20S869 
F:TGCTTTGTGTGACTGACCA 
R:TGTCAACAGCCAGGTCCTA RP5-914P20 PAC 
RP5-1009H6 PAC 20q13.13 SHGC-144024 
F:CTTCAACTGGTTGTGCTGAAATG 
R:AATCTTTGTGGCAGAAATGGAAA 
957F3 YAC 
20q13.13 D20S857 
F:GGGCACCCATAGGTCTCT 
R:TTTCACAGGGAGTAGGGCT RP5-994O24 PAC
 
RP5-1114A1 PAC 20q13.13 SHGC-83700 
F: GCTCCTGATACTGGTCTGGAAAA 
R:GCAAGGCAAAGATACCCTAGTCA 
RP5-827A12 PAC 20q13.13 D20S185 
F:CTAGGGCCTGGCTGGT 
R:GGGCCTTCATGCTTCA 
RP5-1112F19 PAC 20q13.13 GDB-315181 
F:TCCAGGTGTGTAAGACAGG 
R:AAACTCTGGAACCTGGGAG 
RP4-756P4 PAC 20q13.13 D20S845 
F:AACCAAATCAGAATACACTGGAA 
R:CTCACAACTTGGCAAGAAA 
RP5-831D17 PAC 20q13.13 D20S1083 
F:GGTGGTGATGGAGTCTGAAG 
R:TATTTTCTATCCTTCAAGCTACCC 
RP4-548G19 PAC 20q13.13 RH94187 
F:TCTTGCATGTACGGTAATTTCG 
R:CGACTTACTCTTTTTCATGGCC 
RP4-698O15 PAC 20q13.13 Z94476 
F:CTCCCTCACCTTTGAACCAA 
R:TGGTGTAGGATGGCTAACAGG 
RP5-965N20 PAC 
20q13.13 D20S1057 
F:TTGGAAATGACAGACCTTATTTAGT 
R:TTCCAGCACTGAACACTGCT 
761F3 YAC 
747E8 YAC 
RP5-911I5 PAC 20q13.13 SHGC-78862 
F:CTGGCTTGGCAATTCAAGACTAC 
R:AAGCTCAGGACAGATGCAGAGAT 
RP11-91L1 BAC 20q13.13 
D20S854 
F:TATTGCAGGTAGGAGTCCC 
R:CTTGAAGGTTGATGGTTGG 845F3 YAC 20q13.2 
931H6 YAC 20q13.2 D20S469 
F:AGCTTTCCTAGCCACTCCAT 
R:AGCAAAGGTTAAAAGCACCC 
RP5-981M18 PAC 20q13.2 G01534 
F:CACATGGCCTGAAATGAGCA 
R:TGACATCTTCTTGGCTACAG 
RP11-195N11 BAC 20q13.2 ns na 
Clones are ordered from centromere to telomere; F, forward; na, not available; ns, not selected; R, reverse. 
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Correspondence between clone position and genome sequence was obtained using the 
Map Viewer resource available at the NCBI website (http://www.ncbi.nlm.nih.gov/mapview/). 
YACs were purchased from Fondation Jean Dausset – CEPH (Paris, France) whereas PACs were 
obtained from BACPAC Resources (Oakland, CA). BACs were kindly supplied by Prof. Mariano 
Rocchi (Universitá di Bari, Italy). Authenticity of clone sequences was confirmed by PCR analysis of 
selected sequence tagged site (STS) markers. Primer sequences were obtained from the UniSTS 
database available at the NCBI website. Standard reactions mixtures and amplification parameters 
were utilized. 
 
 
3.3.4.3. DELIMITATION OF THE 20q DELETION BOUNDARIES USING MICROSATELLITE POLYMORPHISMS 
 
The methanol:acetic acid solution was removed from frozen bone marrow cell culture 
pellets after centrifugation. Pellets were digested in cell lysis solution [0.1 M NaCl, 0.001 M EDTA, 
0.01 M (hydroxymethyl)aminomethane (Tris)-HCl (pH 8.0), 0.5% sodium dodecyl sulphate 
(SDS) and 0.1 mg/ml proteinase K] at 56 ⁰C for 3 hours in a thermomixer block. Proteins 
were precipitated by addition of a saturated ammonium acetate solution (11.6 M) followed by 
centrifugation. The DNA in the supernatant was precipitated with 100% ethanol, dried and 
ressuspended in 15 µl Tris EDTA (TE) buffer. 
Six polymorphic STS markers located at 20q13.13 were analysed by PCR (Table VII). Primer 
sequences were obtained from the UniSTS database at www.ncbi.nlm.nih.gov/unists. A 25-µl 
reaction mixture was prepared with 9.55 µl of reaction mix (from AmpFlSTR Profiler Plus PCR 
Amplification Kit, Applied Biosystems), 2 µM of 6-carboxyfluorescein (6-FAM)-labelled forward 
primer, 2 µM of non-labelled reverse primer, 0.05 U/µl AmpliTaq Gold DNA polymerase (Applied 
Biosystems) and 2.5 ng of DNA. Reactions were carried out with an initial denaturation of 11 min 
at 95 ⁰C followed by 28 cycles of 1 min at 94 ⁰C, 1 min at 54-60 ⁰C and 1 min at 72 ⁰C. A final 
extension step of 45 min at 60 ⁰C was performed. Each DNA sample was amplified twice on 
different days. Samples were subsequently analyzed by capillary electrophoresis using the ABI 
Prism 3130xl Genetic Analyzer (Applied Biosystems). The 400HD ROX molecular weight marker 
was used as the internal lane size standard (Applied Biosystems). DNA electropherograms and 
allele areas were obtained using the GeneMapper v3.7 software (Applied Biosystems). Areas of 
alleles with overlapping stutter peak positions were corrected by subtracting the corresponding 
percentage of stutter peak calculated from samples with non-overlapping peak positions. 
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Table VII. STS markers used for delimitation of the 20q deletion. 
STS name 
UniSTS 
no. 
GenBank 
accession 
no. 
Repeat motif Primer sequence (5´-3´) 
Amplicon 
size (bp) * 
Annealing 
temperature 
(⁰C) 
D20S196 80427 Z24373.1 dinucleotide 
F: TTGGTGACCCTGAGACAGAGTG  
145-176 58 
R: AACGAACTACCTGTTGATTTGCTCC 
D20S869 72669 Z51140.1 dinucleotide 
F: TGCTTTGTGTGACTGACCA  
236-286 58 
R: TGTCAACAGCCAGGTCCTA 
D20S857 54045 Z52686.1 dinucleotide 
F: GGGCACCCATAGGTCTCT 
204-220 54 
R: TTTCACAGGGAGTAGGGCT 
D20S185 36005 Z23858.1 dinucleotide 
F: CTAGGGCCTGGCTGGT 
196-214 60 
R: GGGCCTTCATGCTTCA 
D20S845 2856 Z52436.1 dinucleotide 
F : AACCAAATCAGAATACACTGGAA  
148-156 54 
R : CTCACAACTTGGCAAGAAA 
D20S428 149228 L30950.1 tetranucleotide 
F: TCTATAAGTTGGGGCTGCAG 
237 58 
R: CTGAAAATTCCCATCTCCTGA 
* Product sizes correspond to those described at the UniSTS database of STS markers (www.ncbi.nlm.nih.gov/unists) and not 
necessarily to those obtained in the present study; The forward primer was labelled with 6-FAM at the 5´ side. F, forward; n.a., not 
available; R, reverse.  
 
 
3.3.4.4. ANALYSIS OF CHROMOSOME REARRANGEMENTS BY WHOLE-GENOME ARRAY 
 
For microarray analysis a granulocyte cell pellet of the patient was digested in cell lysis 
solution as indicated above. Purification of genomic DNA was obtained by standard phenol-
chloroform extraction and ethanol precipitation. DNA was eluted in TE buffer and quantified 
spectrophotometrically using the Biophotometer (Eppendorf). Approximately 100 ng of DNA were 
analysed using the cytogenetics whole-genome 2.7M array (Affymetrix) which contains 
approximately 2.361 million non-polymorphic markers and 400 thousand SNP markers with an 
average marker spacing of 1000 bp. Results were analyzed using the Chromosome Analysis Suite 
(ChAS) 1.1 software (Affymetrix). Signal intensity values of the sample were compared to those 
from a factory-loaded reference file provided by Affymetrix in the software. 
 
 
3.3.4.5. RAPID AMPLIFICATION OF CDNA ENDS 
 
The 3´ RACE system (Invitrogen) and the 5´ RACE system v. 2.0 (Invitrogen) were used 
according to the manufacturer´s instructions to detect truncated WWOX and NFATC2 transcripts, 
respectively. Briefly, for 3´ RACE analysis 2 μg of total RNA from mononuclear cells were 
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converted to cDNA. PCR was performed using abridged universal amplification primer (AUAP) in 
combination with WWOX-ex8F primer (Table VIII). A semi-nested PCR was performed using AUAP 
in conjunction with WWOX-ex8F1 primer. Amplified products were electrophoresed on a 2% 
agarose gel and purified from the gel using the NucleoSpin Extract II (Macherey-Nagel) kit. For 5´ 
RACE analysis approximately 1.0 µg of total RNA from granulocytes was converted to cDNA using 
a mixture of NFATC2-ex7R1, NFATC2-ex9R, NFATC2-3´A and NFATC2-3´B primers in equivalent 
amounts. An initial amplification reaction was performed using abridged anchor primer in 
conjunction with NFATC2-ex7R1 or NFATC2-3´B primer. A second round of amplification was 
performed using universal amplification primer or AUAP in conjunction with NFATC2-ex6R1 (or 
NFATC2-ex6R2) or NFATC2-ex9R primer, respectively. Amplification products were analysed in 2% 
ethidium bromide stained-agarose gels. Products were purified from the gel using the Jetquick Gel 
Extraction Spin Kit (Genomed) or directly from the PCR mixture using the DNA clean & 
concentrator-5 kit (Zymo Research). Purified products were sequenced in a 10 μl-reaction mixture 
containing 200 nM of primer and 0.5-2 μl of BigDye terminator ready reaction mix v1.1 (Applied 
Biosystems). Sequencing products were analyzed using the ABI Prism 3130xl Genetic Analyzer 
(Applied Biosystems). 
 
 
Table VIII. Primers used for 3´ and 5´ RACE analyses. 
Gene Localization Primer name Primer sequence (5´-3´) 
WWOX exon 8 WWOX-ex8F AGTCGCCTCTCTCCAACAAA 
WWOX exon 8 WWOX-ex8F1 AGGTCCAAGCTCTGCAACAT 
NFATC2 exon 6 NFATC2-ex6R1 GTAAAGTTCTGCCCCGTGAG 
NFATC2 exon 6 NFATC2-ex6R2  AGGCAGCTGTCTGTGTCTTG 
NFATC2 exon 7 NFATC2-ex7R1 TGGCTTCCATCTCCCAAA 
NFATC2 exon 9 NFATC2-ex9R CTGCTGGTTGGTGGGTGAGT 
NFATC2 3´ region NFATC2-3´A TTTACGTCTGATTTCTGGCAG 
NFATC2 3´ region NFATC2-3´B TCATAATATGTTTTGTATCCAGC 
 
 
3.3.4.6. EXPRESSION ANALYSIS OF NFATC2 IN NORMAL HUMAN TISSUES 
 
The expression pattern of NFATC2 in human tissues was determined using the Human 
Multiple Tissue cDNA Panels I and II (Clontech). PCR was performed using a Biometra 
thermocycler in a 25 µl-reaction volume containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM 
MgCl2, 0.001% (wt/vol) gelatine, 0.2 mM each dNTP, 4.8 ng/μl of each primer (NFATC2-ex3FA: 5´-
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GGGCCCACTATGAGACAGAA-3´ and NFATC2-ex7R1: 5´-TGGCTTCCATCTCCCAAA-3´), 0.03 U/µl 
AmpliTaq DNA Polymerase (Applied Biosystems) and 2.5 µl of cDNA. Cycling conditions were 5 
min at 94 ⁰C, followed by 35 cycles of 1 min at 95 ⁰C, one min at 58 ⁰C and 1 min at 72 ⁰C, ending 
with 5 min at 72 ⁰C. The G3PDH transcript (loading normalizer) was amplified likewise using 
primers included in the Human Multiple Tissue cDNA Panels I and II (Clontech). Amplification 
products were run on 2% agarose gels stained with ethidium bromide. 
 
 
3.3.4.7. DETECTION OF A TRANSCRIBED SINGLE NUCLEOTIDE POLYMORPHISM IN THE NFATC2 GENE 
 
Genomic DNA samples were screened for the presence of a heterozygous SNP (A/C) in exon 
4 of NFATC2 (SNP database: rs6013193). Approximately 100-250 ng of genomic DNA was 
amplified essentially as described above using primers designed in the flanking region of the SNP 
(Table IX). Amplification products were purified using the Jetquick PCR Purification Spin Kit 
(Genomed) or the DNA clean & concentrator-5 kit (Zymo Research). Sequencing reactions were 
performed basically as described above (see section 3.3.4.4.) using PCR primers as sequencing 
primers. 
 
 
Table IX. Primers used for detection of the rs6013193 SNP in NFATC2 genomic DNA. 
Localization Primer name Primer sequence (5´-3´) 
Amplicon 
size (bp) 
Annealing temperature 
(⁰C) 
Exon 4 
NFATC2-ex4F GCCATCAACAGCTGCTTCCA 
358 60 
NFATC2-ex4R CACACCCCGCACCTTAATGA 
 
 
Total RNA was extracted from mononuclear cells using the RNeasy Mini Kit (QIAGEN). 
Removal of contaminating genomic DNA was performed using in-column DNA digestion with 
DNase (QIAGEN). One to three micrograms of total RNA were used to prepare cDNA using the 
Ready-to-go You-prime first-strand beads (Amersham) and random hexamers (Invitrogen) as 
synthesis primers. PCR primer pairs were designed based on available GenBank mRNA sequences 
to amplify a partial transcribed region of NFATC2 in heterozygous individuals for the exon 4 SNP 
(Table X). PCR was performed essentially as described in section 3.3.4.5. Purification and 
sequencing of PCR products were performed as described above. PCR primers were used as 
sequencing primers. 
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Table X. Primers used for detection of a transcribed SNP (rs6013193) in exon 4 of NFATC2. 
Localization Primer name Primer sequence (5´-3´) 
Amplicon 
size (bp) 
Annealing temperature 
(⁰C) 
Exons 3-6 
NFATC2-ex3FA GGGCCCACTATGAGACAGAA 
550 56 
NFATC2-ex6R1 GTAAAGTTCTGCCCCGTGAG 
 
 
3.3.4.8. MUTATIONAL ANALYSIS OF JAK2 AND NFATC2 GENES 
 
Peripheral blood samples from 20 ET patients were analyzed for the JAK2V617F mutation 
and screened for genetic alterations in NFATC2. Mutational analysis was performed using whole 
blood leukocytes or separated cell fractions [in the patient with t(X;20;16)]. Genomic DNA was 
obtained from granulocytes and mononuclear cells by incubation in cell lysis solution as described 
above followed by standard phenol-chloroform purification and ethanol precipitation. The 
presence of JAK2V617F was analyzed by allele specific-polymerase chain reaction (AS-PCR), PCR-
BsaXI digestion, and/or direct sequencing analysis of JAK2 exon 14 PCR products, essentially as 
described (Baxter et al., 2005; Arellano-Rodrigo et al., 2006). All exon and flanking intronic 
sequences of NFATC2 were amplified using primers described in Table XI. The Primer3 software 
available at http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi (Rozen & Skaletsky, 2000) 
was used for primer design. PCR was performed using a Biometra thermocycler in a 50 µl-reaction 
volume containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 0.001% (wt/vol) gelatine, 
0.2 mM each dNTP, 3.0 ng/μl each primer, 0.03 U/µl AmpliTaq DNA Polymerase (Applied 
Biosystems) and 150 ng of genomic DNA. General cycling conditions were 5 min at 94 ⁰C, followed 
by 35 cycles of 1 min at 95 ⁰C, one min at 58-68 ⁰C and 1 min at 72 ⁰C, ending with 3 min at 72 ⁰C. 
Due to the high CG content (74.5%) of exon 1, amplification of the corresponding fragment was 
performed using the ThermalAce polymerase (Invitrogen) essentially as described in the 
manufacturer´s protocol. Amplicons were purified with Jetquick PCR Purification Spin Kit 
(GenoMed Inc.) and sequenced in both directions as described above. Sequences were aligned to 
each other using the ClustalW multiple alignment tool 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html) and further inspected manually for nucleotide 
alterations. 
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Table XI. Primers used for amplification of NFATC2 exons and corresponding flanking exon/intron boundaries. 
Amplicon Primer name Primer sequence (5´-3´) 
Amplicon size 
(bp) 
Annealing 
temperature (⁰C) 
exon 1 
NFATC2-ex1FA CCTCCGGAGCAGGAAGCTC 
433 68 
NFATC2-ex1RA AGGACTCCTGTGCCCAGTCC 
exon 2 
NFATC2-ex2A1F GATTGCTCTGCACCGGGAGT 
591 60 (a) 
NFATC2-ex2A1R GGCGAGGTTCTGGGGGAATA 
NFATC2-ex2B1F CCTGCGTCTCGCCCAATAAC 
743 66 (b) 
NFATC2-ex2B1R AGGGTCTCGCAACCAGCAAG 
exon 3 
NFATC2-ex3F GCAACAAACAGTGGGTCAGCA 
292 60 
NFATC2-ex3R GGTTTATTGCACACATGGCTGAT 
exon 4 
NFATC2-ex4F GCCATCAACAGCTGCTTCCA 
358 60 
NFATC2-ex4R CACACCCCGCACCTTAATGA 
exon 5 
NFATC2-ex5F CGGGTACCTCGCCCAGAATA 
335 60 
NFATC2-ex5R GCAGCTTTGGGGGTGATCTT 
exon 6 
NFATC2-ex6F TGCATGATTCTGGGGGACAG 
297 60 
NFATC2-ex6R GGTGACACAGGTGGGCAGAG 
exon 7 
NFATC2-ex7F AGGGAAACGTGAGGGGGATT 
242 60 
NFATC2-ex7R CGTGCACATATTGACACACACC 
exon 8 
NFATC2-ex8F TCCTGAGCCCTGTGCCTGTA 
264 60 
NFATC2-ex8R CCTGGATGCGCTTAGGGTCT 
exon 9 
NFATC2-ex9AF CCGTAGGCCATGCAGTGAAC 
388 60 
NFATC2-ex9AR GCCTCGCCTGTGATCCACTA 
NFATC2-ex9BF CTGCTGGTTGGTGGGTGAGT 
526 64 
NFATC2-ex9BR GGACTCCCAAGGCCATGTTC 
exon 10 
NFATC2-ex10F TTCTCGGATCAAAGATCACAGTCA 
156 60 
NFATC2-ex10R CGGCATGAGTTGGAAGCGTA 
exon 11 
NFATC2-ex11F AGAAGGTGAGGGGCTGTGGA 
177 58 
NFATC2-ex11R CCCTCTCACTTGCCCCATTC 
(a) cycling conditions were 3 min at 98⁰C, followed by 35 cycles of 30 sec at 98⁰C, one min at 60⁰C and 1 min at 72 ⁰C, ending with 10 
min at 72 ⁰C; (b) cycling conditions were 4 min at 98⁰C, followed by 35 cycles of 40 sec at 98⁰C, one min at 66⁰C and 1 min at 72 ⁰C, 
ending with 10 min at 72 ⁰C. 
 
 
3.3.4.9. INHIBITION OF THE CALCINEURIN/NFAT SIGNALING PATHWAY  
 
The megakaryocytic SET-2 cell line (Uozumi et al., 2000) was purchased from Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig, Germany) and 
maintained in RPMI medium supplemented with 20% fetal bovine serum (Invitrogen). 
Approximately 5x105 cells were seeded in 35 mm diameter-culture dishes and incubated for 24 hr 
with dymethyl sulfoxide (DMSO)-diluted NFAT inhibitor, cell permeable (Calbiochem) (Noguchi et 
al., 2004) at concentrations of 1, 5, 10 and 20 μM or with an equivalent volume of DMSO (control 
cells). Cell cultures were also independently treated with inhibitor for 2 hr and subsequently 
stimulated for 15 min with 0.5 µM ionomycin, calcium salt Streptomyces conglobatus 
(Calbiochem) to activate the calcineurin/NFAT signaling pathway (Lee, 1993). After incubation 
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cells were ressupended, transferred to 2.0 ml microtubes, centrifuged and ressuspended again in 
RPMI medium. A 50 μl cell aliquot was removed and incubated in trypan blue solution (Gibco) for 
viability analysis. The remaining cells were ressupended in RLT lysis buffer (Qiagen) and processed 
for total RNA extraction and cDNA synthesis essentially as described in section 3.3.4.6. 
 
 
3.3.4.10. IN VITRO SUPPRESSION OF NFATC2 USING A SHORT INTERFERING RNA 
 
A specific siRNA oligonucleotide (5´-GCAUAUCCGCACACCUGUATT-3´) for NFATC2 
(siNFATC2) was designed using the online siMAX-Design software of Eurofins MWG Operon 
(http://www.eurofinsdna.com/service-corner/sirna-design.html). The siNFATC2 oligo targets 
transcript variant 1 of NFATC2 at exon 8 between nucleotides 2164 and 2182 (GenBank accession 
number NM_012340). Multiple alignment of mRNA sequences from NFATC1, NFATC2, NFATC3 
and NFATC4 confirmed that siNFATC2 would not cross-hybridize with other NFAT-family 
members. Approximately 5x105 SET-2 cells were transfected with Lipofectamine 2000 (Invitrogen) 
and 400 pmol of siNFATC2 or siRNA control (siControl) for GFP (see table V in section 3.2.4.8). 
After 24 hr incubation viable cells were splited in 2 aliquots and lysed with RLT buffer as described 
above for RNA analysis or 1x Laemmli sample buffer supplemented with 5 mM MgCl2 and 50 U 
Benzonase (Sigma) for Western-blot analysis, respectively. Evaluation of the level of suppression 
of the NFATC2 transcript was conducted using Q-PCR as described below (section 3.3.4.12). 
Protein lysates were run on 10% SDS-PAGE gels. NFATC2 protein was detected with NFAT-1 
antibody (clone 1, BD Biosciences), cyclin E was detected using mouse anti-cyclin E monoclonal 
antibody (clone HE12, Abcam, Cambridge, United Kingdom) and tubulin was detected using 
mouse monoclonal anti-α-tubulin antibody (clone B-5-1-2, Sigma). Goat anti-mouse IgG (H+L)-HRP 
conjugate (Biorad) was used as a secondary antibody. Densitometric analysis of protein blots was 
performed using the ImageJ software. 
 
 
3.3.4.11. QUANTIFICATION OF GM-CSF RNA EXPRESSION IN SET-2 CELLS 
 
Primers for Q-PCR analysis were designed using the Primer Express 2.0 program (Applied 
Biosystems) (Table XII). Amplification mixture contained 1X TaqMan Universal Master Mix 
(Applied Biosystems), 0.3 μM of each GM-CSF-306F and GM-CSF-381R primers, 0.2 μM of GM-
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CSF-339P probe and 5 μl of cDNA in a final volume of 25 μl. In addition, expression of the death 
inducer-obliterator-1 (DIDO1) gene was quantified using a TaqMan gene expression assay 
(Hs00223101_m1, Applied Biosystems) according to the manufacturer´s instructions. 
Amplification of the glucuronidase beta (GUSB) transcript was performed for normalization of 
results with primers and probe described in Beillard et al. (2003). The reaction mixture contained 
1X TaqMan Universal Master Mix, 1.8 μM of each primer, 0.6 μM of probe and 5 μl of cDNA in a 
final volume of 25 μl. Amplifications were carried out using the ABI Prism 7000 Sequence 
Detection System (Applied Biosystems). Cycling parameters for DIDO1 and GUSB consisted of 
50⁰C-2 min, 95⁰C-10 sec and 40 cycles of 95⁰C-15 sec and 60⁰C-1 min whereas those for GM-CSF 
were of 50⁰C-2 min, 95⁰C-10 min, and 40 cycles of 95⁰C-20 sec, 55⁰C-20 sec and 60⁰C-1 min. Two 
replicates from each sample were included in the assays. Fold-expression variation was 
determined using the ΔΔCt method. 
 
 
Table XII. Primers and probe used for analysis of GM-CSF expression by Q-PCR. 
Primer name Sequence (5´-3´) Exon-exon junction Amplicon size (bp) 
GM-CSF-306F F: GGCCCCTTGACCATGATG   
GM-CSF-381R R: TCTGGGTTGCACAGGAAGTTT  3-4 76 
GM-CSF-339P P: FAM-CAGCACTGCCCTCCAACCCCG-TAMRA   
F, forward primer; R, reverse primer; P, probe. 
 
 
3.3.4.12. QUANTIFICATION OF NFATC2 RNA LEVELS IN PATIENTS WITH ESSENTIAL 
THROMBOCYTHEMIA AND CONTROLS 
 
Quantification of NFATC2 RNA was conducted in 12 ET patients and 10 healthy individuals 
using Q-PCR. Normal samples were obtained from anonimized peripheral blood samples collected 
after informed written consent from individuals tested for genetic conditions not involving the 
hematopoietic system. Isolation of peripheral blood granulocytes and extraction of total RNA 
were performed as described above. Spectrophotometric quantification of total RNA was 
conducted using a NanoDrop (Thermo Scientific). Synthesis of cDNA was carried out according to 
the standardized Europe Against Cancer protocol (Gabert et al., 2003) using 50 ng of total RNA as 
template. Complementary DNA samples were diluted to a final volume of 32 µl using diethyl 
pyrocarbonate-treated H2O. NFATC2 Q-PCR reaction mixture contained 1X of TaqMan Universal 
Master Mix (Applied Biosystems), 1X TaqMan gene expression assay (Hs00905451_m1, Applied 
Biosystems) and 5 µl of cDNA. ABL1 was used as the endogenous reference gene as described 
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(Beillard et al., 2003). Samples were amplified in triplicate for each gene using the ABI Prism 7000 
Sequence Detection System (Applied Biosystems). PCR efficiency for each gene was evaluated by 
inclusion in each Q-PCR assay of serial 10-fold dilutions of a cDNA sample. The following cycling 
parameters were used: Incubation for 2 min at 50 ⁰C, denaturation of 10 min at 95 ⁰C, followed by 
40 cycles of 15 seconds at 95 ⁰C and 1 min at 60 ⁰C. Quantification of NFATC2 gene expression for 
each sample was performed using the 2(-ΔCt) normalized values (Schmittgen & Livak, 2008). 
Statistical analysis was performed with the SPSS 17.0 for Windows software. 
 
 
3.3.5. RESULTS 
 
3.3.5.1. DETECTION OF SUBMICROSCOPIC INTERSTITIAL DELETIONS AT 20q13.13 AND 16q23.1 IN A 
PATIENT WITH ESSENTIAL THROMBOCYTHEMIA 
 
The bone marrow karyotype of a patient with ET showed a single acquired abnormality 
consisting in an apparently balanced translocation involving bands Xp11.2 and 20q13 (Fig. 21A). 
However, FISH with WCP probes revealed that the 20q13-20qter region was translocated to the 
long arm of chromosome 16 instead of chromosome X, whereas the chromosome 16q material 
was translocated to chromosome X (Fig. 21B). These findings demonstrated that the translocation 
was a 3-way rearrangement between chromosomes X, 20 and 16 with breakpoints at Xp11.2, 
20q13.13 and approximately 16q23, respectively (Fig. 21C). 
We next mapped the 20q breakpoint in cells with t(X;20;16) using FISH with several probes 
mapping between bands 20q12 and 20q13.2. Results revealed that the breakpoint region was 
overlapped by YAC 957F3 which displayed hybridization signals on the der(20) and der(16) 
chromosomes (results not shown). To define the breakpoint region more precisely, a set of 10 
PAC probes mapping within the region covered by YAC 957F3 was used. In addition to the signals 
on the normal chromosome 20, two probes (RP5-1009H6 and RP5-994O24) showed signals on the 
der(20) whereas 4 probes (RP5-831D17, RP4-548G19, RP4-698O15 and RP5-965N20) displayed 
signals on the der(16) (results not shown). The intervening 4 probes (RP5-1114A1, RP5-827A12, 
RP5-1112F19 and RP4–756P4) showed no hybridization signals on either the der(20) or der(16) 
chromosomes, indicating the presence of a small interstitial deletion within band 20q13.13 (Fig. 
21D). Subsequent interfase FISH studies of peripheral blood samples from an additional 18 ET 
patients disclosed no deletions of the 20q13.13 region as seen in the patient with t(X;20;16) 
(results not shown). 
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Figure 21. Results of cytogenetics and FISH analyses on bone marrow cells with t(X;20;16). 
(A) Partial G-banding karyogram showing normal chromosomes 20 and X, and corresponding derivative chromosomes. 
Arrows indicate the approximate location of translocation breakpoints. (B) Successive hybridization of a metaphase cell 
with WCP probes for chromosomes X, 20 and 16.  Left: Chromosome 20 (red signal) and chromosome X (green signal). 
Right: chromosome 16 (green signal) and chromosome 20 (red signal). (C) Diagrammatic representation of derivative 
chromosomes involved in the formation of a 3-way t(X;20;16) as evidenced by FISH analyses. Dashed lines are used to 
indicate the movement of material between each of the chromosomes involved in the rearrangement. Vertical color 
lines at the right of the chromosomes show the location of chromosome X (green), 20 (red) and 16 (orange) materials 
after formation of the translocation. (D) Delimitation of the breakpoint region at 20q13.13 using FISH. Three different 
PAC probes mapping to 20q13.13 were used in co-hybridization experiments with the more centromeric RP11-72F10 
BAC probe. Left panel: The RP5-994O24 PAC probe (green signal) and the control probe (red signal) showed a co-
localization of hybridization signals on the der(20) and normal chromosome 20, indicating that the breakpoint lied 
telomeric to the PAC probe. Right panel: In addition to the normal chromosome 20, the RP5-831D17 PAC probe (green 
signal) hybridized on the der(16) whereas the control probe (red signal) hybridized on the der(20), indicating that the 
breakpoint was localized centromeric to the PAC probe. Middle panel: The intervening RP4-756P4 PAC probe (green 
signal) displayed a hybridization signal only on the normal chromosome 20, revealing an interstitial deletion of 
chromosome 20 material. 
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According to the results of karyotyping, the bone marrow sample of the patient contained 
approximately one third of normal cells. Thus, it was not possible to determine a loss of 
heterozigosity by direct comparison between this sample and a normal sample of the patient 
using STR polymorphisms because both alleles of heterozygous polymorphisms are expected to 
be detected. In this context, we choose to use allele areas of heterozygous STR polymorphisms 
determined after capillary electrophoresis of PCR products as a surrogate way to determine which 
markers were absent as a result of the 20q deletion. 
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Figure 22. Results of capillary electrophoresis analysis of heterozygous polymorphisms located at 20q13.13. 
(A) Partial electropherograms of PCR products corresponding to the amplification of D20S869, D20S196, D20S857, 
D20S185, D20S845 and D20S428 polymorphisms in the patient with t(X;20;16) and in a control sample. Both individuals 
were heterozygous for each of the STR polymorphisms. Alleles of heterozygous polymorphisms are represented by 
letters A and B. The A allele was arbitrarily defined for each polymorphism as the allele peak with higher fluorescence 
intensity. Scale above allele peaks indicates the size of PCR products in bp. (B) Graphical representations of the allele 
proportions obtained for each of the STR polymorphisms in the normal (left graph) and patient (right graph) samples. A 
balanced allele proportion was observed in the normal sample for each of the polymorphisms and in the patient sample 
for polymorphisms D20S869, D20S196 and D20S428. In contrast, an unbalanced allele proportion was detected for 
polymorphisms D20S857, D20S185 and D20S845 in the patient sample, indicating hemizygous deletion of the region 
comprised between D20S857 and D20S845. Vertical bars indicate standard deviation obtained from 2 independent 
experiments. Cen, centromere. Tel, telomere. 
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If the 2 alleles of a heterozygous polymorphism are present in equivalent amounts in the 
original template DNA sample and amplify accordingly, then the area of each allele at the end of 
the amplification reaction should be approximately 50% of the total allele area. Using this 
theoretical approach we calculated allele proportions obtained in the patient sample with those 
obtained in a sample from an individual with a normal karyotype, both of which displayed 
heterozygosity for each polymorphism. The mean allele proportions in the sample with a normal 
karyotype were of 53.1%:46.9% (range: 51.9-54.4%:45.6-48.1%), thus reflecting a balanced 
amount of the 2 alleles. A similar allele proportion was obtained in the patient sample for 
polymorphisms D20S869, D20S196 and D20S428 (mean: 53.0%:47.0%; range: 50.0-55.3%:44.7-
50%). In contrast, an unbalanced mean allele proportion of 69.3%:30.7% (range: 65.4-73.2%:26.8-
34.6%) was seen for the other 3 polymorphisms in-between (Fig. 22). 
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Figure 23. Schematic representation of human chromosome 20 and of an enlarged 20q13.13 region targeted by the 
breakpoints of a complex t(X;20;16). 
The breakpoints were associated with an interstitial deletion comprising ATP9A, SALL4 and the 5´ side of NFATC2. The 
chromosomal region located centromeric to the proximal breakpoint remained on the der(20) chromosome whereas 
the region located telomeric to the distal breakpoint was translocated to chromosome 16. YAC and PAC clones used as 
probes in FISH experiments are represented as black or grey lines according to their inclusion outside or inside the 
deleted region, respectively. Clones were mapped in respect to STS markers indicated in Table VI. Dashed terminus of 
probes represents regions of uncertainty regarding the precise end of clones. The localization of the NFATC2, ATP9A, 
SALL4 and ZFP64 genes is shown as black boxes in the lower part of the figure. Horizontal arrows indicate the 
orientation of gene transcription. Physical distance is measured in Mb starting from the tip of the short arm of 
chromosome 20 and is scaled at 100 kb intervals according to the NCBI36 (March 2006) Homo sapiens sequence build. 
Approximate locations of molecular markers used in this study are shown below the scale. 
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Taken together, these results indicated that each of the D20S857, D20S185 and D20S845 
loci was included in the 20q13.13 deletion, thus resulting in uneven proportion of each allele. 
Thus, the combined results of FISH and PCR established the presence of an interstitial deletion at 
chromosome band 20q13.13 comprising the 5´ side of the NFATC2 gene as well as the ATP9A and 
SALL4 genes (Fig. 23). 
We next performed a whole-genome array analysis of a granulocyte DNA sample of the 
patient as an attempt to define the proximal and distal deletion boundaries more precisely. These 
were found to correspond to nucleotide positions 49.508.399 and 50.121.389, respectively, of the 
Homo sapiens reference genome build NCBI36 (March 2006), indicating that the length of the 
deleted region was of approximately 613 kb (Fig. 24).  
 
20q13.13 
0
1
2
3
4
5
-2
-1
0
1
2
NFATC2 ATP9A SALL4 ZFP64
Weighted Log2 Ratio
Smooth Signal
Genes
↓↓ ↓↓ ↓↓ ↓↓ ↓↓ ↓↓ ↓↓ ↓↓
49.2 Mb 50.4 Mb49.4 Mb 49.6 Mb 49.8 Mb 50.2 Mb50.0 Mb
50.121.38949.508.399
0
1
2
3
4
5
-2
-1
0
1
2
Tel →← Cen
 
 
Figure. 24. Results of whole-genome array analysis of chromosome region 20q13.13. 
Partial graphical output of array data showing the presence of an interstitial deletion at 20q13.13. Note the deviation of 
the pink smooth signal line from the normal diploid level (2). The deletion was only detected at a low level of mosaicism 
indicating that the granulocyte sample of the patient was mostly composed of normal cells. The weighted log2 ratio 
represents a running median of a genomic region of log2 ratios (i.e., intensity of a marker normalized to a reference and 
to sample variation) which excludes outliers. The smooth signal represents the smoothed log2 ratio. The purple dashed 
vertical lines indicate the approximate locations of breakpoints of the deleted region. Numbers adjacent to deletion 
boundaries indicate nucleotide positions of each breakpoint (in Mb) according to the NCBI36 (March 2006) human 
genome sequence. Images were produced using the ChAS 1.1. software (Affymetrix). The orientation of each gene is 
represented by a horizontal arrow below the corresponding symbol. A scale is shown on the bottom of the figure. The 
directions of the centromere (cen) and telomere (tel) are indicated by arrows below the scale. 
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According to these results, exons 1 to 5 of NFATC2 were contained in the deleted region, 
thus confirming results obtained by FISH and PCR analyses. Using RACE analysis we did not find 
putative fusion transcripts resulting from joining of the 3´ part of NFATC2 to chromosome X 
sequences in the patient sample (results not shown), suggesting that NFATC2 was not activated by 
the translocation. However, because we were also unable to detect normal NFATC2 transcripts in 
the same sample we cannot completely exclude the presence of a fusion gene. 
Analysis of the array data for chromosome 16 also revealed the presence of an interstitial 
deletion at 16q23.1-16q23.2 at a similar level of mosaicism as the 20q deletion (Fig. 25). Because 
of the lack of patient material we could not confirm by FISH that the 16q23 deletion was 
contiguous to the chromosome 16 breakpoint involved in the t(X;20;16). However, its localization 
is compatible with the breakpoint position determined in WCP studies, strongly suggesting that it 
consisted of a breakpoint-adjacent deletion. 
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Figure 25. Results of whole-genome array analysis of chromosome region 16q23.1-16q23.2 
Partial graphical output of array data showing the presence of an interstitial deletion at 16q23 involving the MAF gene. 
Note the deviation of the pink smooth signal line from the normal diploid level (2). As in the case of chromosome 
20q13.13 the deletion at chromosome 16q23 was only detected at a low level of mosaicism. The weighted log2 ratio 
represents a running median of a genomic region of log2 ratios (i.e., intensity of a marker normalized to a reference and 
to sample variation) which excludes outliers. The smooth signal represents the smoothed log2 ratio. The purple dashed 
vertical lines indicate the approximate locations of breakpoints of the deleted region. Numbers adjacent to deletion 
boundaries indicate nucleotide positions of each breakpoint (in Mb) according to the NCBI36 (March 2006) human 
genome sequence. Images were produced using the ChAS 1.1. software (Affymetrix). The orientation of each gene is 
represented by a horizontal arrow below the corresponding symbol. A scale is shown on the bottom of the figure. The 
directions of the centromere (cen) and telomere (tel) are indicated by arrows below the scale. 
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The 16q deletion comprised a length of approximately 1.2 Mb between nucleotide 
positions 77.458.293 and 78.656.539 of the NCBI36 (March 2006) human genome sequence. This 
alteration resulted in the deletion of the v-maf musculoaponeurotic fibrosarcoma oncogene 
homologue (MAF) gene and in the truncation of the last exon of the WW domain containing 
oxidoreductase (WWOX) gene. Detailed inspection of chromosome X array data did not show the 
existence of a deleted segment at band Xp11, indicating that the breakpoint involved in the 
t(X;20;16) was not associated with an adjacent deletion (results not shown).  
 
 
3.3.5.2. THE WWOX GENE IS NOT REARRANGED IN THE PATIENT WITH t(X;20;16) 
 
The WWOX gene is located in the fragile site FRA16D region of chromosome 16 which is 
frequently targeted by hemizygous deletions and translocation breakpoints in breast cancer 
(Bednarek et al., 2000). Moreover, this gene is deleted and/or is not expressed in various other 
tumor types including ovarian cancer, osteosarcoma and hematopoietic malignancies (Paige et al., 
2001; Ishii et al., 2003; Kurec et al., 2010; Yang et al., 2010). In our case the truncated WWOX 
gene became juxtaposed to the coding sequence of ZFP64 on the long arm of chromosome 16 
following the translocation. Because these genes are oriented in opposite directions at the long 
arm of chromosome 16 and of chromosome 20, respectively, no WWOX-ZFP64 fusion gene is 
expected to be generated. However, an abnormal WWOX transcript containing sequences from 
chromosome 20 on its 3´ side could potentially be generated. To exclude this possibility we 
performed 3´ RACE analysis of WWOX transcripts using mononuclear cells of the patient. We 
identified 3 types of alternatively-spliced WWOX transcripts which only contained sequences from 
chromosome 16, indicating that the translocation did not produced an abnormal WWOX 
transcript (Fig. 26). Interestingly, two of the mature transcripts included the presence of exon 
sequences not yet described in the transcript database of the Ensembl Genome Browser 
(http://www.ensembl.org). One of these transcript sequences did not contain a stop codon 
upstream of the poly-A signal, indicating that it is not functional. Despite these findings, our data 
indicate that rearrangement of the WWOX gene did not have a pathogenetic role in the patient 
with t(X;20;16). 
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Figure 26. Results of 3´ RACE analysis of WWOX transcripts. 
(A) Agarose gel electrophoresis analysis of nested PCR products. Three bands of different sizes (A, B and C) were 
amplified in the patient sample. The molecular weight marker is HyperLadder I (Bioline). Sizes of representative marker 
bands are shown on the left side of the gel image in bp; (B) Schematic representation of each transcript configuration 
following direct sequencing of PCR products. Transcript A consists in a direct fusion of exon 8 to exon 9 of WWOX and is 
followed by a 3´ untranslated region (3´UTR). Its sequence matches the sequence of the WWOX-206 transcript 
ENST00000408984 (1245 bp/414 aminoacids) in the Ensembl genome browser database (http://www.ensembl.org). 
Transcript B corresponds to a fusion of exon 8 to a novel exon sequence (here designated as 8b) located in intron 8 of 
WWOX. Transcript C contains 2 additional exon sequences (here designated as 8a and 8c) located 3´ of exon 8. This 
transcript does not contain a stop codon before the poly-A signal and is therefore expected to be non-functional. Boxes 
represent exons. The numbers below the boxes and between them indicate the size of exons and introns in bp, 
respectively. Introns are not shown to scale. Stop codons are indicated by an asterisk (*). (C) Partial sequences of 
transcripts B and C. Exon sequences are shown in alternating black and blue colors beginning with a partial exon 8 
sequence. The poly-A signal AATAAA is underlined in each of the sequences. The stop codon (TAG) located in exon 8b of 
transcript B is shown in bold. The poly-A tail is shown in italics. Sequences were compared to the Homo sapiens 
chromosome 16 genomic contig, genome reference consortium GRCh37 (February 2009) primary assembly (accession 
number NT_010498.15) following a BLAST analysis. 
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3.3.5.3. NFATC2 IS UBIQUITOUSLY EXPRESSED IN NORMAL HUMAN CELLS AND BOTH ALLELES ARE 
PRESENT IN PERIPHERAL BLOOD LEUKOCYTES OF PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA 
 
Except for brain tissue, we detected expression of NFATC2 in all other human tissues tested 
(Fig. 27). However, expression levels differed widely between tissues. In particular, the level of 
NFATC2 expression was highest in leukocytes and spleen, which is in agreement with its role as a 
hematopoietic transcription factor (Hogan et al., 2003). 
 
 
NFATC2 618 bp
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Figure 27. Expression of NFATC2 in normal human tissues. 
Gel electrophoresis analyses showing RT-PCR results of NFATC2 and G3PDH expression in 16 different normal human 
tissues. NFATC2 is expressed in all tissues except brain. Expression of G3PDH was used as a normalizer. Sizes of PCR 
products are shown in bp on the right side of the figure. Please note: The gel photo corresponding to G3PDH is the 
same as the one used in Fig. 15A. 
 
 
We next investigated if both alleles of NFATC2 are expressed in peripheral blood 
leukocytes. We hypothesized that if mono-allelic expression of NFATC2 occurs in hematopoietic 
cells, deletion of chromosome 20q13.13 sequences could result in the absence of expression if 
the transcribed allele is located on the der(20). To test this hypothesis, we firstly identified in 
genomic DNA samples from different ET patients a heterozygous transcribed SNP in exon 4 of 
NFATC2. We then searched using RT-PCR and sequencing analysis for both alleles in RNA 
extracted from mononuclear cells. Both alleles of NFATC2 were detected in each sample analysed, 
indicating that in cells with a del(20q) one copy of the gene is still expressed (Fig. 28). Similarly, 
we found that both alleles of ATP9A and SALL4 are expressed in peripheral blood cells (data not 
shown).  
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Figure 28. Expression of NFATC2 in hematopoietic cells. 
Partial sequencing traces showing the presence of a heterozygous A/C SNP in exon 4 of NFATC2 obtained from genomic 
DNA (left electropherogram) and mRNA (right electropherogram) of the same ET patient. Both alleles of NFATC2 are 
expressed in peripheral blood cells. Arrows indicate the nucleotide position of the SNP. 
 
 
3.3.5.4. THE NFATC2 GENE IS NOT MUTATED IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA 
 
We studied 20 ET patients for the presence of the JAK2V617F mutation by AS-PCR and 
BsaXI digestion. Eleven of the 20 patients (55%) including the patient with t(X;20;16) showed the 
presence of JAK2V617F by both methods (Fig. 29A), whereas in the remaining 9 patients the 
mutation could not be identified using either technique. Sequencing analysis of JAK2 exon 14 in 
isolated granulocytes of the patient with t(X;20;16) showed a higher burden of the mutated allele 
compared to the wild-type allele, indicating that the majority of clonal granulocytes were 
homozygous for JAK2V617F (Fig. 29B). 
We next conducted a mutation screening of all NFATC2 exons and flanking intronic regions 
in the 20 ET patients. However, except for several SNPs no additional alterations were found, 
indicating that inactivating mutations of NFATC2 may not play a role in ET. We also could not 
identify mutations of ATP9A or SALL4 in ET patients (results not shown). These results indicate 
that NFATC2 may exert its pathogenetic role in cells with a del(20q) by a mechanism other than 
loss-of-function. 
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Figure 29. Analysis of JAK2V617F mutation in the patient with t(X;20;16). 
(A) Gel electrophoresis analysis of AS-PCR products showing the presence of the JAK2V617F mutation in the patient 
granulocytes. The positive control is a 1:81 dilution of a JAK2V617F-positive homozygous DNA into a JAK2 wild-type 
DNA. PCR fragments corresponding to the internal AS-PCR control and to the mutant allele are indicated on the right 
side of the gel photo. (B) Partial sequencing traces of JAK2 exon 14 showing the presence of a G to T mutation (arrow) 
corresponding to JAK2V617F. The mutant allele peak (T) is higher than the wild-type allele peak (G) in the granulocyte 
fraction, thus indicating the presence of a JAK2V617F-positive homozygous clone in this cell population. 
 
 
3.3.5.5. NFATC2 EXPRESSION IS DIMINISHED IN GRANULOCYTES OF PATIENTS WITH ESSENTIAL 
THROMBOCYTHEMIA 
 
We used real-time Q-PCR analysis to measure the levels of NFATC2 mRNA in granulocytes 
of 12 ET patients, seven (58%) of which were JAK2V617F-positive, and in 10 granulocyte RNA 
samples of normal individuals. Because the PCR efficiencies for both genes were similar we used 
2(-∆Ct) values of individual samples to compare NFATC2 expression levels between patients and 
controls. 
The mean 2(-∆Ct) of ET patients was 0.92±0.30 whereas that for normal individuals was 
1.24±0.61 (P=0,122, independent samples t-test), indicating a mean 1.4-fold reduction in the 
expression of NFATC2 mRNA in ET patients compared to controls (Fig. 30). These results suggest 
that NFATC2 levels in granulocytes of patients may be diminished as a consequence of 
mechanisms other than chromosome deletions. 
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Figure 30. Comparison of NFATC2 mRNA expression in granulocytes of ET patients and normal individuals. 
The mean NFATC2 expression is lower in ET patients but not significantly different from normal individuals 
(independent samples t-test, P=0,122). Ct values of NFATC2 expression were normalized to Ct values of ABL1 
expression. The normalized 2
-(∆Ct) values were used for statistical analysis. (A) Descriptives of normalized NFATC2 
expression in patients and normal individuals. (B) Graphical representation of NFATC2 expression levels between ET 
patients and normal individuals. The box represents the value range between the 25
th
 and the 75
th
 percentile. The 
median value corresponds to the horizontal black bold line. Bars indicate the range of values. The black dot represents 
an outlyer value.  
 
 
3.3.5.6. INHIBITION OF NFAT ACTIVATION IN VITRO IS ASSOCIATED WITH MEGAKARYOCYTIC 
PROLIFERATION 
 
Because NFATC2 mutations were not identified in the non-rearranged 20q allele of the 
patient with t(X;20;16) we hypothesized that haplo-insufficiency manifested as a reduction in the 
NFATC2 protein levels could have a role in megakaryocytic growth and proliferation. To test this 
hypothesis, we treated SET-2 cell cultures in vitro with a small inhibitor peptide (VIVIT) which 
selectively hampers interaction between NFAT proteins and calcineurin by binding to the NFAT-
docking site in calcineurin without inhibiting its phosphatase activity (Aramburu et al., 1999; 
Roehrl et al., 2004). The commercially available 11R-VIVIT inhibitor contains an 11-arginine repeat 
which greatly facilitates cell permeability (Noguchi et al., 2004). We choose to use SET-2 cells as 
the cell model because these were derived from a patient with ET (Uozumi et al., 2000), harbor 
the JAK2V617F mutation (results not shown) and have no deletion of the NFATC2 gene by FISH 
analysis (Fig. 31A). 
Induced dephosphorylation and nuclear translocation of NFAT proteins may be rapidly 
accomplished in vitro by stimulation of cells with the Ca2+ ionophore ionomycin which acts as a 
mobile ion carrier for Ca2+ (Lee, 1993; Okamura et al., 2000). To test if the inhibitor was effective 
in blocking NFATC2 activation in SET-2 cells, we performed semi-quantitative RT-PCR analysis of 
the IL-2 gene, known to be transcriptionally regulated by NFATC2 (Rothenberg & Ward, 1996), in 
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inhibitor-treated cells following ionomycin stimulation. We observed that IL-2 mRNA levels were 
lower in cells treated with inhibitor compared to non-treated cells, indicating that NFATC2 was 
effectively blocked by the inhibitor (Fig. 31B). In this setting incubation for 24 hr with NFAT 
inhibitor alone at concentrations between 1 µM and 10 µM was associated with 1.27- and 1.76-
fold increases in the number of SET-2 cells respectively, compared to untreated cells (Fig. 31C), 
whereas incubation with concentrations equal or greater than 20 µM led to an increase in cell 
death likely as a result of cellular toxicity. These results indicate that the calcineurin-NFAT 
signaling pathway contributes to proliferation control in JAK2V617F-positive megakaryocytes. 
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Figure 31. Inhibition of NFAT activation in SET-2 cells. 
(A) FISH analysis of a SET-2 metaphase cell with PAC probes RP5-827A12 (red signal) and RP5-994024 (green signal) 
demonstrating the presence of the NFATC2 gene on both chromosome 20 homologues. (B) Gel electrophoresis analysis 
of semi-quantitative RT-PCR results showing decreasing IL-2 mRNA expression in cells treated with NFAT inhibitor 
comparatively to non-treated cells after stimulation with 0.5 μM ionomycin. Expression of ABL1 was used as a loading 
normalizer. Sizes of PCR products are shown on the right side of the gel photos. (C) Graphic representation of the fold 
number variation of SET-2 cells treated with NFAT inhibitor normalized to the number of non-treated cells (fold cell 
number 1.0). Incubation for 24 h with NFAT inhibitor led to between 1.27- and 1.76-fold increases in the number of cells 
at concentrations of 1 µM and 10 µM, respectively. Vertical bars indicate standard deviation calculated from the results 
of 3 independent experiments.  
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3.3.5.7. SUPPRESSION OF NFATC2 RNA PROMOTES CELL PROLIFERATION IN VITRO 
 
The use of an inhibitory drug targeting calcineurin-NFAT interaction did not allow us to 
separate NFATC2-specific effects on proliferation from those occurring with other NFAT-family 
members which are also regulated by calcineurin (reviewed in Medyouf & Ghysdael, 2008). 
Therefore, to investigate an explicit role of NFATC2 on cell proliferation we suppressed 
endogenous NFATC2 expression in SET-2 cells by RNA interference. After 24 hr incubation with 
siRNA oligos we observed a 48.2% decrease in NFATC2 protein levels in cells transfected with 
siNFATC2 in comparison with those transfected with siControl, thus simulating haplo-insufficiency 
of NFATC2 (Fig. 32). 
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Figure 32. Suppression of NFATC2 transcripts in SET-2 cells. 
Upper left: Summary of Q-PCR data obtained for NFATC2 and ABL1 expression in cells transfected with siNFATC2 and 
siControl. Ct, cycle threshold. Upper right: Corresponding graphic representation of Q-PCR results showing an 
approximately 20% reduction of NFATC2 mRNA in cells transfected with siNFATC2. The percentage of NFATC2 
suppression was normalized to the level of NFATC2 transcripts in siControl-treated cells (100%). Vertical bars indicate 
standard deviation calculated from 2 independent experiments. Lower left: Western-blot analysis of NFATC2 and cyclin 
E in SET-2 cells transfected with siNFATC2 and siControl. A reduction in the levels of NFATC2 is associated with an 
increase in cyclin E levels. Tubulin was used as a loading normalizer. Lower right: Corresponding graphical 
representation of the densitometric analysis of Western-blot results showing an approximately 50% reduction of 
NFATC2 protein in cells transfected with siNFATC2. The percentage of NFATC2 suppression in siNFATC2-treated cells 
was normalized to the level of NFATC2 in siControl-treated cells (100%). 
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The suppression level of the NFATC2 transcript was of only 19.4% in the same sample, 
suggesting that maximal RNA suppression had occurred at a previous time point. Under these 
conditions SET-2 cells showed a mean 1.38-fold increase in cell number (paired samples t-test, 
P=0,014) (Fig. 33). Proliferation was associated with an increase in the levels of cyclin E protein, 
indicating that it was related to progression through the cell cycle. Moreover, cells transfected 
with siNFATC2 also displayed a larger size compared to cells transfected with siControl, suggesting 
that cell growth is coupled to cell cycle progression. 
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Figure 33. Effect of NFATC2 suppression in proliferation of SET-2 cells. 
Transfection with siNFATC2 leads to a higher cellular density and increased cell size in comparison with cells transfected 
with siControl. Left: Graphic representation of the fold number variation of SET-2 cells treated with siNFATC2 
normalized to the number of siControl-treated cells (fold cell number 1.0). siNFATC2-treated cells showed a mean 1.38-
fold significant increase in cell number relatively to control cells (paired samples t-test, P=0,014). Vertical bars indicate 
standard deviation obtained from 5 independent experiments. Right: Representative microscopic images of SET-2 
megakaryocytes transfected with siNFATC2 or siControl. Cell plates were observed using a Zeiss light microscope 
Axiovert 40C equipped with a Zeiss objective A-Plan (magnification 10x). Images were acquired using a Canon 
PowerShot G5 digital camera (magnification 4x).  
 
 
3.3.5.8. REDUCED NFATC2 EXPRESSION OR INHIBITION OF NFATC2 ACTIVITY INCREASES GM-CSF 
EXPRESSION IN SET-2 CELLS  
 
We next asked if proliferation of SET-2 megakaryocytes was related to a dysregulation of 
cytokine expression as a downstream effect of NFATC2 protein inhibition or of NFATC2 mRNA 
suppression. We choose GM-CSF to address the effect because this cytokine acts on the 
megakaryocytic cell lineage (Metcalf, 2008) and is transcriptionally regulated by NFATC2 (Tsuboi 
et al., 1994; Cockerill et al., 1995; Luo et al., 1996). 
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Figure 34. Partial suppression of NFATC2 mRNA promotes GM-CSF expression in SET-2 cells. 
Left: Summary table of Q-PCR data obtained from analysis of GM-CSF and GUSB expression in SET-2 cells treated with 
siNFATC2 and siControl; Quantification of GM-CSF expression was performed using the ΔΔCt method;  right: Graphical 
representation of the fold-expression variation in the levels of GM-CSF between siNFATC2- and siControl-treated cells. 
Vertical bar indicates the standard deviation obtained from 2 independent experiments. Mean fold-expression value of 
GM-CSF in siNFATC2-treated cells was calibrated to that of control cells (GM-CSF fold-expression = 1.00). 
 
 
Using Q-PCR we calculated the variation in the expression levels of GM-CSF between cells 
treated with siNFATC2 or NFAT inhibitor and correspondent control cells. We observed that 
suppression of NFATC2 mRNA led to an average 2.12-fold increase in the levels of GM-CSF 
transcript compared to control cells (Fig. 34). In inhibitor-treated cells a maximum of 99.2-fold 
increase in GM-CSF mRNA was observed at 10 μM concentration of inhibitor after 2 hr incubation. 
Moreover, a 48.4-fold increase was observed after 24 hr incubation at 20 μM concentration (Fig. 
35). To verify if alteration of GM-CSF expression levels was related to a specific inhibition of 
NFATC2 transcriptional activity, we quantified in the same samples the levels of the DIDO1 gene. 
This gene is expressed in myeloid cells from MPN patients (Fütterer et al., 2005) and was not yet 
recognized as an NFAT target gene. We observed that the levels of DIDO1 remained unaltered in 
inhibitor-treated cells after 2 or 24 hr incubation in the various concentrations of the inhibitor. 
Taken together, the results of the in vitro assays indicate that proliferation of SET-2 cells in culture 
was related to an increase in GM-CSF cytokine levels in the medium, which in turn was a 
consequence of diminished NFATC2 transcriptional activity. 
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Figure 35. Inhibition of NFAT activity promotes GM-CSF expression in SET-2 cells. 
(A) Summary table of Q-PCR data obtained from analysis of GM-CSF, DIDO1 and GUSB expression in SET-2 cells after a 2 
hr- or 24 hr-incubation in the absence or in the presence of different concentrations of NFAT inhibitor. Quantification of 
GM-CSF and DIDO1 expression was performed using the ΔΔCt method; (B) Graphical representation of the GM-CSF 
(left) and DIDO1 (right) fold-expression variation in SET-2 cells incubated for 2 hr (upper graphs) or 24 hr (lower graphs) 
in the presence of different concentrations of NFAT inhibitor. Fold-expression values were calibrated relatively to cells 
incubated in the absence of inhibitor (GM-CSF fold-expression = 1.0; DIDO1 fold-expression = 1.0). 
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3.3.6. DISCUSSION 
 
In this work we describe NFATC2 as a negative regulator of megakaryocyte proliferation 
and propose that abnormalities in cytokine regulation are associated with ET. Using FISH, PCR and 
whole-genome array techniques, we identified a 613 kb deletion at chromosome band 20q13 in a 
patient with ET presenting with a novel 3-way t(X;20;16)(p11.2;q13.13;q23.1). The 20q13 deletion 
removed the 5´ region of the NFATC2 gene and eliminated a complete copy of the ATP9A and 
SALL4 genes. Despite the fact that 3 different genes were affected by the 20q chromosomal 
breakpoints, we focused our interest on NFATC2 as a candidate gene in ET for 2 reasons. 
Firstly, NFATC2 is located at the long arm of chromosome 20, a genomic region frequently 
targeted by large interstitial deletions in MPN patients (Bench et al., 1998a). Secondly, studies in 
normal myeloid cells have shown that NFATC2 is characterized among the various NFAT-family 
members by its high levels of expression in CD34+ cells and megakaryocytes and low or absent 
expression in neutrophils, monocytes and erythrocytes (Kiani et al., 2004), suggesting that 
NFATC2 has a lineage-specific role within myelopoiesis. Because NFAT proteins are involved in the 
transcriptional regulation of myelopoietic cytokines, either as dimers or in cooperation with other 
transcription factors such as AP-1 (FOS/JUN) (reviewed in Rao et al., 1997), we hypothesized that 
low levels of NFATC2 protein in megakaryocytes could have important consequences for the 
regulation of cytokine expression and, as a consequence, for megakaryocyte proliferation. To test 
these hypotheses we simulated the loss of NFATC2 in an ET cell line in vitro through the 
suppression of its transcript or through inhibition of protein activation with a selective peptide 
(Nogushi et al., 2004). 
We observed that the mRNA abundance of the myeloid lineage cytokine GM-CSF increased 
either in the presence of low levels of the NFATC2 transcript or as a result of inhibition of NFATC2 
protein activation. These data indicates that NFATC2 may play a dual role in regulating GM-CSF 
expression, either as a transcriptional repressor in megakaryocytes or as a transcriptional 
activator in lymphoid cells (Tsuboi et al., 1994; Cockerill et al., 1995; Luo et al., 1996). In 
megakaryocytic cells of MPN patients, relieving of NFATC2 transcriptional repression as a result of 
a del(20q) will promote cell growth and proliferation through increased availability of GM-CSF. 
Consistent with this hypothesis, we observed that diminished levels of NFATC2 mRNA or protein 
were associated with proliferation of megakaryocytic cells in vitro, indicating that NFATC2 
negatively regulates megakaryocyte proliferation. 
The consequences of the loss of NFATC2 in myeloid cells have not yet been addressed in 
vivo. However, it was shown that NFATC2-null mice have hyperproliferation of lymphocytes 
(Hodge et al., 1996) whereas NFATC2/NFATC3-double null mice develop a marked 
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lymphoproliferative disorder (Rengarajan et al., 2002), indicating a close relationship between 
proliferation of lymphoid cells and absence of NFATC2. In our in vitro culture assays we observed 
that proliferation of megakaryocytes was associated with an increase in cyclin E levels, suggesting 
that proliferation was a consequence of cell cycle progression. Although these may be considered 
preliminary results which require further study, they are in line with previous data showing that 
hyperproliferation of NFATC2 -/- lymphocytes in culture is correlated with overexpression of 
several cyclin proteins including cyclin E (Caetano et al., 2002). Moreover, both NFATC2- and 
calcineurin Aα-null mice have elevated levels of cyclin-dependent kinase 4, the catalytic partner 
of D-type cyclins at the G1-to-S phase transition of the cell cycle, showing that the calcineurin-
NFAT signaling pathway has a negative regulatory role in cell cycle progression (Baksh et al., 
2002). 
Constitutive activation of the calcineurin-NFAT pathway was observed in several 
hematological malignancies involving the lymphoid lineage. In particular, dephosphorylation of 
NFATC2 was documented in samples of patients with diffuse large B-cell lymphoma (DLBCL) and 
T-cell lymphoma whereas NFAT activation was demonstrated in cell lines derived from patients 
with DLBCL and T-cell ALL (reviewed in Medyouf & Ghysdael, 2008). Recently, a role for NFATC2 as 
an oncogene was also demonstrated in 4 cases of Ewing sarcoma associated with the formation of 
a fusion gene between NFATC2 and the EWSR1 gene at chromosome 22 (Szuhai et al., 2009). In 
contrast to its role as an oncogene, NFATC2 may also act as a tumour suppressor gene in Burkitt 
lymphoma cells by promoting apoptosis when activated by calcineurin (Kondo et al., 2003). 
However, there is no other study to our knowledge implicating NFATC2 in myeloid disorders. We 
did not find mutations in the non-rearranged NFATC2 allele in our patient with a t(X;20;16), 
suggesting that haplo-insufficiency of this gene as a result of 20q deletions is the most likely 
pathogenetic mechanism in ET and possibly other myeloid disorders. In 10 out of 23 patients 
(43%) with myeloid neoplasms and del(20q) analyzed by Huh et al. (2010), the extent of the 20q 
deletions also encompassed NFATC2, indicating that this gene is also haplo-insufficient in a 
significant proportion of patients with a del(20q). Taken together, these data indicate that 
different genetic mechanisms contribute to the involvement of the NFATC2 gene in the 
pathogenesis of hematopoietic malignancies. 
In addition to the del(20q) we also found, using array analysis, a 1.2-Mb deletion at 
chromosome region 16q23.1-16q23.2. The deleted region encompassed the entire MAF gene and 
the most 3´ coding exon of the WWOX gene. MAF is the human homologue of the transforming 
gene of the avian retrovirus AS42, which encodes a transcription factor protein belonging to the 
bZIP protein family (Kataoka et al., 1993). This family is characterized by the presence of a leucine 
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zipper domain and also includes as members the NRL, FOS, JUN and NF-E2 genes (Swaroop et al., 
1992; Andrews et al., 1993; Kataoka et al., 1993; Kataoka et al., 1994; Kerppola & Curran, 1994). 
Interestingly, NF-E2 is an erythroid lineage-transcription factor overexpressed in megakaryocytes, 
erythrocytes and granulocytic precursors within the bone marrow of PV patients (Goerttler et al., 
2005). NF-E2 overexpression delays erythroid maturation and, consequently, increases the 
number of erythroid progenitor cells (Mutschler et al., 2009). Similarly, MAF operates in myeloid 
lineage cells by inhibiting erythroid differentiation through repression of Ets-1-mediated 
transactivation of the transferrin receptor (Sieweke et al., 1996; Sieweke et al., 1997). These data 
highlights a possible role of the MAF protein in erythrocyte accumulation associated with PV. 
Similarly to NFAT proteins, MAF also operates as a transcription regulator of several 
cytokine genes. MAF inhibits IL-12 and activates IL-4 and IL-10 in macrophages (Cao et al., 2002; 
Cao et al., 2005), and induces GM-CSF expression in T cells (Gilmour et al., 2007). In addition, MAF 
can also form heterodimers with FOS and JUN and bind to AP-1 sites (Kerppola & Curran, 1994) 
which are found in a number of other cytokine genes. Thus, although the consequences of MAF 
deletion on cytokine expression have not been investigated in our study, our findings in the 
patient with t(X;20;16) suggest that haplo-insufficiency of MAF may have complemented NFATC2 
deletion to disturb normal cytokine signaling in MPN cells. 
In summary, characterization of the molecular abnormalities resulting from a complex 3-
way t(X;20;16) in an ET patient led us to implicate the NFATC2 gene in abnormal cytokine 
expression and megakaryocyte proliferation. Our results further suggest that haplo-insufficiency 
of NFATC2 may cooperate with the JAK2V617F mutation to disturb the overall cytokine signaling 
circuit in hematopoietic cells. Preliminary results have shown that NFATC2 mRNA levels in 
granulocytes of ET patients are lower than those of normal granulocytes. These data warrants 
further studies to validate NFATC2 expression as a marker of megakaryocyte proliferation in ET. 
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It is widely accepted that cancer is a multistep phenomenon which requires alterations of 
several different cellular pathways in order to achieve its full transforming potential (Hanahan & 
Weinberg, 2000). This model of tumourigenesis has already been put in evidence in hematological 
malignancies, particularly in AML. The identification of major cytogenetic abnormalities as well as 
the detection of somatic gene mutations allowed the categorization of genetic alterations in AML 
patients according to a 2-hit leukemogenic model (Frankfurt et al., 2007). This theory postulates 
that one class of mutations is responsible for the differentiation arrest of AML cells and the other 
for an increased and disregulated proliferative potential of the neoplastic cells. The first type is 
mostly typified by recurrent balanced chromosomal rearrangements such as t(8;21), inv(16), 
t(15;17) and 11q23/MLL translocations, which result in direct (e.g., RUNX1, CBFB or RARA) or 
indirect (e.g., MLL) disregulated transcription factor activity. MLL fusion oncoproteins act by 
disregulating the transcription of homeobox genes, which in turn modifies transcription of target 
genes, or by conversion of hematopoietic progenitors into leukemic stem cells expressing a self-
renewal program (reviewed in Faber & Armstrong, 2007; Haferlach, 2008). The second class of 
mutations accounts for an increased cell proliferation as a consequence of activating mutations in 
genes encoding for tyrosine kinase proteins including FLT-3, c-KIT and JAK2, for instance. In 
addition to these 2 categories a third class of AML mutations has also been proposed which 
includes genes involved in cell cycle regulation and apoptosis (Renneville et al., 2008). The typical 
examples include NPM1 mutations, which constitute the most frequent genetic alterations in 
AML, and TP53 deletions or mutations (Haferlach, 2008). 
Therefore, fusion genes generated by recurrent chromosomal translocations in 
hematopoietic malignancies are just one type of alteration which contributes to the overall 
leukemic phenotype. One possible way to identify additional genetic lesions is through the 
analysis of complex chromosome translocations. The extra breakpoints involved in these 
rearrangements may indicate the location of genes which also can have a relevant role in the 
pathogenesis and that usually remain unnoticed because of their inconsistent nature and low 
frequency. In this perspective, we sought to identify and/or characterize the genes involved in the 
extra breakpoint locations of complex translocations associated with different hematological 
neoplasms, including a t(12;6;15), a t(9;11;19) and a t(X;20;16), and define their role in 
tumourigenesis. 
In section 3.1 of this dissertation we have characterized by FISH analysis the breakpoints 
involved in different structural rearrangements detected in 2 B-cell ALL patients and in one 
patient with MDS/MPN, U. These rearrangements had in common the involvement of the short 
arm of chromosome 12. In one of the B-cell ALL cases we uncovered a 3-way translocation 
t(12;21;5) associated with a recurrent fusion between the ETV6 (12p13) and the RUNX1 (21q22) 
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gene on the der(21) chromosome, as observed in patients with a t(12;21)(p13;q22) (Golub et al., 
1995; Romana et al., 1995). However, the consequences of the extra breakpoint at 5q13 to B-cell 
ALL pathogenesis remain to be addressed. In contrast to the B-cell ALL patient, we found that a 3-
way t(12;6;15) associated with a MDS/MPN, U did not involve the formation of a fusion gene 
between ETV6 and a putative partner gene at 6p24~25. Instead, we detected a 1.2-Mb interstitial 
deletion at chromosome band 12p13 which included ETV6 and 8 other genes. Through an 
extensive mapping of the deleted region we determined that its borders were internally delimited 
by ETV6 on the telomeric side and CDKN1B on the centromeric side. 
The absence of ETV6 in mouse embryos impairs angiogenesis within the yolk sac and leads 
to premature embryonic death (Wang et al., 1997). Moreover, ETV6 is absolutely required for 
production of erythroid, myeloid, lymphoid, mast, and megakaryocytic cells in mice bone marrow 
(Wang et al., 1998b). In turn, CDKN1B, which encodes the cyclin-dependent kinase inhibitor 
protein P27, whose levels are elevated during quiescence, is important for blocking cell cycle 
progression in resting cells (Kato et al., 1994; Nourse et al., 1994). In this setting, the finding of a 
concomitant loss of a transcription factor (ETV6) and of a cell cycle regulator (CDKN1B) in the 
myeloid lineage cells of the patient with a t(12;6;15) parallels the 2-hit model of AML 
pathogenesis (Frankfurt et al., 2007). Although the molecular consequences of the breakpoints at 
chromosomes 6 and 15 have not been addressed, these findings support the notion that different 
cellular pathways important for tumourigenesis may be targeted by a single complex 
chromosomal rearrangement. 
In another B-cell ALL patient with a dicentric chromosome rearrangement dic(9;12), we also 
identified a large deletion which included the genomic region between band 12p13 and the 
telomere of the short arm of chromosome 12. In addition, this patient also presented with a 
major deletion of chromosome 9 sequences extending from band 9p13 to the telomere of the 
short arm of chromosome 9. The dic(9;12) is associated in some B-cell ALL cases with the 
formation of an in-frame PAX5-ETV6 fusion (Strehl et al., 2003). In our patient with a dic(9;12) we 
found that both genes were deleted, initially suggesting that a different pathogenic mechanism 
was operating in this patient. However, a more recent study has shown that PAX5 expression 
levels are equally reduced in patients with dicentric chromosomes independently of the presence 
of a PAX5-derived fusion gene or of a PAX5 deletion (An et al., 2008). Moreover, the PAX5 allele 
on the normal chromosome 9 may present with inactivating point mutations or intragenic 
deletions in some patients, indicating that PAX5 loss-of-function is also relevant for the 
pathogenesis of B-cell ALL in patients with dicentric chromosomes leading to deletion of PAX5 (An 
et al., 2008). Significantly, the AML-related FLT3 gene, a PAX5-target gene, is overexpressed in B-
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cell ALL patients with PAX5 alterations (An et al., 2008). These results suggest that the inactivation 
of transcription factor genes (ETV6 and PAX5) through chromosomal rearrangement, together 
with the indirect activation of proliferation genes (FLT3) as a result of PAX5 alterations in B-cell 
ALL with dic(9;12) also agree to a double-hit model of leukemogenesis. However, the molecular 
consequences for tumourigenesis that may derive from the loss of other genes located at the 
12p13-12pter and 9p13-9pter genomic regions remain to be further investigated. 
In section 3.2 of this thesis we described the molecular rearrangements resulting from the 
formation of a complex 3-way t(9;11;19) associated with AML. This translocation produced an in-
frame MLL-MLLT3 fusion gene as seen in other AML patients with a t(9;11) (Iida et al., 1993; 
Nakamura et al., 1993). However, the complex translocation also resulted in the disruption of a 
gene previously identified as FLJ10374 at chromosome band 19p13 (Vieira et al., 2006). This gene, 
now referred to as CCDC94, was found to encode a nuclear protein which negatively controls cell 
cycle progression and proliferation. Because CCDC94 was haplo-insufficient in the AML patient 
with MLL-MLLT3 fusion, we hypothesize that both genetic changes concurred to disturb different 
cellular pathways and induce the AML phenotype. In this setting, a single complex chromosomal 
rearrangement may affect cell cycle regulation and normal myeloid differentiation simultaneously 
in accordance with the requirements of the double genetic hit model (Frankfurt et al., 2007). It is 
not known if CCDC94 inactivating mutations occur in other MLL-MLLT3-positive acute leukemias 
or if our findings in the patient with t(9;11;19) are exclusive. However, in view of these productive 
cooperating events, it constitutes an attractive hypothesis which deserves future investigation. 
Disregulation of cell cycle control proteins by chromosomal breakpoints may constitute a 
recurrent theme in acute leukemia patients presenting with complex translocations involving 
formation of MLL fusion proteins. Raffini et al. (2002) reported that a CDK6-MLL fusion was 
generated in a MLL-AF4-positive B-cell ALL patient as a result of a complex t(4;11) involving an 
extra breakpoint at chromosome band 7q22. CDK6 is activated by any of the 3 D-type cyclin 
proteins during the early G1 phase of the cell cycle (Sherr & Roberts, 1999). Activated CDK6 
phosphorylates and inactivates the RB1 protein, thereby releasing sequestered E2F transcriprion 
factors that lead to expression of various S-phase promoting genes (reviewed in Vieira & Gomes 
da Silva, 2008). The predicted configuration of the CDK6-MLL fusion protein includes the PLSTIRE 
aminoacid sequence and the catalytic cleft of CDK6 fused to the zinc-finger and activation 
domains of MLL (Raffini et al., 2002). The PLSTIRE sequence motif in CDK6 functions as an 
interaction site for cyclins (Jeffrey et al., 2000). Although Raffini et al. (2002) did not provide 
functional data for the CDK6-MLL fusion protein, it is possible that the catalytic domain of CDK6 
present in the CDK6-MLL fusion was constitutively activated by the MLL moiety of the fusion 
protein, therefore promoting cell cycle progression of MLL-AF4-positive cells, similarly to our case 
  
 
108 
with t(9;11;19). Increased expression of CDK6 was also found to occur in some patients with B-cell 
lymphomas in association with recurrent translocations of band 7q21 (Corcoran et al., 1999; 
Brito-Babapulle et al., 2002; Hayette et al., 2003). 
A few other studies have provided direct or indirect evidence that genes located at the 
extra breakpoints involved in complex translocations of myeloid neoplasms are likely to play a 
role in their pathogenesis. One of the first examples in CML is the glutathione S-transferase Pi 
(GSTP1) gene, a member of the family of glutathione S-transferase enzymes involved in the 
detoxification of endogenous and exogenous electrophilic substrates (Strange et al., 2001). The 
GSTP1 gene localizes at chromosome band 11q13, a frequent hotspot of extra breakpoints in CML 
(De Braekeleer, 1987). The 11q13 breakpoint has been localized within the GSTP1 sequence or at 
a distance of only 100-250 kb distant from the gene in 2 patients with a t(9;22;11)(q34;q11;q13) 
(Koduru et al., 1993; Morris et al., 1996). This suggests that GSTP1 is a non-random target gene in 
CML patients with extra 11q13 breakpoints and reinforces the possible pathogenic role of this 
gene in the disease. 
The GSTP1 gene is regulated at the transcriptional level by the tumour suppressor protein 
P53, which binds to a specific site within intron 4 (Lo et al., 2008). Interestingly, the P53 gene, 
which localizes at band 17p13.1, is frequently lost in CML patients in blast crisis as a result of the 
formation of an isochromosome of the long arm of chromosome 17, i(17q) (Johansson et al., 
2002). Moreover, nucleotide mutations of the P53 gene have been shown to occur in CML 
patients in blast crisis with or without the presence of i(17q), but not in chronic phase disease 
(Nakai et al., 1992). Taken together, these observations suggest that down-regulation of the 
GSTP1 gene as a result of P53 loss of function may occur frequently in advanced CML. In this 
context it may be hypothesized that haplo-insufficiency of GSTP1 through physical disruption as 
observed in the patient with t(9;22;11) reported by Koduru et al. (1993) may operate similarly to 
the loss of the P53 protein, which is observed at later disease stages. The consequences of 
reduced GSTP1 protein levels in CML cells and their putative association with disease status are 
yet unknown. Nevertheless, a possible role of GSTP1 in the pathogenesis of hematological 
malignancies was reinforced by a more recent observation that expression of this gene is 
diminished in human lymphoma (Rossi et al., 2004). 
Perhaps the most striking example of the relevant role of additional breakpoints in 
hematological neoplasms was provided by the study of a 4-way t(3;9;17;22)(q26;q34;q22;q11) 
detected in a CML patient in blast crisis (De Weer et al., 2008). In this rearrangement, 
justaposition of chromosome 17 sequences to sequences from band 3q26 led to an increased 
expression of the EVI1 oncogene at 3q26 in CML cells. The EVI1 gene is the translocation partner 
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of RUNX1 in the t(3;21)(q26;q22) associated with the blast crisis phase of CML (Mitani et al., 
1994). The RUNX1-EVI1 fusion protein contains the entire EVI1 protein sequence fused to the N-
terminal region of RUNX1 including the runt homology domain (Mitani et al., 1994). Because EVI1 
is not normally expressed in hematopoietic cells, its expression is greatly increased by the 
t(3;21)(q26;q22) (Ogawa et al., 1996). Remarkably, over-expression of EVI1 is also detected in 
CML patients in blast crisis in the absence of 3q26 abnormalities (Ogawa et al., 1996). The 
consequences of EVI1 over-expression in a myeloid cell line model were shown to consist in a 
blockage of granulocytic differentiation (Tanaka et al., 1995). Although De Weer et al. (2008) have 
proposed a 2-step mechanism for the generation of t(3;9;17;22), it is highly likely that in the CML 
patient over-expression of EVI1 concurred with the presence of the BCR-ABL1 fusion gene to 
promote rapid progression to an acute disease phase. 
 Taken together, although additional breakpoints in complex translocations in leukemia 
target genes involved in different cellular pathways, the changes described here reinforce the 
concept that genetic alterations at those breakpoints may independently contribute to disease 
progression, particularly by mimicking specific chromosomal alterations which are usually 
observed in aggressive disease stages. 
The double-hit model of AML pathogenesis dictates that at least 2 genetic changes affecting 
the pathways of differentiation, proliferation and/or cell cycle/apoptosis regulation must occur to 
induce the overt AML phenotype (Frankfurt et al., 2007). We have provided evidence from the 
analysis of 2 complex translocations in myeloid disorders that genes implicated in cellular 
differentiation and cell cycle regulation, located at different genomic regions, may be 
simultaneously targeted by a single complex chromosomal rearrangement. In section 3.3 of this 
dissertation, we provide evidence that a complex translocation t(X;20;16) in a patient with ET 
affected genes with similar functions which map to different breakpoint regions. The 
translocation resulted in the deletion of the NFATC2 gene at 20q13 and the MAF gene at 16q23, 
both of which encode transcription factors implicated in the regulation of cytokine genes. We 
showed that inhibition of NFATC2 protein or the suppression of its mRNA sequence in a model ET 
cell line increases the expression of GM-CSF, a cytokine involved in the proliferation of various 
myeloid lineages (Metcalf, 2008). Although MAF also regulates expression of GM-CSF, we have 
not addressed the consequences of MAF loss-of-function in our cell line model as we did for 
NFATC2. However, given their similar functions, it is fair to hypothesize that haplo-insufficiency of 
both transcription factor genes in our ET patient with t(X;20;16) contributed to dysregulate the 
normal pattern of cytokine expression in myeloid cells. 
NFATC2 protein is activated by the Ca2+/calmodulin–dependent calcineurin phosphatase in 
the cytosol as a consequence of an increase in intracellular [Ca2+] (Hogan et al., 2003). This 
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dependency on Ca2+ ions suggests that in addition to deletion of NFATC2, genetic defects involving 
other members of cellular Ca2+ signaling could also contribute to an impaired NFATC2 activity. In 
our patient with t(X;20;16) we found that the ATP9A and SALL4 genes were also included in the 
deleted region at 20q13. ATP9A codes for a putative phospholipid-transporting (P-type) 
membrane ATPase involved in the transport of Ca2+ and other cations. Using the predicted ATP9A 
protein sequence as template, we confirmed using bioinformatics analyses that ATP9A shares 
domain-specific aminoacid sequence similarities of 38-39% with the secretory pathway Ca2+ 
ATPase 1, sarco-endoplasmic reticulum Ca2+ ATPase 1 and plasma membrane Ca2+ ATPase 4b 
proteins (data not shown). Moreover, preliminary cellular assays indicate that ATP9A is an 
endoplasmic reticulum membrane protein (data not shown). Although no experimental data yet 
exists to confirm that ATP9A indirectly activates the calcineurin-NFAT pathway through an 
increase in cytosolic [Ca2+], it is plausible that pumping of Ca2+ ions from the reticulum lumen to 
the cytosol may activate the pathway, similarly to extracellular Ca2+ stimulation. Consequently, 
loss of both NFATC2 and ATP9A through chromosomal deletion may cooperate to impair 
activation of the calcineurin-NFAT pathway in myeloid cells. 
The interstitial 20q13 deletion in our ET patient with t(X;20;16) also encompassed the 
SALL4 gene. This gene is homologous to the spalt gene of Drosophila melanogaster and encodes a 
zinc-finger transcription factor which modulates pluripotency of embryonic stem cells and early 
embryonic development (Zhang et al., 2006). Germline mutations of SALL4 are responsible for 
several clinical phenotypes including the Duane-radial ray syndrome and the Okihiro syndrome 
(OS), the acro-renal-ocular syndrome and, more rarely, the Holt-Oram syndrome (Kohlhase et al., 
2002; Kohlhase et al., 2003). Mutations of SALL4 are predominantly nonsense mutations or gene 
deletions, leading to a haplo-insufficiency of SALL4. In addition, a SALL4 mutation was found in 
several affected individuals of a large Venezuelan family with Instituto Venezolano de 
Investigaciones Cientìficas (IVIC) syndrome (Paradisi & Arias, 2007), initially described as an 
autossomal dominant condition characterized mainly by upper limb malformations (Arias et al., 
1980). Although some of the affected individuals with IVIC displayed moderate thrombocytosis, 
there is no evidence for the development of hematopoietic abnormalities or of a 
myeloproliferative phenotype, including ET, in patients with SALL4-associated disorders 
(Kohlhase, 2008). In contrast, over-expression of SALL4 was documented in human AML samples, 
indicating that it may operate as an oncogene in this disorder (Ma et al., 2006). 
In a few patients with OS, multigene deletions involving SALL4 and other neighbouring 
genes, including NFATC2, have been described as an alternative mechanism to inactivating SALL4 
mutations (Borozdin et al., 2004; Borozdin et al., 2007). Although these OS patients presented 
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with additional clinical features, there was also no evidence of hematological alterations despite 
haplo-insufficiency of NFATC2 in hematopoietic cells (Borozdin et al., 2007). This suggests that 
loss of one NFATC2 allele may only provide a proliferative advantage to a hematopoietic 
precursor cell if other genetic changes are also acquired, namely JAK2V617F. This hypothesis is 
supported by a study showing that the vast majority of MPN patients with del(20q) are also 
positive for JAK2V617F, as in the case of our patient, indicating that both genetic alterations are 
cooperating events in disease development (Campbell et al., 2006). In agreement with this 
hypothesis, our results showing an association between inactivation of NFATC2 and cell 
proliferation in vitro were obtained using a JAK2V617F-positive cell line. Taken together, the 
results obtained in our patient with a complex t(X;20;16) also support a 2-hit model for the 
pathogenesis of ET. In particular, an activating mutation (JAK2V617F) promoted cell proliferation 
whereas inactivating alterations (deletion of NFATC2 and MAF) affected myeloid lineage 
development. 
The results described in this thesis clearly highlight a fundamental role for extra breakpoint 
locations in the pathogenesis of hematological neoplasms. As in the case of standard 2-way 
translocations, extra chromosomes involved in complex translocations are neither lost nor further 
rearranged by other chromosomal mechanisms during clonal evolution. Moreover, the 
configuration of complex chromosomal rearrangements in the same patient is identical at initial 
diagnosis and at relapse following a period of cytogenetic remission (Huntly et al., 2001), 
reinforcing the notion that the stability of extra rearranged chromosomes is of importance to 
leukemic cells throughout the course of the disease. 
These clinical-cytogenetic evidences may imply that positive selection pressures are 
operating at the level of the leukemic clone to maintain the integrity and functionality of all 
rearranged chromosomes originated by a complex translocation. This apparent selection of 
breakpoint locations in tumour-related abnormalities is stressed by studies of mammalian 
chromosome evolution. Nadeau & Taylor (1984) initially proposed that there would exist 
approximately 180 conserved genomic blocks with preserved gene orders between man and 
mouse. These so-called synteny blocks, which contain at least 2 orthologous genes shared by both 
species, vary in length between 1 and 24 centimorgans (Nadeau & Taylor, 1984). If the frequency 
of the various blocks is plotted as a function of their length, the resulting histogram fits well into 
an exponential distribution curve where frequency diminishes as a function of block length. On 
this basis, a “random breakage model” was proposed, which sustained that chromosome 
evolution derived from the occurrence of randomly distributed breakpoints throughout the 
genome (Nadeau & Taylor, 1984). However, studies of human and mouse genome 
rearrangements have revealed that a significant number of breakpoints are located at hotspots, 
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implying the existence of small synteny blocks (< 1 Mb) that remained undetected in most cases 
even after the draft human and mouse genome sequences were published (Pevzner & Tesler, 
2003a; Pevzner & Tesler, 2003b). If the length of these 190 small blocks is again plotted as a 
function of their frequency, the resulting histogram will show that larger blocks have a higher 
frequency than some of the smaller ones (Pevzner & Tesler, 2003b). This data does not fit an 
exponential distribution, where frequency is a function of the block length, and is therefore 
incompatible with the “random breakage model”. In this context, an alternative “fragile breakage 
model” has been proposed (Pevzner & Tesler, 2003b) which sustains that certain chromosomal 
regions are more prone than others to chromosomal rearrangements, and therefore are “reused” 
in different mammalian species during chromosome evolution (Pevzner & Tesler, 2003b; 
Kemkemer et al., 2009). This model of breakpoint hotspots is compatible with a skewed or 
clustered distribution of breakpoints that are revealed by cytogenetic studies in newborns with 
malformations, in tumours and in families carrying constitutional translocations (Cohen et al., 
1996; Sankoff D et al., 2002; Burrow et al., 2009). Although no studies have yet been done to 
associate breakpoint locations of complex translocations with evolutionarily fragile breakpoint 
regions, the significant degree of hotspot clustering observed in some hematological 
malignancies, is highly suggestive that extra breakpoint locations are also under positive selection 
forces. 
These data clearly highlights a correlation between evolutionary-related chromosome 
breakage and structural rearrangements in human cancer. Support for this hypothesis was 
provided by a molecular study of a 4-way complex t(9;22;10;17)(q34;q11;p13;q21) detected in a 
CML patient (McKeithan et al., 1992). Chromosome band 17q21 is a non-random breakpoint 
location in CML patients with complex rearrangements (De Braekeleer, 1987). Comparison 
between the 4 derivative chromosome junctions and their normal counterpart sequences showed 
a divergence at both the 10;17 and 17;9 chromosomal junctions. Using FISH with a probe directed 
to the 17q21 breakpoint region, McKeithan et al. (1992) also observed a signal at chromosome 
band 17q23 on normal hematopoietic cells. By comparing high-resolution karyotypes between 
humans and other primate species the authors detected that both regions on chromosome 17 
corresponded to the breakpoint locations of a paracentric inversion that occurred during the 
evolution from an ancestral chromosome 17 to the definite human chromosome 17 (McKeithan 
et al., 1992). In conclusion, if breakpoints at additional chromosomes involved in complex 
leukemia translocations are evolutionarily conserved, the molecular identification and 
characterization of their target genomic sequences may prove a successful means to identify 
novel tumour-related genes. 
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In summary, we undertook in this dissertation a study of 4 different complex chromosomal 
rearrangements including a t(12;21;5), t(12;6;15), t(9;11;19) and t(X;20;16), and of a dicentric 
translocation dic(9;12) associated with distinct hematological neoplasms. These studies allowed 
us to derive 2 main conclusions regarding the role of complex translocations in leukemia. Firstly, 
when complex translocations are associated with the production of recurrent fusion genes, 
additional breakpoint locations may target genes which obey the double-hit model of 
leukemogenesis; secondly, if complex translocations are recurrently associated with breakpoint-
adjacent deletions and no fusion genes are present, the deletion of at least 2 genes operating in 
the same or in complementary cellular pathways may be necessary to promote leukemogenesis. 
In other words, the multi-hit stepwise model of cancer development may be obviated by 
simultaneous genetic hits through the occurrence of a complex translocation or of breakpoint-
associated deletions, thereby avoiding the need for subsequent mutations. 
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